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i	
INTRODUCCIÓN			
	
La	tuberculosis	(TB)	es	una	de	las	enfermedades	más	antiguas	y	devastadoras	que	ha	
acompañado	 al	 ser	 humano	 desde	 hace	 cientos	 de	 años.	 A	 pesar	 de	 ser	 una	
enfermedad	 tratable	 y	 prevenible	 desde	 el	 descubrimiento	 de	 los	 fármacos	 activos	
frente	a	su	agente	causal	Mycobacterium	tuberculosis	(Mtb),	la	TB	sigue	siendo	una	de	
las	diez	causas	de	mortalidad	más	frecuentes	en	el	mundo.		En	2014	se	declararon	1.5	
millones	de	muertes	por	esta	causa,	concentrándose	el	80%	de	casos	en	22	países	en	
vías	 de	 desarrollo.	 A	 pesar	 de	 esta	 distribución,	 la	 TB	 no	 es	 exclusiva	 de	 los	 países	
pobres:	 Mtb	 no	 conoce	 fronteras	 y	 ningún	 país	 ha	 logrado	 nunca	 eliminar	 esta	
enfermedad.	
El	reservorio	de	Mtb	es	casi	exclusivamente	humano,	aunque	antaño	y	todavía	ahora	
en	países	del	tercer	mundo,	ha	existido	transmisión	zoonótica	a	través	de	la	ingesta	de	
leche	 no	 pasteurizada	 de	 ganado	 vacuno	 enfermo.	 El	 paciente	 enfermo	 de	 TB	 es	
fuente	 de	 contagio	 para	 el	 resto	 de	 personas:	 al	 toser	 o	 al	 hablar	 está	 dispersando	
secreciones	 respiratorias	microscópicas	que	 contienen	Mtb.	 Se	 sabe	que	este	bacilo	
puede	mantener	 su	 viabilidad	 varios	 días	 expuesto	 al	 ambiente,	 lo	 que	 hace	 que	 el	
contagio	sea	extremadamente	difícil	de	prevenir.		
Al	 ser	 inhalado	 y	 alcanzar	 el	 espacio	 alveolar,	Mtb	 se	 enfrenta	 a	 los	macrófagos,	 la	
primera	barrera	que	le	presenta	el	sistema	inmunitario.	Tras	un	complejo	sistema	de	
citoquinas	 estimuladoras	 e	 inhibidoras	 de	 otros	 grupos	 celulares,	 se	 organizará	 el	
granuloma.	Esta	estructura	histológica	definitoria	y	característica	de	la	reacción	a	Mtb,		
contendrá	 la	 infección	 en	 estado	 latente	 en	 la	 mayoría	 de	 los	 casos.	 El	 organismo	
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humano	 no	 puede	 aclarar	 la	 infección	 tuberculosa,	 pero	 es	 capaz	 de	 mantener	 un	
equilibrio	 a	 su	 favor.	 Sólo	 si	 se	 pierde	 dicho	 equilibrio,	 el	 paciente	 desarrollará	 TB.	
Clásicamente	se	ha	diferenciado	el	desarrollo	de	TB	tras	el	contagio	(primoinfección)	o	
tras	un	periodo	de	latencia	que	puede	llegar	a	ser	de	varias	décadas	(reactivación).	
Desde	el	descubrimiento	de	la	estreptomicina	en	1944	y	la	isoniazida	en	1952,	además	
de	tratar	a	los	individuos	enfermos,	el	British	Medical	Council	diseñó	5	ensayos	clínicos	
a	 gran	 escala	 que	 permitieron	 demostrar	 la	 eficacia	 del	 tratamiento	 preventivo	 de	
infección	 latente	 para	 el	 desarrollo	 de	 TB.	 Los	 pacientes	 aleatorizados	 a	 la	 rama	de	
tratamiento	tenían	una	menor	tasa	de	TB	que	los	que	habían	recibido	placebo	tras	un	
periodo	de	seguimiento	de	5	años	o	más.	
A	 pesar	 de	 que	 la	 principal	 arma	 para	 conseguir	 controlar	 la	 epidemia	 de	 TB	 es	 la	
precocidad	en	el	 diagnóstico	 y	 tratamiento	adecuado	de	 los	 individuos	enfermos,	 la	
estrategia		global	de	control	de	la	enfermedad	propuesta	por	la	Organización	Mundial	
de	 la	 salud	 (OMS)	para	después	de	2015	 incluye	el	 tratamiento	de	 las	personas	 con	
infección	tuberculosa	latente	(ITL),	de	donde	surgirán	los	futuros	enfermos	de	TB.	Éste	
es	el	centro	del	presente	proyecto	de	investigación.	
Se	ha	estimado	que	un	tercio	de	 la	población	mundial	está	 infectada	por	Mtb	y	que	
aproximadamente	un	10%	desarrollará	TB	a	 lo	 largo	de	su	vida.	En	 la	mayoría	de	 los	
casos	existirá	una	condición	inmunosupresora	que	favorecerá	la	pérdida	del	equilibrio	
entre	Mtb	y	la	inmunidad	del	huésped:	son	ejemplos	las	edades	extremas	de	la	vida,	la	
malnutrición	 y	 enfermedades	 debilitantes,	 así	 como	 los	 tratamientos	 que	 alteran	 la	
inmunidad	celular.		
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En	cuanto	al	diagnóstico	de	 infección	tuberculosa	en	el	paciente	sano,	no	es	posible	
confirmar	 el	 diagnóstico	 mediante	 cultivo.	 El	 bacilo	 está	 inmerso	 en	 la	 compleja	
arquitectura	 del	 granuloma	 y	 del	 organismo	 del	 huésped,	 lo	 que	 hace	 que	 sea	
inaccesible	 para	 la	 toma	 de	muestras.	 La	 ITL	 sólo	 puede	 diagnosticarse	 de	manera	
indirecta	 en	 un	 individuo	 asintomático,	 a	 través	 de	 la	 reacción	 inmunológica	 que	
desencadenen	sus	linfocitos	al	ser	estimulados	in	vivo	o	in	vitro	con	antígenos	de	Mtb.		
Dado	que	no	existe	ninguna	prueba	diagnóstica	“gold	estándar”	de	ITL,	la	sensibilidad	
y	 especificidad	 de	 las	 pruebas	 diagnósticas	 utilizadas	 va	 a	 calcularse	 de	 manera	
imperfecta	con	los	resultados	de	infección	en	los	pacientes	enfermos,	ya	que	en	éstos	
sí	 que	 se	 tiene	 certeza	 de	 la	 infección.	 Los	 individuos	 enfermos	 serán	 utilizados	
entonces	 como	 marcador	 subrogado	 de	 ITL,	 a	 pesar	 de	 la	 imperfección	 del	
comparador:	 de	 100	 individuos	 con	 TB	 confirmada	 por	 cultivo,	 sólo	 70	 tendrán	 una	
reacción	positiva	a	la	prueba	de	la	tuberculina	(PT).		
Hasta	la	última	década,	únicamente	se	disponía	de	PT	para	el	diagnóstico	de	infección	
tuberculosa.	 Esta	 prueba	mide	 “in	 vivo”	 la	 respuesta	 de	 los	 linfocitos	 sensibilizados	
frente	a	determinados	antígenos	de	Mtb	contenidos	en	el	derivado	proteico	purificado	
o	PPD,	que	se	inyecta	en	la	dermis	de	la	cara	volar	del	antebrazo	del	paciente	(técnica	
de	Mantoux).	Estos	antígenos	son	comunes	a	la	cepa	de	M.	bovis-BCG	utilizado	para	la	
vacunación	 infantil	 contra	 la	 TB,	 así	 como	 a	 algunas	micobacterias	 no	 tuberculosas	
(MNT).	Por	este	motivo,	un	resultado	positivo	de	la	PT	no	será	exclusivo	de	la	infección	
por	Mtb,	sobre	todo	en	los	individuos	vacunados.	Un	metaanálisis	de	la	última	decada	
mostró	 que	 la	 proporción	 de	 resultados	 positivos	 de	 la	 PT	 en	 pacientes	 vacunados	
podría	variar	entre	un	0-90%,	reflejando	la	variablidad	de	los	resultados	en	función	del	
	 iv	
reactante,	la	técnica,	el	punto	de	corte	para	considerar	un	resultado	como	positivo,	el	
técnico	que	leía	el	resultado	o	la	población	donde	se	realizaban	dichos	estudios.	
En	 los	 últimos	 quince	 años	 se	 han	 implementado	 las	 técnicas	 de	 detección	 de	
interferon-gamma	 in	 vitro	 (IGRAs),	 con	 capacidad	 de	 detectar	 inmunidad	 específica	
frente	a	Mtb	en	una	muestra	de	sangre	periférica.	Los	antígenos	utilizados	en	los	dos	
IGRAs	 disponibles:	 QuantiFERON-TB®	 Gold	 In-Tube	 (QFT-GIT)	 (Cellestis	 Limited,	
Carnegie,	Victoria,	Australia)	y	T-SPOT.TB®	(Oxford	Immunotec,	Oxford,	UK),	no	están	
presentes	en	la	cepa	de	M.	bovis-BCG	contenida	en	la	vacuna,	por	lo	que	no	existirán	
“falsos	IGRA	positivos”	de	causa	vacunal.		
Ambas	 técnicas,	 PT	 e	 IGRAs	 ven	 disminuida	 su	 sensibilidad	 diagnóstica	 en	 los	
pacientes	 inmunosuprimidos,	ya	sea	por	enfermedades	de	base	o	por	el	tratamiento	
con	corticoides	o	fármacos	que	alteran	la	funcionalidad	de	los	linfocitos	y	les	impiden	
generar	 una	 repuesta	 adecuada	 ante	 antígenos	 contra	 los	 que	 habían	 sido	
sensibilizados.	 Ninguna	 de	 las	 dos	 técnicas	 es	 capaz	 de	 distinguir	 si	 la	 infección	 es	
antigua	o	reciente,	ni	si	está	en	forma	activa	o	latente.	Tampoco	han	demostrado	ser	
capaces	 de	 predecir	 el	 desarrollo	 de	 enfermedad	 tuberculosa.	 El	 diseño	 ideal	 para	
determinar	 las	 diferencias	 en	 el	 valor	 predictor	 de	 tuberculosis	 entre	 IGRA	 y	 PT	
consistiría	en	dejar	a	todos	los	sujetos	de	ambos	grupos	sin	tratar,	y	comprobar	que	la	
incidencia	de	tuberculosis	en	IGRA	positivo	es	mayor	que	en	PT	positiva.	Sin	embargo,	
este	diseño	plantea	un	problema	ético,	ya	que	implicaría	dejar	sin	tratar	a	personas	en	
riesgo	de	desarrollar	TB	activa	tras	la	primoinfección.	La	única	manera,	por	tanto,	de	
evaluar	 la	 eficacia	 de	 los	 IGRAs	 en	 las	 poblaciones	 de	 riesgo,	 es	 comprobar	 que	 las	
decisiones	 terapéuticas	 basadas	 en	 sus	 resultados	 disminuyen	 el	 riesgo	 de	 TB	 a	
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prácticamente	 cero	 (en	 un	 país	 de	 baja	 endemia	 y	 asegurando	 la	 toma	 del	
tratamiento).	
El	punto	clave	es	dilucidar	a	qué	 individuos	debe	 indicarse	cribado	y	 tratamiento	de	
ITL,	 ya	 que	 a	 pesar	 de	 afectar	 a	 un	 tercio	 de	 la	 población	 mundial,	 el	 riesgo	 de	
reactivación	y	desarrollo	de	TB	es	sólo	del	10%.	No	debe	practicarse	la	prueba	si	no	se	
tiene	la	intención	de	ser	consecuente	con	el	resultado	de	la	misma.	Deben	someterse	
a	 una	 prueba	 diagnóstica	 aquellos	 individuos	 en	 riesgo	 de	 desarrollar	 enfermedad	
activa	 en	 caso	 de	 estar	 infectados.	 Son	 dos	 los	 grupos	 de	 riesgo	 identificados	 en	 la	
literatura:	 los	 pacientes	 inmunodeprimidos	 (fundamentalmente	 pacientes	 con	
infección	 por	 VIH,	 trasplantados	 y	 aquellos	 afectos	 de	 enfermedades	 inflamatorias	
inmunomediadas	 que	 precisan	 agentes	 biológicos)	 y	 los	 individuos	 con	 exposición	
reciente	a	un	paciente	enfermo	de	tuberculosis.		
En	estos	grupos	de	riesgo	y	en	la	toma	de	decisiones	en	función	del	resultado	de	las	
pruebas	 diagnósticas	 de	 ITL	 se	 han	 centrado	 los	 trabajos	 recogidos	 en	 esta	 tesis	
doctoral.		
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CONTEXTO	DE	LA	INVESTIGACIÓN	
	
En	 países	 de	 baja	 endemia	 el	 control	 de	 TB	 se	 concentra	 en	 la	 prevención	 de	
tuberculosis	a	través	del	cribado	de	infección	tuberculosa	latente	pacientes	en	riesgo	
de	desarrollar	enfermedad	activa.	La	Unidad	Clínica	de	TB	del	Hospital	Universitari	de	
Bellvitge	dispone	de	personal	a	tiempo	completo	con	amplia	experiencia	en	educación	
sanitaria	 y	 protocolos	 asistenciales	 sistemáticos	 para	 los	 diferentes	 perfiles	 de	
pacientes.	 A	 raíz	 de	 la	 introducción	 de	 los	 IGRAs	 se	 realizaron	 tres	 estudios	
prospectivos	 que	 incluían	 estas	 técnicas	 para	 el	 cribado	 de	 ITL	 en	 poblaciones	 de	
riesgo	para	el	desarrollo	de	TB,	y	que	sirvieron	de	base	para	la	realización	de	una	tesis	
doctoral	en	2012.		
Desde	entonces	los	IGRAs	se	han	incluido	en	la	práctica	clínica.	A	pesar	de	que	varias	
guías	 internacionales	 y	 recomendaciones	 de	 expertos	 los	 incluyen	 como	 parte	 del	
proceso	diagnóstico	de	ITL,	la	realidad	es	que	no	existen	directrices	uniformes	para	su	
uso.	La	ausencia	de	“gold	standard”	para	el	diagnóstico	de	ITL	dificulta	la	comparación	
de	sus	resultados	con	los	obtenidos	con	la	PT.	En	este	sentido,	la	OMS	definió	en	2011	
una	escala	jerárquica	del	grado	de	evidencia	que	podía	generar	el	uso	de	los	IGRAs.	El	
primer	paso	consistía	en	valorar	la	concordancia	de	PT	e	IGRAs.	El	segundo,	en	valorar	
la	 sensibilidad	 y	 la	 especificidad	 de	 los	 IGRAs	 en	 pacientes	 con	 TB	 activa.	 En	 tercer	
lugar,	estudiar	la	correlación	de	los	resultados	de	los	IGRAs	con	el	grado	de	exposición	
a	Mtb	o	en	su	defecto,	a	los	factores	de	riesgo	que	se	han	asociado	clásicamente	a	TB.	
El	 cuarto	 y	 penúltimo	 escalón	 estaba	 definido	 por	 el	 establecimiento	 de	 los	 valores	
predictivos	 positivo	 y	 negativo	 para	 el	 desarrollo	 de	 TB,	 y	 hasta	 este	 punto,	 la	
literatura	 científica	 ha	 generado	 resultados	 en	 esta	 progresión	 en	 la	 generación	 de	
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evidencia.	 En	 el	momento	 de	 la	 realización	 de	 este	 estudio,	 y	 aún	 ahora	 al	 haberlo	
finalizado,	no	se	han	publicado	estudios	que	satisfagan	el	objetivo	del	último	escalón	
propuesto	por	la	OMS:	la	valoración	de	la	eficacia	del	tratamiento	preventivo	que	se	
ha	prescrito	a	tenor	de	los	resultados	de	los	IGRAs.		
Con	el	objetivo	de	generar	 resultados	con	 la	evidencia	necesaria	para	dar	 respuesta	
definitiva	al	valor	de	los	IGRAs,	se	diseñó	un	ensayo	clínico	en	el	contexto	del	estudio	
de	 contactos	 de	 tuberculosis,	 comparando	 la	 estrategia	 habitual	 de	 PT	 a	 una	
estrategia	secuencial	que	combina	PT	y	su	confirmación	con	QFT-GIT,	y	su	eficacia	en	
prevenir	el	desarrollo	de	TB	a	 los	dos	años	de	seguimiento.	Éste	ha	sido	el	principal	
proyecto	de	investigación	de	esta	tesis.	Durante	la	realización	del	mismo	se	ha	llevado	
a	cabo	un	meta-análisis	que	valora	la	capacidad	de	los	IGRAs	en	reducir	la	proporción	
de	pacientes	 candidatos	a	 recibir	 tratamiento	preventivo,	 sin	que	aumente	el	 riesgo	
de	 TB	 ulterior.	 Asimismo	 se	 han	 llevado	 a	 cabo	 tres	 estudios	 longitudinales	 que	
describen	 la	experiencia	del	uso	de	 los	 IGRAs	en	 la	Unidad	Clínica	de	TB	de	nuestro	
centro	 en	 tres	 poblaciones	 de	 riesgo,	 comparándolos	 con	 los	 resultados	 de	 las	
estrategias	 previas	 que	 no	 los	 incluían.	 Estas	 poblaciones	 de	 riesgo	 incluyen	 los	
contactos	 recientes	 de	 TB	 y	 dos	 grupos	 de	 inmunosupresión	 bien	 conocida:	 los	
pacientes	 sometidos	 a	 agentes	 anti-factor	 de	 necrosis	 tumoral	 (anti-TNF)	 y	 los	
candidatos	a	trasplante.		 	
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HIPÓTESIS	DE	TRABAJO		
Premisas	
	
1. A	mayor	proporción	de	diagnósticos	de	ITL	entre	los	cribados	como	población	en	
riesgo	 de	 desarrollar	 TB,	 más	 eficaz	 será	 la	 estrategia	 de	 prevención	 de	
enfermedad	 activa.	 Por	 este	 motivo	 se	 ha	 utilizado	 el	 booster	 y	 todavía	 se	
recomienda	en	algunas	Guías	Clínicas.		
2. No	existe	evidencia	sólida	sobre	cuál	es	la	mejor	técnica	diagnóstica	para	ITL.	Los	
IGRAs	 han	 demostrado	 superioridad	 en	 precisión	 diagnóstica	 (sensibilidad,	
especificidad	 y	 valores	 predictivos)	 y	 de	 hecho	 se	 han	 incorporado	
progresivamente	 a	 la	 práctica	 clínica	 ya	 sea	 sustituyendo	 o	 acompañando	 a	 PT,	
pero	 no	 existen	 estudios	 sólidos	 que	 favorezcan	 su	 uso.	 Esto	 se	 traduce	 en	 la	
heterogeneidad	 de	 las	 recomendaciones	 de	 expertos	 o	 en	 las	 directrices	 de	
sociedades	científicas.	
3. Los	IGRAs	pueden	mejorar	la	estrategia	diagnóstica	de	ITL	en	poblaciones	en	riesgo	
de	desarrollar	enfermedad	activa.	
3.1. Pacientes	inmunodeprimidos:	los	IGRAs	pueden	optimizar	la	sensibilidad	de	la	
estrategia	diagnóstica	si	se	añaden	a	 la	PT,	ya	que	éstos	han	demostrado	no	
estar	tan	influenciados	por	la	inmunosupresión	como	la	PT.	
3.2. Pacientes	sanos	con	exposición	reciente	a	Mtb:	 los	 IGRAs	pueden	mejorar	 la	
especificidad	del	diagnóstico.	En	diferentes	series	 los	 IGRAs	han	demostrado	
un	 alto	 valor	 predictivo	 negativo,	 por	 lo	 que	 los	 pacientes	 con	un	 resultado	
negativo	 no	 estarían	 en	 riesgo	 de	 desarrollar	 TB	 aún	 sin	 tratamiento	
preventivo.	
		
	
ix	
4.	Las	pruebas	diagnósticas	constituyen	una	parte	fundamental	del	manejo	de	la	 ITL.	
No	 obstante,	 el	 control	 de	 la	 adherencia	 y	 de	 los	 efectos	 secundarios	 son	 también	
fundamentales	para	conseguir	la	compleción	del	tratamiento,	y	por	ende,	su	eficacia.	
Hipótesis	
El	manejo	de	ITL	es	un	componente	crucial	en	la	prevención	de	TB	en	poblaciones	de	
riesgo	.	Una	buena	estrategia	de	cribado	que	incluya	la	compleción	del	tratamiento	es	
garantía	de	eficacia.	Aumentar	la	proporción	de	diagnósticos	de	ITL	no	es	sinónimo	de	
mejoría	de	los	resultados.	Al	contrario,	puede	conducir	a	un	aumento	de	tratamientos	
preventivos	innecesarios.	
1. En	 pacientes	 inmunosuprimidos:	 Partiendo	 de	 la	 mayor	 sensibilidad	 de	 los	
IGRAs	 respecto	 a	 PT	 en	 este	 grupo	 de	 pacientes,	 la	 implementación	 de	 los	
IGRAs	 en	 la	 estrategia	 de	 cribado	 de	 ITL	 podría	 aumentar	 el	 número	 de	
individuos	 diagnosticados	 y	 tratados	 de	 ITL,	 evitando	 los	 resultados	 falsos	
negativos	de	la	PT	y	disminuyendo	así	el	riesgo	de	reactivación	de	TB.		
2. En	pacientes	sanos	expuestos	a	Mtb	 (estudios	de	contactos):	Asumiendo	una	
sensibilidad	equivalente	y	una	mayor	especificidad	de	los	IGRAs	respecto	a	PT,	
su	 utilización	 y	 la	 toma	 de	 decisiones	 en	 función	 de	 su	 resultado	 podrían	
optimizar	 la	 estrategia	 de	 selección	 de	 pacientes	 candidatos	 a	 recibir	
tratamiento	 de	 ITL	 en	 el	 estudio	 de	 contactos,	 reduciendo	 el	 número	 de	
pacientes	tratados,	sin	aumentar	el	riesgo	de	TB.	
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OBJETIVOS	
	
Objetivo	 general:	 mejorar	 el	 manejo	 de	 ITL,	 especialmente	 a	 través	 de	 la	
implementación	 de	 los	 IGRAs,	 en	 poblaciones	 en	 riesgo	 de	 desarrollar	 enfermedad	
activa.	
	
Objetivos	específicos:	
1. En	el	grupo	de	pacientes	inmunosuprimidos	
1.1. Candidatos	a	recibir	tratamiento	con	agentes	anti-TNF	
• Determinar	 la	 eficacia	 de	 un	 protocolo	 sistemático	 de	 cribado	 y	
tratamiento	 de	 ITL	 en	 estos	 pacientes	 para	 prevenir	 el	 desarrollo	 de	
TB.	
• Determinar	la	eficacia	y	la	seguridad	de	la	estrategia	que	incluye	PT	en	
un	 tiempo	y	QFT-GIT	comparándola	con	práctica	previa	de	PT	en	dos	
tiempos	 (booster),	 en	 términos	 de	 reducción	 de	 tratamientos	
preventivos	sin	que	exista	un	aumento	de	riesgo	de	desarrollo	de	TB.	
• Determinar	de	 la	rentabilidad	de	 la	repetición	sistemática	del	cribado	
de	ITL	tras	un	resultado	inicial	negativo.		
	
1.2. Candidatos	a	trasplante	
• Valorar	la	utilidad	de	QFT-GIT	y	comparación	con	la	utilidad	de	PT	para	
la	 predicción	 del	 desarrollo	 de	 TB	 activa	 en	 pacientes	 candidatos	 a	
trasplante	hepático	y	de	precursores	hematopoyéticos.	
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2. En	pacientes	sanos	con	exposición	reciente	a	Mtb	(estudio	de	contactos)	
• Determinar	si	la	implementación	de	los	IGRAs	puede	reducir	el	número	de	
pacientes	 candidatos	 a	 recibir	 tratamiento	 preventivo	 sin	 aumentar	 el	
riesgo	de	TB	activa	ulterior.		
• Comprobar	 la	 no-inferioridad	 de	 una	 estrategia	 secuencial	 de	 PT	
confirmada	 con	QFT-GIT	 comparada	 con	 la	 estrategia	basada	únicamente	
en	PT	para	la	prevención	de	TB.		
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METODOLOGÍA		
	
Investigación	Clínica	
Todos	 los	 estudios	 se	 han	 realizado	 en	 la	 Unidad	 Clínica	 de	 TB	 del	 Hospital	 de	
Bellvitge,	 que	 desde	 el	 año	 1988	 funciona	 como	 una	 consulta	 monográfica,	
ocupándose	de	todos	 los	pacientes	con	TB	pulmonar	y	extrapulmonar,	el	estudio	de	
contactos,	programas	de	prevención	de	TB	con	protocolos	de	cribado	de	ITL	para	cada	
población	de	 riesgo,	 y	 además	es	 referente	de	 infecciones	por	MNT	 y	 cepas	MDR	y	
XDR	de	Mtb.		
El	protocolo	sistemático	de	cribado	de	ITL	incluye	
1. Evaluación	 clínica	 basal	 y	 descarte	 de	 enfermedad	 TB	 activa	 mediante	
radiografía	 de	 tórax	 	 y	 despistaje	 de	 síntomas,	 con	 recogida	 de	 datos	
demográficos,	 comorbilidades	 y	 tratamiento	 durante	 los	 últimos	 tres	meses,	
antecedentes	 de	 tuberculosis	 o	 ITL,	 estado	 de	 vacunación	BCG	 y	 factores	 de	
riesgo	de	tuberculosis.			
2. Diagnóstico	 de	 infección	 tuberculosa	 latente:	 En	 los	 pacientes	 con	
antecedentes	de	TB	o	ITL	documentadas,	no	se	realizan	pruebas	diagnósticas.	
Si	nunca	han	recibido	tratamiento	se	les	ofrece	tratamiento	preventivo	en	caso	
de	 que	 el	 riesgo	 sea	 superior	 a	 los	 inconvenientes	 del	 tratamiento.	 En	
pacientes	 que	 nunca	 han	 sido	 sometidos	 a	 pruebas	 de	 detección	 de	
tuberculosis,	se	administra	la	PT	mediante	el	método	de	Mantoux	utilizando	2	
UT	de	PPD	RT23	(Statens	Serum	Institute,	Copenhague,	Dinamarca)	en	la	cara	
volar	del	antebrazo.	Tanto	la	administración	como	su	lectura	a	las	48-72	horas,	
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son	 evaluadas	 por	 dos	 enfermeras	 con	 experiencia	 en	 la	 Unidad	 de	
Tuberculosis.	En	caso	de	requerir	un	IGRA,	QFT-GIT	se	realiza	antes	de	la	PT	y	
de	acuerdo	con	las	instrucciones	del	fabricante.	
3. Tratamiento	de	ITL:	Todos	los	recién	diagnosticados	de	ITL	reciben	seis	meses	
de	 tratamiento	 con	 isoniazida.	 El	 régimen	 alternativo	 es	 de	 cuatro	meses	 de	
rifampicina.	 Los	 candidatos	 a	 recibir	 tratamiento	 reciben	 un	 amplio	
asesoramiento	 sobre	 la	 infección	 tuberculosa,	 su	 tratamiento	 y	 posibles	
efectos	 secundarios.	Durante	el	periodo	de	 tratamiento,	 los	pacientes	 tienen	
acceso	telefónico	directo	a	 la	Unidad	de	Tuberculosis	5	días	a	 la	semana.	Las	
visitas	 de	 refuerzo	 y	monitorización	 junto	 con	 las	 analíticas	 de	 control	 de	 la	
función	hepática	se	realizan	en	los	meses	1,	3	y	6.	La	adherencia	a	la	isoniazida	
se	 evalúa	mediante	 la	 detección	 de	metabolitos	 del	 fármaco	 en	orina	 con	 la	
prueba	de	Eidus-Hamilton.	El	control	de	lo	pacientes	que	toman	rifampicina	se	
comprueba	con	el	color	de	la	orina.	
	
Los	 trabajos	 observacionales	 que	 componen	 esta	 tesis	 han	 seguido	 la	 misma	
metodología.	 Los	 datos	 de	 los	 pacientes	 incluidos	 en	 los	 estudios	 se	 recogían	 de	
manera	 prospectiva	 como	 parte	 del	 trabajo	 asistencia	 de	 la	 Consulta.	 Para	 el	
desarrollo	de	TB	se	revisaron	mediante	un	protocolo	específico	de	recogida	de	datos	
las	historias	clínicas	 informatizadas	de	ámbito	hospitalario	y	de	 la	Atención	Primaria.	
En	caso	de	no	poder	obtener	los	datos	necesarios,	se	realizaba	una	llamada	telefónica	
al	paciente.	En	caso	de	pérdida	de	seguimiento,	los	datos	del	paciente	se	contrastaban	
con	el	registro	de	declaraciones	de	TB	en	Cataluña.	
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Para	el	Ensayo	Clínico	se	creó	la	RED	OPTIMIST,	compuesta	de	12	centros	hospitalarios	
repartidos	por	toda	la	geografía	nacional.	Algunos	de	estos	centros	trabajaban	con	un	
sistema	 parecido	 al	 del	 Hospital	 de	 Bellvitge	 antes	 del	 Ensayo	 (atención	 de	 los	
contactos	en	relación	a	cada	caso	índice,	control	sistemático	de	la	adherencia	y	de	los	
efectos	 secundarios),	 como	por	ejemplo	el	Complexo	Hospitalario	de	Pontevedra,	el	
Hospital	 de	 Mendaro;	 Son	 Llàtzer	 o	 el	 Hospital	 de	 Jerez	 de	 la	 Frontera.	 En	 otros	
centros	se	comenzó	a	trabajar	con	esta	organización	a	raíz	del	inicio	del	Ensayo	Clínico	
OPTIMIST	(H.	Gregorio	Marañón,	H.V.	Macarena,	Parc	Taulí).	
Aspectos	Éticos		
Los	 tres	 estudios	 observacionales	 fueron	 aprobados	 por	 el	 Comité	 Ético	 de	
Investigación	 Clínica	 (CEIC)	 del	 H.	 Universitario	 de	 Bellvitge.	 En	 cuanto	 al	 Ensayo	
Clínico	OPTIMIST,	el	CEIC	del	H.	Bellvitge	actuó	como	Comité	de	referencia,	y	aprobó	
igual	que	en	todos	los	centros	participantes,	la	realización	del	estudio.	
Financiación	
La	 doctoranda	 recibió	 una	 Beca	 del	 Hospital	 de	 Bellvitge	 (julio	 2009	 –	 junio	 2010).	
Además,	en	el	año	2010	el	ISCIII	se	le	concedió	una	“Ayuda	Predoctoral	de	Formación	
en	Investigación	de	la	Salud”	(Expediente	FI10/00443).		
El	 ensayo	 clínico	 “Optimist”,	 cuyo	 investigador	 principal	 es	 el	 Dr.	 Miguel	 Santín,	
director	 de	 la	 presente	 tesis,	 ha	 recibido	 financiación	 del	 ISCIII	 en	 su	 convocatoria	
2009	 del	 subprograma	 de	 proyectos	 de	 investigación	 clínica	 no	 comercial	 con	
medicamentos	de	uso	humano	(Expte	EC	09/00113-TRA126).	
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RESULTADOS		
1.	En	el	grupo	de	pacientes	inmunosuprimidos	
1.1	Candidatos	a	recibir	tratamiento	con	agentes	anti-TNF.		
Artículo	1.	“Prevención	de	 la	 tuberculosis	asociada	agentes	anti-TNF:	estudio	de	una	
cohorte	longitudinal	durante	10	años”	(Clin	Infect	Dis	2015;	60:	349-356).					
En	 este	 estudio	 se	 incluyeron	 726	 pacientes	 con	 enfermedades	 inflamatorias	
inmunomediadas	 candidatas	 a	 recibir	 agentes	 anti-TNF	 de	 los	 Servicios	 de	
Reumatología,	 Dermatología	 y	 	 Gastroenterología	 del	 Hospital	 de	 Bellvitge.	 Se	
compararon	 tres	 estrategias	 diagnósticas	 en	 tres	 periodos	 consecutivos:	 la	 primera	
incluía	 la	 PT	 en	 dos	 tiempos,	 la	 segunda	 añadía	QFT-GIT	 a	 la	 PT	 en	 dos	 pasos,	 y	 la	
tercera	 simplificaba	 la	 estrategia	 a	 QFT-GIT	 y	 PT	 en	 un	 tiempo.	 Se	 evaluaron	 las	
diferencias	 en	 la	 incidencia	 de	 TB	 en	 dos	 años	 de	 seguimiento	 entre	 los	 pacientes	
expuestos	a	TNF	y	los	no	expuestos	y	entre	los	3	períodos	de	estudio.	
Cuatro	pacientes	desarrollaron	TB	en	el	primer	año	de	seguimiento	tras	el	cribado	de	
ITL.	La	incidencia	de	TB	fue	de	2,85	casos	por	1000	pacientes-año	entre	los	expuestos	
(3/	1052	pacientes-año)	y	de	1.77	por	1000	pacientes-año	en	los	no	expuestos	(1/	566	
pacientes-año).	No	se	produjeron	casos	más	allá	del	primer	año	de	tratamiento.	En	el	
tercer	periodo	del	estudio	 (utilizando	TST	en	un	 tiempo	y	QFT-GIT)	 la	proporción	de	
ITL	 fue	de	26-5%,	 suponiendo	una	descenso	 significativo	 respecto	al	 primer	periodo	
(TST	en	dos	tiempos)	(42.5%;	P	<0.001)	y	al	segundo	(TST	en	dos	tiempos	y	QFT-GIT)	
(38.5%;	 P	 =	 0.02).	 La	 incidencia	 de	 tuberculosis	 entre	 los	 pacientes	 expuestos	 a	
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agentes	 anti-TNF	 no	 se	 modificó	 en	 los	 3	 períodos	 (2.63	 ,	 3.91	 y	 2.4	 por	 1000	
pacientes-año,	respectivamente).		
1.2	Candidatos	a	trasplante.	
Artículo	 2	 “Valores	 predictivos	 de	 las	 pruebas	 inmunodiagnósticas	 de	 ITL	 para	 la	
progresión	 a	 tuberculosis	 en	 pacientes	 receptores	 de	 trasplante”	 (Transplant	 Direct	
2015;1:e12).	
En	este	estudio	se	incluyeron	50	candidatos	a	trasplante	hepático	(LT)	y	26	candidatos	
a	trasplante	de	células	madre	hematopoyéticas	(HSCT)	del	Hospital	de	Bellvitge.	Todos	
los	 pacientes	 fueron	 cribados	mediante	 PT	 y	QFT-GIT	 y	 ninguno	 recibió	 tratamiento	
preventivo	por	decisión	En	 la	cohorte	de	LT,	un	paciente	 (4,5%)	entre	 los	22	sujetos	
con	resultado	positivo	de	QFT-GIT	desarrolló	TB	activa.	Ningún	paciente	con	QFT-GIT	
negativo	desarrolló	TB.	En	la	cohorte	de	HSCT,	ninguno	de	los	7	pacientes	con	QFT-GIT	
positivo	desarrolló	TB,	mientras	que	un	caso	(5,3%)	progresó	a	TB	activa	entre	los	19	
pacientes	 con	QFT-GIT	 negativo.	 Se	 obtuvieron	 resultados	 similares	 con	 la	 PT:	 en	 el	
grupo	de	 LT,	 1	de	23	pacientes	 con	PT-positiva	 y	ninguno	de	 los	 27	 sujetos	 con	PT-
negativa	desarrollaron	TB;	En	el	 grupo	de	HSCT,	ninguno	de	 los	8	pacientes	 con	PT-
positiva	y	uno	de	los	18	pacientes	con	PT-negativa	progresaron	a	TB	activa.	
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Artículo	 3.	 “IGRAs	 vs.	 prueba	 de	 la	 tuberculina	 para	 la	 selección	 de	 candidatos	 a	
tratamiento	preventivo:	Una	revisión	basada	en	la	evidencia”	(J	Infect	2013;	66:	381-7)	
En	 esta	 revisión	 sistemática	 se	 incluyeron	 los	 estudios	 longitudinales	 que	 incluían	
pacientes	cribados	para	ITL	con	resultados	de	PT	e	IGRAs,	entre	enero	de	2005	y	mayo	
de	 2012.	 Se	 evaluaron	 las	 reducciones	 en	 diagnósticos	 de	 ITL	 y	 el	 aumento	 de	 la	
incidencia	de	TB	en	personas	consideradas	no	infectadas,	utilizando	IGRAs	en	lugar	de	
PT	o	como	prueba	confirmatoria	de	PT	(estrategia	secuencial).	En	comparación	con	la	
estrategia	basada	únicamente	en	PT,	la	reducción	de	la	proporción	de	diagnósticos	de	
ITL	al	sustituir	la	PT	por	un	IGRA	fueron	de	16.7%	y	5.8%	con	los	puntos	de	corte	de	PT	
en	 5	 y	 10	 mm	 respectivamente.	 Con	 la	 estrategia	 secuencial	 la	 reducción	 de	
diagnósticos	de	ITL	fue	de	24.5%	y	12.4%	con	los	puntos	de	corte	de	PT	en	5	y	10	mm	
respectivamente.	 En	 comparación	 con	 la	 estrategia	 basada	 únicamente	 en	 PT,	 la	
incidencia	 de	 TB	 entre	 las	 personas	 consideradas	 no	 infectadas	 aumentó	 con	 la	
estrategia	 secuencial	 (0.94%	 con	 T-SPOT.TB	 y	 1.1%	 con	 QFT-GIT)	 en	 uno	 de	 siete	
estudios	realizados	en	países	ricos.	En	los	países	con	ingresos	medios	o	bajos,	dos	de	
cuatro	 estudios	 presentaron	 aumentos	 (0.08	 y	 0.03	 por	 100	 pacientes-año,	
respectivamente)	con	la	estrategia	secuencial.	
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2.	En	pacientes	adultos	sanos	con	exposición	reciente	a	Mtb:	estudio	de	contactos	
Artículo	4:	“Utilidad	de	QuantiFERON®-TB	Gold	 In-Tube	para	el	estudio	de	contactos	
de	tuberculosis	en	pacientes	vacunados	con	BCG”.	En	revisión	(Plos	One).	
En	 este	 estudio	 se	 compararon	 dos	 estrategias	 diagnósticas	 de	 ITL	 en	 el	 estudio	 de	
contactos	 de	 TB,	 correspondientes	 a	 dos	 periodos	 consecutivos	 en	 el	 Hospital	 de	
Bellvitge.	En	el	primer	periodo,	el	diagnóstico	de	ITL	se	basaba	en	la	PT	solamente	(≥	5	
mm).	 En	 el	 segundo,	 se	 añadió	QFT-GIT	 para	 el	 diagnóstico	 de	 ITL	 en	 los	 contactos	
vacunados	con	BCG.		
Se	 incluyeron	671	 contactos	en	el	 estudio	de	 los	 cuales	290	estaban	vacunados	 con	
BCG.	En	el	segundo	periodo	se	redujo	la	proporción	de	diagnósticos	de	ITL	(77.4%	vs.	
51.2%	 p	 <0.01)	 y	 de	 tratamientos	 preventivos	 prescritos	 (62.1%	 vs.	 48.2%	 p=	 0.02)	
respecto	al	primer	periodo,	entre	los	contactos	vacunados	con	BCG	.	Después	de	una	
mediana	de	seguimiento	de	5	años,	no	hubo	diferencias	en	las	 incidencia	acumulada	
de	TB	(0.62	vs.	0.29%;	p=	0.59)	entre	el	primer	y	segundo	periodo.		
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Artículo	5	:	“Ensayo	clínico	comparativo	de	dos	estrategias	para	la	toma	de	decisiones	
terapéuticas	en	el	estudio	de	contactos	de	 tuberculosis:	estrategia	estándar,	basada	
en	 la	 prueba	 de	 la	 tuberculina	 (PT)	 sola,	 frente	 a	 la	 combinación	 de	 PT	 y	
QuantiFERON®-TB	 Gold	 In-Tube;	 Estudio	 OPTIMIST”	 (Núm.	 EUDRACT:	 2009-017430-
49).	En	revisión	(Annals	of	Internal	Medicine)	
Estudio	prospectivo,	multicéntrico	y	comparativo	de	dos	estrategias	de	diagnóstico	de	
infección	 tuberculosa	 en	 12	 hospitales	 de	 España	 con	 programas	 de	 estudio	 de	
contactos.	 Los	 sujetos	 del	 estudio	 fueron	 adultos	 sanos	 contactos	 convivientes	 de	
pacientes	afectos	de	 tuberculosis	pulmonar	y/o	 laríngea,	 confirmada	por	 cultivo,	 los	
cuales	fueron	asignados	de	manera	aleatoria	a	una	de	las	dos	estrategias:	Rama	PT,	en	
la	cual	la	decisión	de	tratamiento	se	llevaba	a	cabo	en	función	del	resultado	de	la	PT;	
Rama	PT/QFT,	en	 la	cual	 la	decisión	de	tratamiento	se	 llevaba	a	cabo	en	función	del	
resultado	 del	 QFT-GIT.	 En	 la	Rama	 PT	 se	 realizaba	 PT,	 y	 en	 la	Rama	 PT/QFT-GIT	 se	
realizaba	 PT,	 y	 en	 caso	 de	 ser	 positiva,	 se	 seguía	 de	 QFT-GIT.	 Los	 sujetos	 con	 PT	
positiva	 (Rama	 PT)	 y	QFT-GIT	 positivo	 (Rama	 PT/QFT-GIT)	 fueron	 diagnosticados	 de	
infección	 tuberculosa	 y	 se	 les	 indicó	 tratamiento	 con	 isoniazida	durante	 seis	meses.	
Todos	los	participantes	fueron	seguidos	durante	dos	años.	El	punto	final	de	evaluación	
fue	 desarrollo	 de	 tuberculosis	 a	 los	 dos	 años	 de	 seguimiento,	 y	 diferencia	 de	 la	
proporción	 de	 contactos	 a	 los	 que	 se	 les	 prescribía	 tratamiento	 de	 infección	
tuberculosa.	El	objetivo	fue	comprobar	la	no	inferioridad	de	la	estrategia	secuencial	de	
PT/QFT-GIT	respecto	al	estándar	de	PT	sola	para	la	prevención	de	TB	en	el	estudio	de	
contactos	con	un	margen	de	no	inferioridad	de	1.5	puntos	porcentuales.	
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Un	total	de	871	contactos	fueron	asignados	al	azar.	Cuatro	contactos	en	la	Rama	PT	y	
dos	en	la	Rama	PT/QFT-GIT	desarrollaron	tuberculosis.	En	el	análisis	por	intención	de	
tratar	modificado,	 la	 incidencia	de	TB	 fue	0.99%	en	 la	Rama	PT	 y	0.51%	en	 la	Rama	
PT/QFT-GIT	 (diferencia	-0.48%,	 intervalo	de	confianza	del	97.5%	[IC],	 -0-90%–1.86%);	
En	el	análisis	por	protocolo,	las	tasas	correspondientes	fueron	de	1.67%	y	0.82%	en	las	
Ramas	PT	y	PT/QFT-GIT	respectivamente	(diferencia	-0.85%;	97.5%	IC	-1.43%	–3.14%).	
De	 los	792	contactos	analizados	en	el	 análisis	por	 intención	de	 tratar	modificado,	 la	
proporción	de	diagnósticos	de	ITL	fue	de	65.3%	en	la	Rama	PT	y	de	42.2%	en	la	Rama	
PT/QFT-GIT	(diferencia	23.1%;	97.5%	IC	16.4%	–30.0%).	
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DISCUSIÓN	
En	los	países	de	baja	incidencia	de	TB,	la	principal	contribución	a	la	estrategia	“End	TB”	
propuesta	por	la	OMS	en	2015	consiste	en	el	diagnóstico	y	tratamiento	de	los	sujetos	
sanos	con	mayor	riesgo	de	desarrollar	tuberculosis	activa.		
Desafortunadamente,	hasta	el	momento	actual,	las	pruebas	diagnósticas	de	ITL	no	son	
lo	suficientemente	precisas	para	seleccionar	qué	individuos	sanos	son	los	que	tienen	
mayor	riesgo	de	desarrollar	tuberculosis	activa.	Existen	unos	factores	de	riesgo	claros	
para	la	reactivación	de	TB,	pero	no	todos	los	individuos	de	esos	grupos	desarrollarán	
TB	aunque	no	reciban	tratamiento	preventivo.	Es	más,	incluso	pautando	tratamiento	a	
todos	 los	 individuos	 en	 riesgo	 no	 se	 podría	 hablar	 de	 ausencia	 de	 riesgo	 para	 el	
desarrollo	posterior	de	tuberculosis.		
El	 manejo	 global	 de	 la	 ITL	 no	 incluye	 únicamente	 el	 diagnóstico.	 Son	 necesarios	 la	
educación	 sanitaria	 y	 el	 control	 de	 la	 adherencia	 y	 los	 efectos	 secundarios	 del	
tratamiento	 para	 asegurar	 el	 éxito	 de	 la	 estrategia	 preventiva.	 Los	 tratamientos	
actualmente	 disponibles	 son	 largos,	 no	 libres	 de	 efectos	 secundarios	 y	 requieren	
controles	 periódicos	 para	 la	 seguridad	 del	 paciente.	 Si	 bien	 se	 están	 investigando	
regímenes	menos	tóxicos,	aprovechar	al	máximo	las	pruebas	diagnósticas	disponibles	
puede	mejorar	la	estrategia	de	prevención	de	TB	activa.		
El	 objetivo	 de	 esta	 tesis	 es	 optimizar	 las	 estrategias	 de	 diagnóstico	 de	 ITL	 en	 dos	
grupos	de	 riesgo:	 los	 individuos	 inmunosuprimidos	en	 los	que	 interesa	maximizar	 la	
sensibilidad	 del	 proceso	 diagnóstico,	 y	 los	 sujetos	 sanos	 después	 de	 una	 exposición	
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reciente	a	Mtb,	en	 los	que	 se	prefiere	mejorar	 la	especificidad	de	 las	pruebas	hasta	
ahora	disponibles.		
En	cuanto	a	 los	grupos	con	deterioro	del	sistema	 inmunitario,	el	estudio	que	recoge	
nuestra	experiencia	en	la	estrategia	de	prevención	de	la	TB	relacionada	con	el	uso	de	
agentes	anti-TNF	ha	proporcionado	tres	resultados	principales:	la	demostración	de	su	
eficacia	sin	poder	anular	por	completo	el	riesgo	de	TB	en	el	primer	año	de	tratamiento	
y	la	evidencia	que	apoya	la	retirada	del	booster	y	la	repetición	sistemática	del	cribado	
de	ITL	tras	un	primer	resultado	negativo.		
A	 pesar	 de	 que	 las	 guías	 españolas	 siguen	 recomendando	 el	 uso	 de	 la	 PT	 en	 dos	
tiempos	 buscando	 el	 “efecto	 booster”,	 nuestros	 resultados	 han	 mostrado	 una	
asociación	 independiente	entre	 la	 vacunación	con	BCG	y	un	 resultado	positivo	de	 la	
segunda	PT,	así	como	con	los	resultados	discordantes	(PT	positiva/	QFT-GIT	negativo),	
sugiriendo	 ambos	 datos	 que	 en	 los	 individuos	 vacunados	 con	 BCG,	 esta	 práctica	
aumenta	el	número	de	diagnósticos	de	 ITL	a	costa	de	 resultados	 falsos	positivos.	En	
nuestro	 estudio,	 la	 retirada	 de	 la	 PT	 en	 dos	 tiempos	 se	 asoció	 con	 una	 reducción	
significativa	del	número	de	diagnósticos	de	ITL	en	comparación	con	el	periodo	que	la	
incluía,	sin	suponer	un	amento	de	riesgo	de	desarrollo	de	TB	posterior.	
En	nuestra	cohorte	no	se	repitió	de	manera	sistemática	el	cribado	en	pacientes	con	un	
resultado	negativo	inicial.	Los	dos	años	de	seguimiento	de	la	cohorte	han	demostrado	
la	seguridad	de	este	protocolo.	Nuestra	recomendación	es	la	de	repetir	el	cribado	en	
caso	 de	 existir	 una	 exposición	 a	 un	 caso	 de	 TB,	 y	 educar	 a	 los	 pacientes	 en	 buscar	
atención	médica	en	caso	de	presentar	fiebre	o	cualquier	otro	síntoma	sistémico.	Los	
casos	de	TB	activa	que	obtuvimos	en	nuestra	cohorte,	se	presentaron	antes	del	año	de	
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la	primera	 valoración,	por	 lo	 tanto	no	 se	hubiesen	podido	detectar	 incluso	 con	esta	
estrategia	supuestamente	más	segura	y	que	reiteradamente	se	plantea	en	los	foros	de	
facultativos	 tratantes	 de	 patologías	 que	 requieren	 agentes	 anti-TNF.	 Esta	 cuestión,	
compartida	por	clínicos	de	diferentes	especialidades,	no	había	tenido	respuesta	en	la	
literatura	hasta	ahora.		
En	 cuanto	 al	 segundo	 grupo	 de	 pacientes	 inmunosuprimidos,	 los	 candidatos	 a	
trasplante	 hepático	 y	 de	 progenitores	 hematopoyéticos,	 nuestra	 cohorte	 aporta	 los	
datos	 se	 seguimiento	 que	permiten	 calcular	 los	 valores	 predictivos	 de	 PT	 y	QFT-GIT	
para	el	desarrollo	de	TB.	Nuestros	resultados	se	suman	a	la	evidencia	de	que	los	IGRA	
son	 pobres	 en	 predecir	 el	 desarrollo	 de	 la	 tuberculosis	 activa	 en	 los	 receptores	 de	
trasplante,	 de	 manera	 similar	 a	 los	 resultados	 reportados	 en	 cuatro	 cohortes	 de	
pacientes	trasplantados	en	el	momento	de	la	publicación	de	este	original.	
Por	 lo	 que	 hace	 a	 las	 personas	 recientemente	 expuestas	 a	 un	 caso	 activo	 de	
tuberculosis,	 se	 ha	 confirmado	 la	 hipótesis	 de	 partida	 de	 este	 proyecto:	 la	
introducción	de	QFT-GIT	en	el	cribado	de	pacientes	en	riesgo	de	desarrollar	TB	activa	
permite	 una	 reducción	 significativa	 de	 los	 tratamientos	 preventivos	 sin	 suponer	 un	
aumento	 de	 riesgo	 de	 TB	 ulterior.	 La	 hipótesis	 se	 ha	 confirmado	 en	 nuestra	 propia	
experiencia	 (estudio	 longitudinal)	 y	 con	 el	 máximo	 grado	 de	 evidencia	mediante	 el	
Ensayo	 clínico	 “OPTIMIST”.	 Ambos	 estudios	 han	mostrado	 además	 una	 alta	 tasa	 de	
compleción	del	tratamiento	(>80%).	Nuestra	experiencia	confirma	que	estas	tasas	son	
posibles	cuando	personal	bien	capacitado	 imparte	educación	sanitaria	 integral	sobre	
el	tratamiento	y	su	toxicidad.		
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Por	 primera	 vez,	 un	 ensayo	 clínico	 controlado	 ha	 confirmado	 el	 beneficio	 de	 la	
inclusión	 de	 los	 IGRAs	 en	 el	 estudio	 de	 contactos	 adultos	 de	 pacientes	 con	 TB	 un	
entorno	 de	 baja	 incidencia.	 El	 beneficio	 estriba	 en	 evitar	 tratamientos	 preventivos	
innecesarios	 (PT	positiva	y	QFT	negativo)	a	pacientes	que	han	demostrado	muy	bajo	
riesgo	de	desarrollo	ulterior	de	TB.	El	ahorro	de	diagnósticos	se	ha	ratificado	no	sólo	
en	 los	 contactos	 vacunados:	 en	 el	 grupo	 de	 los	 no	 vacunados	 y	 en	 los	 contactos	
valorados	 como	 de	 máximo	 riesgo	 (contactos	 íntimos	 de	 pacientes	 bacilíferos	 con	
cavitación	 en	 la	 radiografía	 de	 tórax)	 también	 se	 ha	 conseguido	 una	 reducción	
significativa	de	diagnósticos	con	la	estrategia	secuencial.		
Aunque	 algunas	 sociedades	 e	 instituciones	 ya	 han	 implementado	 los	 IGRAs	 en	 su	
práctica	 cotidiana,	 las	 guías	 nacionales	 no	 los	 han	 incluido	 hasta	 el	 momento,	 en	
ausencia	de	evidencia	firme	de	su	beneficio	y	su	mayor	coste	económico	por	unidad	
de	 test	diagnóstico.	El	 ahorro	de	prácticamente	el	25%	de	 los	 tratamientos,	 con	 sus	
controles,	 potenciales	 toxicidades	 y	 costes	 indirectos	 de	 su	 indicación	 supera	 con	
creces	la	diferencia	económica	de	ambas	pruebas.	
Varias	 preguntas	 quedan	 pendientes	 de	 respuesta.	 El	 estudio	 coste-efectividad	 es	
necesario	 antes	 de	 implementar	 cualquier	 estrategia.	 Se	 necesitarán	 otros	 ensayos	
clínicos	 que	 comparen	 los	 resultados	 a	 largo	 plazo	 de	 decisiones	 basadas	 en	 el	
resultado	 de	 los	 IGRAs	 en	 otros	 grupos	 de	 riesgo.	 Los	 países	 con	 perfiles	
epidemiológicos	diferentes	necesitarán	sus	propios	ensayos	para	determinar	la	mejor	
estrategia	en	términos	de	eficacia	y	rentabilidad.	Por	otra	parte,	la	nueva	generación	
de	 QFT-GIT	 (Plus)	 y	 de	 tuberculina	 específica	 (C-tb)	 suponen	 un	 aumento	 de	 las	
posibilidades	diagnósticas	 respecto	a	 los	años	del	 inicio	de	esta	 tesis	doctoral.	 Estas	
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nuevas	técnicas	deberán	ser	probadas	en	las	poblaciones	de	alto	riesgo,	no	sólo	para	
comparar	 sus	 resultados	 con	 los	 de	 PT	 e	 IGRAs	 “tradicionales”,	 sino	 para	 tomar	
decisiones	basadas	en	sus	resultados	y	calcular	la	incidencia	de	TB	ulterior.	Disminuir	
la	 posibilidad	 de	 desarrollar	 tuberculosis,	 reducirá	 el	 número	 de	 enfermos,	 y	 por	
tanto,	de	contagios.	Con	esta	estrategia	se	pretende,	además	de	la	mejora	individual	
de	los	sujetos,	obtener	beneficios	en	términos	de	salud	pública.		
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CONCLUSIONES	
	
Los	resultados	de	estos	estudios	proporcionan	evidencia	firme	sobre	los	beneficios	de	
incluir	 los	 IGRA	 en	 el	 proceso	 de	 selección	 de	 los	 sujetos	 que	 se	 más	 se	 pueden	
beneficiar	del	tratamiento	preventivo	para	el	desarrollo	de	TB,	dentro	del	conjunto	de	
las	poblaciones	en	riesgo	de	enfermar.		
1. En		cuanto	a	los	pacientes	candidatos	a	recibir	agentes	anti-TNF,		
1.1. La	 incidencia	 de	 tuberculosis	 asociada	 a	 estos	 tratamientos	 puede	 reducirse	
en	 gran	 medida	 a	 través	 de	 un	 protocolo	 sistemático	 de	 despistaje	 de	
infección	tuberculosa	latente,	sin	poder	eliminar	completamente	el	riesgo	de	
TB,	sobre	todo	en	el	primer	año	de	anti-TNF.	
1.2. La	estrategia	de	prueba	de	 la	 tuberculina	en	dos	pasos	 supone	un	aumento	
sustancial	 en	 la	 proporción	 de	 diagnósticos	 y	 tratamientos	 de	 infección	
tuberculosa,	 sin	 que	 ello	 modifique	 la	 incidencia	 de	 tuberculosis	 activa	
posterior.	Esta	práctica,	por	 tanto	no	está	 justificada,	a	pesar	de	que	conste	
todavía	como	parte	de	las	recomendaciones	actuales	en	nuestro	país.	
1.3. No	 se	 requiere	 la	 repetición	 periódica	 y	 sistemática	 de	 las	 pruebas	
diagnósticas	 de	 infección	 tuberculosa	 latente	 si	 éstas	 han	 sido	 negativas	 al	
inicio.		
2. En	 cuanto	 a	 los	 receptores	 de	 trasplante	 hepático	 y	 de	 progenitores	
hematopoyéticos,	el	valor	predictivo	positivo	de	QFT-GIT	es	bajo,	y	comparable	al	
de	la	prueba	de	la	tuberculina.	Por	tanto,	la	elección	de	una	u	otra	técnica	deberá	
fundamentarse	 en	 la	 especificidad	 esperada	 en	 cada	 entorno,	 factores	
operacionales	y	logísticos,	económicos	y	en	las	preferencias	de	los	pacientes.	
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3. Por	 último,	 en	 individuos	 adultos	 sanos	 con	 exposición	 reciente	 a	 un	 caso	
tuberculosis	 activa	 en	 un	 entorno	 de	 baja	 incidencia	 de	 TB,	 el	 uso	 de	
QuantiFERON®-TB	 Gold	 In-Tube	 para	 confirmar	 los	 resultados	 positivos	 de	 la	
prueba	de	la	tuberculina,	permite	una	reducción	significativa	de	los	diagnósticos	y	
tratamientos	 de	 infección	 tuberculosa,	 sin	 aumentar	 el	 riesgo	 posterior	 de	
enfermedad	activa.	
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AFB	 Acid-Fast	Bacilli	
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1.	TUBERCULOSIS:	MAGNITUDE	OF	THE	PROBLEM		
Tuberculosis	(TB)	is	one	of	the	most	ancient	and	devastating	diseases,	yet	it	still	represents	a	
global	 health	 challenge.	 The	 last	 World	 Health	 Organisation	 (WHO)	 Global	 tuberculosis	
report	 estimated	 that	 in	 2014,	 9.6	million	 people	 had	 fallen	 ill	with	 tuberculosis,	 and	 1.5	
million	people	had	died.1	Alongside	with	HIV,	tuberculosis	ranks	as	a	leading	cause	of	death	
worldwide.	The	risk	of	contracting	and	dying	of	tuberculosis	is	not	uniform	around	the	globe,	
with	 maps	 of	 high-incidence	 countries	 showing	 the	 same	 tendencies	 of	 poverty	 and	
overcrowding.	
	
	
Global	 efforts	 to	 control	 tuberculosis	 were	 reinvigorated	 in	 1991,	 when	 a	 World	 Health	
Assembly	 resolution	 recognised	TB	as	a	major	global	public	health	problem	 in	 the	 light	of	
the	AIDS	pandemic:	“Noting	with	concern	that	the	current	strategy	for	tuberculosis	control	
has	begun	to	lose	its	effectiveness	in	the	industrialized	countries,	and	that	in	these	countries	
Figure	1.	Estimated	tuberculosis	incidence	rates	in	2014.		
Extracted	from	WHO	Global	tuberculosis	report.	Geneva,	2015.	
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the	 declining	 trend	 of	 incidence	 has	 either	 slowed	 down	 or	 been	 reversed”.2	 For	 the	 past	
decade,	 the	 Stop	 TB	 Strategy,3	 developed	 for	 the	 period	 2006–2015,	 was	 WHO’s	
recommended	approach	to	achieving	global	targets	for	reductions	in	the	occurrence	of	the	
tuberculosis	 disease.	 These	 targets	 aimed	 to	 halt	 and	 begin	 to	 reverse	 the	 incidence	 of	
tuberculosis	 by	 2015,	 and	 to	 reduce	 prevalence	 and	 death	 due	 to	 tuberculosis	 by	 50%	
compared	to	a	baseline	of	1990.	Such	targets	were	achieved	on	time	globally	and	in	16	of	
the	22	high	TB	burden	countries.	
As	for	incidence,	the	rate	has	fallen	at	an	average	rate	of	1.5%	per	year	since	2000.	Globally,	
the	mortality	rate	in	2015	was	47%	lower	than	in	1990:	the	target	of	a	50%	reduction	was	
almost	met.	Globally,	the	tuberculosis	prevalence	rate	in	2015	was	42%	lower	than	in	1990.	
Particularly	in	the	European	region,	the	absolute	number	of	incident	cases	is	slowly	falling,	
at	an	average	rate	of	3%	per	year	 (2009-2015).1	Spain	notified	5,018	tuberculosis	cases	 in	
2014,	 equivalent	 to	 10.8	 cases	 per	 100,000	 population.	 This	 rate	 is	 10%	 lower	 than	 the	
previous	year	-12.04	cases	per	100,000-.4	
	
	
	
								Pulmonary	TB		
								Meningeal	TB	
								Other	forms	of	active	TB		
	
The	 dark	 black	 line	 shows	 the	
evolution	 of	 the	 incidence	 rate	
in	the	last	years.	
Figure	 2.	 Tuberculosis	 Incidence	 rates	 expressed	 in	 cases	 per	 100,000	 population.	
Extracted	from	the	Epidemiologic	report	of	tuberculosis	in	Spain,	2014.4	
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The	year	2015	was	a	watershed	moment	 in	 the	battle	against	 tuberculosis.	 It	marked	 the	
deadline	for	global	targets	set	in	2006,	and	the	transition	from	the	Stop	TB	Strategy	to	the	
End	TB	Strategy.	From	2016	onward,	the	goal	is	to	end	the	global	tuberculosis	epidemic	by	
implementing	the	End	TB	Strategy	by	means	of	reducing	the	number	of	tuberculosis	deaths	
by	90%	by	2030	(compared	to	2015	levels)	and	reduce	the	number	of	new	cases	by	80%.5	
	
2.	TUBERCULOSIS:	THE	FIGHT	AGAINST	THE	EPIDEMIC	
2.1.	From	Koch’s	fluid	to	modern	chemotherapy		
Soon	 after	 the	 discovery	 of	Mycobacterium	 tuberculosis	 (Mtb)	 as	 the	 causative	 agent	 of	
tuberculosis	 in	 1882,	 Robert	 Koch	 created	 Koch’s	 fluid	 (“a	 glycerin	 extract	 of	 pure	
cultivations	of	tubercle	bacilli”,6	for	use	as	a	live	vaccine;	 it	turned	out	to	be	an	ineffective	
preventive	agent.	Koch´s	fluid,	which	was	given	the	name	of	tuberculin,	later	proved	to	be	a	
valuable	 diagnostic	 tool	 for	 active	 tuberculosis	 in	 cattle.	 Koch	 fluid	 experiments	 on	 cattle	
showed	 that	 some	 cows	 developed	 a	 febrile	 reaction	 14-18	 hours	 after	 tuberculin	
administration.7,8	 Although	 apparently	 healthy,	 reactive	 cattle	were	 slaughtered;	 some	 of	
the	 necropsies	 revealed	 active	 tubercles,	while	 others	 showed	 no	 active	 disease.	 Positive	
reactions	 in	 cattle	without	 tubercles	were	attributed	 to	dormant	Mtb	bacilli,	 as	quiescent	
tuberculous	foci	were	identified	in	some	of	the	necropsies.8	
The	 first	 attempts	 to	 use	 tuberculin	 in	 humans	 caused	 highly	 symptomatic	 reactions	 that	
hampered	 further	 investigation.9	 However,	 description	 of	 a	 new	 technique	 to	 administer	
tuberculin	 (the	“tuberculin	skin	 test”	 (TST))	by	Charles	Mantoux	 in	1908,	 together	with	 its	
improved	composition	in	1934	(purified	protein	derivative	(PPD)),	made	its	use	as	a	human	
diagnostic	 method	 possible,	 as	 systemic	 reactions	 were	 not	 observed	 in	 tested	 subjects;	
positive	responders	showed	only	an	induration	of	the	skin	where	the	intradermal	injection	
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had	been	administered.10	The	 first	 trials,	which	tested	tuberculin	on	tuberculosis	patients,	
also	showed	positive	results	in	healthy	controls.	It	was	at	this	time	that	the	notion	of	latent	
bacteria	or	bacillary	allergy	emerged.11	
In	 the	pre-antibiotic	era	of	 sanatoriums,	bed	rest	and	physical	 interventions	were	used	 to	
treat	 tuberculosis.12	 The	 most	 common	 surgical	 procedure	 consisted	 of	 therapeutic	
pneumothorax:	collapsing	an	infected	lung	to	“rest”	and	favour	the	healing	process.13	
In	1944	Albert	Schatz,	Elizabeth	Bugie,	and	Selman	Waksman	isolated	Streptomyces	griseus	
or	 streptomycin,	 the	 first	 antibiotic	 and	 first	 bacterial	 agent	 effective	 against	Mtb.14	 This	
discovery	is	generally	considered	the	beginning	of	the	modern	era	of	TB,	although	the	true	
revolution	began	some	years	later,	in	1952,	with	the	development	of	isoniazid,	the	first	oral	
mycobactericidal	drug.15	The	advent	of	rifampicin	in	the	1970s	shortened	recovery	times,16	
and	significantly	reduced	the	number	of	tuberculosis	cases	until	the	1980s.	Since	1976	there	
have	 been	 no	 changes	 in	 the	 short-course	 chemotherapy	 for	 pan-susceptible	 organisms,	
comprising	 two	 months	 of	 a	 quadruple	 regimen	 (isoniazid,	 rifampicin,	 pyrazinamide	 and	
ethambutol),	followed	by	four	months	of	isoniazid	and	rifampicin.17	During	the	last	decade,	
the	 emergence	 of	 resistant	 TB	 encouraged	 the	 development	 of	 new	drugs,	 new	dosages,	
and	new	indications	and	combinations	of	drugs.18	Several	bactericidal	drugs	were	found	to	
have	anti-mycobacterial	effects,	such	as	quinolones	and	linezolid,	which	are	now	included	as	
part	of	regimens	that	cannot	rely	upon	isoniazid	and	rifampicin.19	Current	trials	are	looking	
at	 shortening	 therapy	 for	 pan-susceptible	 strains	 from	 six	 to	 four	months	 by	 substituting	
rifapentine	 for	 rifampicin,20	 using	 high-dose	 rifapentine21	 and	 switching	 ethambutol	 for	
moxifloxacin,22	 or	 isoniazid	 for	 moxifloxacin.23	 As	 for	 multi-drug	 resistant	 (MDR)	 and	
extremely	 resistant	 (XDR)	 strains,	 bedaquilin24	 and	 delamanid25	 have	 been	 recently	
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introduced	as	highly	effective	anti-tuberculous	drugs.	Currently	several	molecules	are	in	the	
pre-clinical	development	phase,	e.g.	Pretomanid	(PA-824),	Sutezolid	(PNU-100480),	SQ109,	
and	benzothiazinones	(BTZ043).26	
As	for	preventive	purposes,	the	twentieth	century	saw	the	introduction	of	several	successful	
vaccines,	 and	 great	 expectations	 for	 an	 effective	 preparation	 against	 TB	 arose.	 In	 1902	
Behring	proposed	to	utilize	the	bacillus	isolated	from	humans	for	the	vaccination	of	cows.27	
Calmette	and	Guérin	passaged	Mycobacterium	bovis,	which	has	similar	antigenic	properties	
to	the	virulent	M.	tuberculosis	bacilli	and	the	ability	to	provoke	antibody	formation	in	man,	
to	 obtain	 the	 attenuated	 Bacillus	 Calmette-Guérin	 (BCG)	 strain.28	 The	 immunological	
responses	to	M.	bovis	and	M.	tuberculosis	are	very	similar,	allowing	the	effective	use	of	BCG	
as	a	vaccine	and	tuberculin	as	a	diagnostic	reagent.	The	significance	of	BCG	vaccination	for	
the	evaluation	of	TST	reactions	lies	in	this	relation.29	BCG	was	successfully	tested	in	infants	
exposed	to	family	cases	of	tuberculosis,	and	although	not	wholly	protective,	BCG	proved	to	
reduce	 the	 incidence	 of	 disseminated	 TB	 disease	 in	 infants	 and	 subsequently	 reduced	
mortality.10	
To	 accomplish	 the	 goals	 of	 the	End	 TB	 Strategy	 there	 is	 a	 need	 to	 either	 develop	 a	 new	
vaccine	for	TB	or	to	enhance	the	efficacy	of	BCG,	the	only	licensed	TB	vaccine	product	in	the	
world.	 There	are	15	TB	vaccines	 in	 clinical	 trials	by	now10	and	 these	employ	one	of	 three	
strategies:	 pre-exposure	 vaccines	 similar	 to	 BCG,	 a	 prime-boost	 strategy	 that	 seeks	 to	
augment	 BCG-vaccinated	 infants	 and	 children,	 and	 a	 therapeutic	 vaccine	 that	 enhances	
medical	therapy.30	
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2.2.	Treatment	of	latent	tuberculosis	infection	as	a	measure	of	tuberculosis	control	
	
Soon	after	the	discovery	of	streptomycin	and	 isoniazid	 for	active	TB,	 the	first	experiments	
using	 isoniazid	 as	 a	 preventive	 treatment	 in	 an	 animal	 model	 were	 undertaken.31	 Initial	
clinical	trials	in	humans	began	in	1957,	with	results	reported	in	the	mid-sixties,	showing	the	
benefits	of	isoniazid	in	preventing	active	TB.32–36	
The	management	of	latent	tuberculosis	infection	(LTBI)	is	viewed	as	a	critical	component	of	
the	new	post-2015	End	TB	Strategy,	and	is	one	of	the	interventions	that	can	help	countries	
to	achieve	the	ambitious	targets	of	a	90%	reduction	in	the	tuberculosis	incidence	rate	and	a	
95%	reduction	in	deaths	by	2035,	compared	to	2015	levels.1	It	is	estimated	that	one	third	of	
the	world’s	 population	 is	 latently	 infected	with	Mtb37,	meaning	 that	 LTBI	 individuals	 as	 a	
group	constitute	a	huge	reservoir	for	future	cases	of	tuberculosis.	However,	given	the	10%	
progression	 rate,	 clinical	and	public	health	services	must	primarily	 focus	 their	energies	on	
groups	 at	 a	 higher	 risk	 of	 disease.	 To	 this	 effect,	 the	 WHO	 issued	 guidelines	 on	 the	
management	 of	 LTBI	 for	 upper-middle	 and	 high-income	 countries	 with	 an	 estimated	
incidence	rate	of	less	than	100	per	100,000	population.38	Preventive	treatment	of	persons	at	
high	 risk	 (people	 living	 with	 HIV,	 adult	 as	 well	 as	 child	 contacts	 of	 pulmonary	 TB	 cases,	
patients	 initiating	 anti-tumour	 necrosis	 factor	 (TNF)	 treatment	 and	 transplant	 recipients)	
has	been	included,	for	the	first	time,	as	one	of	the	four	integrated,	patient-centred	care	and	
prevention	components	of	the	End	TB	Strategy	for	the	years	2016-2035.	
2.2.1.	Natural	history	of	tuberculosis.	Latent	tuberculosis	infection		
The	most	important	reservoir	of	Mtb	is	humans,	while	cattle	are	the	equivalent	host	for	M.	
bovis.	 Zoonotic	 transmission	 of	 M.	 bovis	 was	 frequent	 in	 ancient	 times;39	 however,	
pasteurization	 of	milk	 and	 the	 testing	 of	 herds	 decreased	 the	 public	 health	 impact	 of	M.	
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bovis	 in	 humans	 in	 wealthy	 countries.40	 There	 are	 many	 developing	 countries	 in	 which	
zoonotic	 transmission	 is	 still	 observed.41	Humans	with	 active	pulmonary	disease	 currently	
play	 the	 dominant	 role	 in	 the	 transmission	 and	 maintenance	 of	 tuberculosis.	 Studies	 by	
Flügge	 in	 1899	 showed	 that	 both	 dried	 tuberculous	 sputum	 dust	 and	 the	 minute	 drops	
coughed	out	by	pulmonary	tuberculosis	patients	were	capable	of	surviving	for	several	days	
while	 remaining	 infectious.42	 These	 tiny	 particles	 containing	 tubercle	 bacilli	 -known	 as	
droplet	nuclei-,	are	easily	 inhaled,	and	constitute	the	route	of	entry	and	first	contact	with	
the	healthy	subject.	Upon	inhalation,	Mtb	reaches	the	main	airway	and	alveoli	and	faces	the	
first	cell-mediated	barrier	of	the	innate	immune	system.	Adaptive	immunity,	however,	can	
take	 as	 long	 as	 42	 days	 after	Mtb	 exposure	 and	 infection	 to	 be	 established.43–45	 Alveolar	
macrophages	 phagocytose	 the	 pathogen	 and	 isolate	 it	 through	 a	 process	 of	 membrane	
invaginations	 that	 finally	 culminates	 in	 phagosome	 formation.	 From	 this	 point,	 infected	
macrophages	and	dendritic	cells	display	Mtb	antigens	via	major	histocompatibility	complex	
(MHC)	 class	 II	 molecules.	 These	 professional	 antigen-presenting	 cells	 expressing	 Mtb	
molecules	travel	to	the	lymph	system	and	then	into	local	mediastinal	 lymph	nodes,	where	
they	will	activate	CD4+	T-helper	cells	(TH).46	Reaching	the	lymph	system	allows	the	dispersal	
of	 infection,	 particularly	 to	well-oxygenated	 areas	 such	 as	 lung	 apices,	 suprarenal	 glands,	
the	 brain	 cortex,	 and	 bone	 and	 growing	 joints.	 From	 two	 to	 four	 weeks	 after	 the	 first	
encounter	between	bacteria	of	the	Mycobacterium	tuberculosis	complex	and	macrophages,	
the	 human	 host	 prepares	 two	 types	 of	 response.47	 The	 first	 is	 a	 delayed-type	
hypersensitivity	 to	 tubercle	bacilli,	which	 is	 tissue	damaging	as	 it	promotes	destruction	of	
non-activated	macrophages	 containing	 proliferating	Mycobacterium.	 The	 second	 is	 a	 cell-
mediated	 response,	 which	 activates	 macrophages	 to	 kill	 bacteria.	 There	 is	 a	 dynamic	
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equilibrium	 between	 these	 two	 responses,	 which	 can	 lead	 to	 either	 TB	 progression	 or	
containment	of	Mtb.48	
Lymphocytes	TH	response	regulate	 the	secretion	of	cytokines	via	endocrine	and	paracrine	
signalling,	 inducing	 a	 localized	pro-inflammatory	 response	 that	 attracts	mononuclear	 cells	
and	T	 lymphocytes	 to	build	up	a	granuloma	“the	hallmark	 tissue	reaction	of	TB”.49	At	 this	
point	 a	 large	number	of	 activated	macrophages	 are	 recruited	 to	 the	 site	 of	 infection	 and	
construct	 the	 granuloma,	 to	 which	 lymphocytes,	 epithelioid	 and	 giant	 cells	 are	 also	
attracted.	By	depriving	the	centre	of	the	granuloma	of	oxygen	and	lowering	the	pH,	necrosis	
occurs	internally,	preventing	bacterial	replication,	but	enabling	dormancy.50	
Asymptomatic	people	considered	to	have	latent	TB	might	be	better	considered	as	part	of	a	
spectrum	of	infection	states	where	at	one	end	infection	may	have	been	eliminated,	while	at	
the	 other	 end	 dis-ease	may	 be	 active	 but	 in	 a	 subclinical	 form,	 and	 between	 these	 two	
extremes	 infection	 is	 controlled	 in	 a	 quiescent	 state.51	Of	 all	 asymptomatic	 subjects,	 only	
about	10%	of	infected	individuals	develop	active	disease;52	most	of	them	will	progress	in	the	
first	two	years	after	exposure.37,53	The	rest	will	reactivate	from	a	latent	stage,	usually	due	to	
a	 failure	of	 the	host	 immune	response.	There	are	two	main	factors	 in	the	maintenance	of	
health	or	development	of	active	disease,	those	depending	on	the	Mtb	and	those	depending	
on	the	host.54	M.	tuberculosis	has	a	series	of	tools	to	enable	survival	inside	the	human	host.	
First,	 a	 unique	 cell	wall	structure	 with	 high	lipid	content	protects	 the	 bacterium	 from	 the	
highly	acidic	pH	of	the	phagosome.	Second,	it	is	able	to	arrest	phagosome-lysosome	fusion.	
Third,	it	interferes	in	antigen	presentation	as	well	as	in	the	normal	function	of	CD8+	T-cells,	
natural	killer	cells	and	the	complement	attack	complex.	Fourth,	Mtb	can	resist	host-derived	
antimicrobial	 substances	 (reactive	 nitrogen	 and	 oxygen	 intermediates).47,49	 As	 described	
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above,	the	human	immune	response	against	Mtb	includes	both	the	innate	defence	system	
(macrophage	and	natural	killer	cells,	complement	activation,	ciliary	clearance	and	secretions	
of	 the	 main	 airways)	 and	 the	 adaptive	 response,	 comprising	 both	 cellular	 and	 humoral	
immunity.	T-cells	are	the	main	component	of	the	cellular	response	that	provides	protection	
against	tuberculosis	and	promotes	memory	response	and	granuloma	formation.49		
The	main	benefit	 of	 the	 adaptive	 response	 is	 the	presence	of	 immunological	memory,	 so	
that	a	copy	of	each	antigen	found	is	stored	in	memory	T-cells	and	will	 lead	to	a	rapid	and	
enhanced	response	to	subsequent	encounters	with	that	same	antigen.10	This	is	the	basis	for	
the	 TST;	 a	 delayed-type	 hypersensitivity	 reaction	 caused	 by	 cytokines	 released	 from	
previously	 sensitized	 T-cells	 when	 they	 are	 exposed	 to	 PPD	 antigens.	 Although	
hypersensitivity	 is	 linked	 to	 protective	 immunity,	 protection	 is	 not	 complete.	 Different	
studies	 have	 shown	 that	 TST-positive	 reactors	 are	 less	 likely	 to	 be	 re-infected	 than	 non-
responders,53,55	but	there	is	no	way	to	prevent	reactivation	without	specific	treatment.	
LTBI	is	defined	by	the	detection	of	a	specific	immune	response	to	Mtb	antigens	in	a	healthy	
subject	 (i.e.	 with	 no	 symptoms	 or	 signs	 of	 active	 disease).56	 Although	 LTBI	 represents	 a	
heterogeneous	condition,	with	a	complex	spectrum	of	metabolic	and	physiologic	states	for	
both	the	host	and	Mtb,57	the	dichotomous	distinction	between	the	active	and	latent	stages	
of	 tuberculosis	 allows	 for	 a	 more	 pragmatic	 and	 approachable	 understanding	 of	 clinical	
decision-making.51	
As	Mtb	can	only	be	isolated	from	humans	when	it	is	causing	illness,	i.e.	in	an	active	phase,	
the	detection	of	the	latent	form	of	tuberculosis	is	wholly	reliant	on	indirect	measurements	
of	 immune	 reactivity	 to	 antigenic	 challenge.	No	 culture	 is	 achievable	 in	 the	 latent	 phase;	
thus,	 there	 is	 no	 gold	 standard	 for	 its	 diagnosis.	 Since	 the	 first	 trials	 on	 isoniazid	
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effectiveness,	positive	reactors	to	TST	were	considered	at	a	high	risk	of	progression	to	active	
TB,	 as	 all	 active	 tuberculosis	 cases	 emerged	 in	 the	 follow-up	 period	 of	 positive	 TST	
individuals.58	It	was	not	the	deep	understanding	of	immune	reactions	that	mattered;	it	was	
the	division	between	two	categories	of	risk	(positive	TST	reactors)	and	low	risk	(negative	TST	
responders)	 for	 the	development	of	 active	 tuberculosis.	 Those	 trials	 showed	 that	positive	
reactors	 who	 received	 preventive	 therapy	 suffered	 an	 equal	 risk	 of	 subsequent	
development	of	tuberculosis	to	individuals	who	were	TST	negative	at	baseline.58	
Progression	 from	 latent	 to	 active	 tuberculosis	 can	 be	 prevented	 with	 antibiotic	
treatment;59–61	the	duration	of	global	standard	regimens	is	six	to	nine	months	with	a	single	
drug,	 or	 at	 least	 three	months	with	 two	 antibiotics.60	 Given	 the	 small	 proportion	 of	 LTBI	
positive	individuals	who	develop	the	active	disease,	the	intrinsic	difficulties	in	LTBI	diagnosis,	
the	length	of	the	treatment,	and	its	associated	side	effects,	the	critical	question	is	therefore:	
who	should	be	targeted	for	treatment?	This	question	is	pertinent	because	none	of	the	tests	
currently	 available	 for	 diagnosing	 latent	 infection	 are	 able	 to	 accurately	 predict	 future	
progression	to	active	tuberculosis.62–65	It	is	widely	recognised	that	the	risk	of	progression	is	
highest	 in	 young	 children,52,66,67	 the	 immunosuppressed,68	 and	 shortly	 after	 infection.69	
Pragmatically,	 therefore,	 these	 individuals	 should	 be	 targeted	 for	 LTBI	 screening	 and	
treatment.		
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2.2.2.	Diagnosis	of	latent	tuberculosis	infection:	From	TST	to	the	Interferon-gamma	
Release	Assays		
As	stated	above,	there	is	no	way	to	directly	diagnose	LTBI,	as	Mtb	cannot	be	recovered	from	
the	 host	 unless	 active	 tuberculosis	 is	 present.	 An	 indirect	 immunological	 assessment	 of	
exposure	 is	 made	 instead,	 by	 ascertaining	 the	 reactivity	 of	 host	 lymphocytes	 to	
mycobacterial	antigens,	either	by	testing	the	 in	vivo	response	with	the	TST	or	 in	vitro	with	
interferon-γ	Release	Assays	(IGRAs).	
The	TST	consists	of	an	intradermal	injection	of	tuberculin.	Although	a	variety	of	approaches	
have	been	used,	the	Mantoux	technique,	which	is	administered	on	the	inner	surface	of	the	
forearm,	is	one	of	the	most	widely	used	globally.	The	more	common	tuberculin	products	are	
PPD-S2	 (Sanofi	 Pasteur	 Limited,	 Swiftwater,	 PA,	 USA)	 and	 PPD-RT23-SSI	 (Statens	 Serum	
Institute,	Copenhagen,	Denmark).	The	standard	doses	are	5	PPD-S	units	(5	Tuberculin	Units	
(TU);	 0.1	 ml)	 or	 2	 TU	 PPD-RT-23,	 which	 are	 equivalent	 to	 each	 other.	 Both	 types	 of	
tuberculin	 contain	a	 complex	mixture	of	antigens,	 including	 those	of	M.	bovis-BCG	strains	
and	 several	 antigens	 of	 non-tuberculous	 mycobacteria,	 as	 well	 as	 antigens	 of	 Mtb.10	
Tuberculin	 will	 stimulate	 a	 delayed-type	 hypersensitivity	 response	 via	 T-lymphocytes.	 A	
positive	TST	can	be	detected	by	an	induration	on	the	site	of	the	injection	after	48-72	hours.	
The	 result	 is	 the	 transverse	 diameter	 of	 the	 induration,	 which	 is	 usually	 recorded	 in	
millimetres.	The	interpretation	of	TST	results	should	take	into	account	immunosuppression	
as	 well	 as	 the	 prevalence	 of	 tuberculosis	 in	 each	 particular	 setting:	 5	 mm	 is	 considered	
positive	 if	 the	 patient	 is	 immunosuppressed,	 but	 will	 be	 considered	 negative	 in	 healthy	
patients	 living	 in	 high-prevalence	 areas,	 for	 whom	 a	 15	 mm	 cut-off	 will	 apply.	 In	 some	
settings	a	uniform	cut-off	of	10	mm	is	used.	These	different	and	subjective	considerations	
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make	 it	 difficult	 to	 compare	 TST	 properties	 between	 studies	 in	 different	 countries	 and	
populations.	
The	main	limitation	of	TST	is	its	low	specificity	due	to	previous	BCG	vaccination70	and	non-
tuberculous	mycobacteria	 infections.71	 Tuberculin	 contains	 several	 antigens	 shared	by	 the	
Mycobacterium	 tuberculosis	 complex,	 M.	 bovis-BCG	 and	 non-tuberculous	 mycobacteria,	
thus	a	positive	TST	does	not	necessarily	equate	to	TB	infection,	especially	in	BCG-vaccinated	
subjects,	among	whom	a	higher	proportion	of	false	positive	results	can	be	found.	There	are	
also	 other	 drawbacks	 in	 this	 apparently	 simple	 test:	 in	 subjects	 with	 chronic	 debilitating	
conditions	or	immunosuppression,	TST	may	have	a	lower	sensitivity	than	in	healthy	people.	
It	must	be	administrated	and	read	by	trained	professionals	so	as	to	avoid	variability	of	the	
results.	 It	 also	 requires	 two	 clinical	 visits,	 and	 a	 positive	 reaction	 may	 interfere	 with	
confidentiality	 issues.	 Finally,	 there	 are	 very	 few	 countries	 (the	 United	 States,	 Spain	 and	
Portugal)	where	the	two-step	TST	or	“booster”	is	heeded.72,73	This	strategy	aims	to	obtain	a	
LTBI	diagnosis	in	older	and	immunosuppressed	patients,	where	an	initial	TST	may	boost	the	
immune	 system	 against	 an	 older	 latent	 infection	 that	would	 be	 evident	 after	 the	 second	
dose	of	tuberculin.	However,	the	effectiveness	of	this	second	test	is	usually	low,	and	several	
studies	have	 reported	a	non-negligible	proportion	of	 false	positive	 results,	mainly	 in	BCG-
vaccinated	individuals.74,75		
Based	 on	 the	 quantification	 of	 the	 cellular	 immune	 response,	 in	 vitro	 immunodiagnostic	
methods	 have	 been	 developed	 by	 detecting	 interferon-gamma	 (IFN-γ)	 released	 by	
sensitized	 T-cells	 stimulated	 with	 specific	 Mtb	 antigens.	 These	 tests	 use	 a	 blood	 sample	
taken	 from	 the	 patient	 to	 measure	 T-cell	 release	 of	 IFN-γ	 in	 vitro	 after	 stimulation	 by	
specific	Mycobacterium	 tuberculosis	 complex	 antigens.	 Two	 IGRAs	 have	 been	 developed:	
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the	 QuantiFERON-TB®	 Gold	 In-Tube	 (QFT-GIT)	 (Cellestis	 Limited,	 Carnegie,	 Victoria,	
Australia)	and	the	T-SPOT.TB®	(Oxford	Immunotec,	Oxford,	UK).76	QFT-GIT	is	an	ELISA-based	
test	 performed	 on	 whole	 blood.	 It	 measures	 levels	 of	 IFN-γ	 in	 the	 supernatant	 of	 a	 cell	
suspension.	The	result	is	easily	processed	by	software	and	is	reported	in	international	units	
per	ml	 (IU/ml).	T-SPOT.TB	 is	an	enzyme-linked	 immunospot	assay	 (ELISPOT)	performed	on	
separated	T-lymphocytes.	The	result	is	reported	as	number	of	IFN-γ	producing	T-cells.	Both	
tests	 use	 the	 early-secreted	 antigenic	 target	 6	 (ESAT-6)	 and	 culture	 filtrate	 protein	 10	
(CFP10),	which	are	encoded	by	genes	located	in	the	region	of	difference	1	(RD-1)	segment	of	
Mycobacterium	tuberculosis	complex	genome.	QFT-GIT	also	includes	a	third	antigen,	TB7.7	
(RD-11).	 A	 new	 generation	 of	 QuantiFERON,	 QuantiFERON-TB	 Plus	 (Qiagen,	 Hilden,	
Germany),	which	 includes	an	additional	antigen	tube	for	the	stimulation	of	both	CD4+	and	
CD8+,	has	recently	been	commercialized.77	
	
	
	
	
Figure	3.	Diagrammatic	
representation	of	elispot	and	
ELISA	for	diagnosing	M.	
tuberculosis	infection.		
	
IGRAs	detect	interferon-gamma	
(IFN-γ)	released	by	sensitized	T-
cells	stimulated	with	specific	M.	
tuberculosis	antigens.	
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Table	1.	Differences	between	both	IGRAs,	extracted	from	Lalvani,	2009.78	
Variables	 ELISpot	(T-SPOT.	TB)	 ELISA	(QuantiFERON	Gold	In	-Tube)	
Antigens	 ESAT-6	and	CFP10	 ESAT-6,	CFP10	and	TB7.7	
Positive	internal	control	 Yes	 Yes	
Potential	for	boosting	
effect	in	repeated	test	
No	 No	
Need	for	return	visit	 No	 No	
Time	required	for	results,	h	 16-20	 16-24	
Readout	units		 IFN-γ	spot-forming	cells	 International	units	of	IFN-γ	
Technology	platform	 ELISpot	 ELISA	
Test	substrate	 Peripheral	blood	
mononuclear	cells	
Whole	blood	
Outcome	measure	 Number	of	IFN-γ-
producing	T	cells	
Serum	concentration	of	IFN-γ	
produced	by	T	cells	
Readout	system	 Enumeration	of	spots	by	
naked	eye,	magnifying	
lens,	or	automated	reader	
Measurement	of	optical	density	
values	using	an	automated	reader	
	
Neither	 TST	nor	 IGRAs	 are	 able	 to	detect	 tuberculosis	 infection	 in	 its	 first	 stages.	As	 they	
measure	the	adaptive	immune	response	to	Mtb,	an	approximately	eight-week	period	after	
infection	is	required	for	a	reliable	result.79	As	there	is	no	“gold	standard”	for	LTBI	diagnosis,	
it	 is	 not	 possible	 to	 properly	 measure	 the	 sensitivity	 and	 specificity	 of	 the	 available	
diagnostic	 tests.	 The	 only	 individuals	with	 proven	 tuberculosis	 infection	 are	 patients	with	
active	disease,	who	act	as	surrogate	markers	of	tuberculosis	infection.	
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The	immune	responses	of	latently	infected	and	active	tuberculosis	patients	are	not	likely	to	
be	identical,	as	tuberculosis	itself	is	a	well-known	cause	of	anergy.80	Thus,	sensitivity	of	both	
TST	and	IGRAs	may	be	even	higher	in	healthy	people.	In	such	individuals	a	negative	TST	or	
IGRA	 rules	 out	 TB	 infection	 and	 has	 an	 almost	 100%	 negative	 predictive	 value	 (NPV)	 for	
progression	to	active	tuberculosis.	A	negative	result,	however,	may	not	be	reliable	in	other	
clinical	 scenarios,	 such	 as	 clinical	 suspicion	 of	 active	 TB	 or	 immunosuppressed	 patients.	
Several	 studies	 have	 tested	 how	 IGRAs	 perform	 in	 these	 specific	 circumstances;	 overall,	
IGRAs	seem	to	be	less	affected	by	immunosuppression	than	the	TST.81–84	
The	main	advantage	of	IGRAs	over	TSTs	is	their	specificity,	as	ESAT-6,	CFP10	and	TB7.7	are	
found	in	the	Mycobacterium	tuberculosis	complex	genome,	but	not	in	M.	bovis-BCG,	nor	in	
the	 majority	 of	 non-tuberculous	 mycobacteria.71	 Moreover,	 IGRAs	 can	 differentiate	 a	
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Figure	4.	Sensitivity	results	 for	TST,	QFT-GIT	and	T-SPOT.TB	when	 tested	on	active	
disease	patients.	Data	extracted	from	Diel	and	Sester’s	metaanlyses.123,124		
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negative	result	from	anergy	by	means	of	a	positive	control,	which	uses	phytohaemagglutinin	
to	stimulate	the	production	of	IFN-γ.85–87	
	
	
	
	
Several	studies	have	tried	to	correlate	the	risk	of	progression	to	the	response	of	both	in	vivo	
tests	 (TST	measurement)	 and	 in	 vitro	 tests.	 This	 is	 the	 real	 and	 valuable	 patient-centred	
outcome.	The	first	published	meta-analysis	on	these	data	showed	a	slightly	better	positive	
predictive	 value	 (PPV)	 with	 IGRAs	 as	 compared	 to	 TSTs	 for	 the	 development	 of	 active	
disease.	As	for	NPV,	IGRAs	presented	significantly	higher	NPV	than	TSTs.88,89		
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Figure	5.	Specificity	results	 for	TST	 in	general	and	 in	BCG-vaccinated	subjects117	and	
for	 both	 QFT-GIT	 and	 T-SPOT.TB123	 in	 healthy,	 native	 residents	 of	 low-	 incidence	
countries	 without	 any	 previously	 known	 exposure	 to	 TB.	 Data	 extracted	 from	 Pai,	
2008	and	Diel,	2010.		
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Table	2.	Positive	(PPV)	and	negative	predictive	values	(NPV)	for	developing	active	TB	of	both	
TST	and	IGRAs	in	overall	and	high-risk	populations.	Data	extracted	from	Diel,	2012.88		
	
	
Overall	
PPV	(95%	CI)	 NPV	(95%	CI)	
	
TST	 1.5%	(1.2-1.7)	 99.4%	(99.2-99.5)	
IGRAs	 2.7%	(2.3-3.2)	 99.7%	(99.5-99.8)	
High	risk	groups	
TST	 2.4%	(1.9-2.9)	 --	
IGRAs	 6.8%	(5.6-8.3)	 --	
	
There	are	three	notable	limitations	shared	by	both	TST	and	IGRAs.	The	first	is	the	previously	
mentioned	 low	 PPV;	 hence,	 neither	 test	 is	 useful	 for	 predicting	 active	 tuberculosis	 or	 to	
select	who	is	at	highest	risk	for	developing	it.	The	second	is	the	inability	of	TSTs	and	IGRAs	to	
distinguish	 between	 LTBI	 and	 active	 disease.90,91	 The	 third	 limitation	 is	 that	 the	 tests	 are	
unable	to	distinguish	between	recent	and	past	infections;	the	response	profiles	for	past	and	
recent	infection	are	identical	according	to	the	current	diagnostic	tools.	Each	result	must	be	
carefully	examined	and	tailored,	as	peculiarities	of	the	host	may	modify	the	sensitivity	and	
specificity	of	both	TSTs	and	IGRAs.	
A	 novel	 specific	 skin	 test	 (C-tb)	 based	 on	 ESAT-6	 and	 CFP10	 antigens	 has	 been	 recently	
released.92	Data	on	safety,	concordance	with	QFT-GIT,	and	association	with	risk	of	infection	
were	published	in	February	2017.93			
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2.2.3.	Screening	for	latent	tuberculosis	infection:	“intention	to	test	is	intention	to	treat”		
Individuals	should	not	be	tested	for	LTBI	unless	the	responsible	clinician	has	a	management	
plan;	 “intention	 to	 test	 is	 intention	 to	 treat”.	 The	 low	 risk	 of	 progression,	 difficulties	 in	
treatment	completion,	as	well	as	the	adverse	effects	of	preventive	therapy	should	be	taken	
into	account	when	testing	is	offered.	
The	 most	 important	 issue	 for	 LTBI	 management	 is	 to	 properly	 target	 candidates	 for	
screening	 and	 giving	 preventive	 therapy.	 There	 are	 three	 main	 populations	 at	 risk	 for	
developing	 tuberculosis:	 newly	 infected	 people	 –specially	 children-,	 immunocompromised	
patients,	and	newly	arrived	migrants	from	high-incidence	settings.38	The	first	two	years	after	
infection	carry	the	highest	risk	for	developing	active	disease.37	For	this	reason,	individuals	at	
risk	for	Mtb	infection	found	to	have	converted	from	a	negative	to	a	positive	result	for	a	LTBI	
diagnostic	test,	as	well	as	individuals	testing	positive	after	a	contact	tracing	study	will	be	the	
most	 likely	 to	 benefit	 from	 preventive	 therapy.	 After	 diagnosing	 an	 individual	 with	
pulmonary	TB	it	is	mandatory	to	get	information	regarding	transmission	settings	in	order	to	
assign	priorities	for	the	investigation.94	The	purpose	of	a	contact	examination	of	a	TB	case	is	
to	evaluate	individuals	for	active	TB	disease	(either	to	find	the	source	or	secondary	cases)	to	
administer	 treatment,	 stop	 further	 transmission,	 and	 enable	 diagnosis	 and	 treatment	 of	
recently	infected	contacts.95	
	
Priorities	for	contact	investigation	depend	upon:	- Characteristics	of	the	index	case,	i.e.	patients	with	cavitation	on	chest	X-ray	and	positive	
acid-fast	bacilli	(AFB)	smear	sputum	are	the	most	infectious96	
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- Susceptibility	 and	 vulnerability	 of	 contacts:	 children	 under	 five	 years	 of	 age	 and	
immunocompromised	patients	are	assigned	the	highest	priority97	and	- Circumstances	of	the	exposure:	household	contacts,	congregate	settings.98	
	
All	 referred	 contacts	 should	 be	 specifically	 asked	 for	 respiratory	 symptoms	 and	 current	
general	health.	 Then,	 a	TST	or	 an	 IGRA	 (either	alone	or	 in	a	 two-step	 strategy)	 should	be	
undertaken.	Patients	with	negative	 results	obtained	prior	 to	eight	weeks	after	 the	end	of	
exposure	 to	 the	 index	 case	 should	 have	 the	 test	 repeated	 so	 as	 to	 avoid	 false	 negative	
results	 in	 the	 window	 period.79	 Subjects	 reporting	 any	 suggestive	 symptom	 of	 active	
tuberculosis	and	all	individuals	with	positive	results	on	the	LTBI	diagnostic	tests	should	have	
a	 chest	 X-ray	 to	 rule	 out	 active	 disease.	 After	 tuberculosis	 disease	 is	 excluded,	 all	 LTBI	
patients	 should	 be	 offered	 treatment	 with	 one	 of	 the	 approved	 regimens.60	 Preventive	
treatment	 implies	 adherence	 control	 and	 screening	 of	 adverse	 events	 related	 to	 drugs,	
specifically	 liver	 toxicity.	 Liver	 function	 tests	 should	 be	 obtained	 before	 the	 beginning	 of	
treatment	and	checked	in	three	to	four	weeks.	
Household	 children	 should	 be	 started	 on	 preventive	 treatment	 even	 though	 a	 negative	
result	may	be	 found	 in	 the	 first	LTBI	 test	 (TST	or	 IGRA).67	Children,	especially	 those	under	
five	years	of	age,	have	an	immature	immune	system	that	both	favours	false	negative	results	
and	has	a	higher	risk	of	developing	active	tuberculosis.	If	active	disease	has	been	excluded	
and	a	second	LTBI	test	remains	negative	after	the	window	period,	treatment	can	be	stopped.	
Although	 small	 children	 diagnosed	 with	 tuberculosis	 are	 rarely	 infectious,	 a	 contact	
investigation	among	their	close	contacts	 is	also	mandatory,	as	 infant	TB	is	usually	the	clue	
for	finding	an	adult	with	active	TB.	
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An	 IGRA	 or	 TST	 may	 be	 used	 for	 persons	 with	 occupational	 exposure	 (i.e.	 health	 care	
workers)	to	Mtb.	If	tuberculosis	infection	is	systematically	tested	for	and	ruled	out	when	the	
individuals	 commence	 their	 new	 jobs,	 and	 then	 every	 two	 years	 as	 long	 as	 they	 remain	
negative	 responders,	 a	 conversion	 from	 negative	 to	 positive	 result	may	 be	 detected	 and	
thus	 treatment	 for	 a	 recent	 infection	 may	 be	 offered	 to	 prevent	 TB	 development.	
Prospective	 studies	 have	 shown	 a	 low	 risk	 of	 TB	 development	 in	 this	 classic	 risk	 group;	
recent	recommendations	do	not	encourage	serial	testing	nor	treatment	of	these	individuals	
in	a	systematic	programme.99,100	
There	is	a	vast	array	of	immunocompromised	patients	who	are	at	risk	of	developing	active	
TB:	people	 living	with	HIV,101	 transplantation	candidates,102,103	 those	exposed	 to	biological	
agents,104	patients	on	corticosteroids,	and	patients	suffering	from	other	chronic	debilitating	
conditions	such	as	malignancies,	end-stage	renal	disease	or	diabetes.	
Screening	 and	 prescription	 of	 preventive	 therapy	 in	 these	 groups	 have	 shown	 to	 reduce	
their	tuberculosis	incidence	rate.	As	a	consequence,	systematic	screening	for	TB	infection	in	
individuals	has	been	recommended.68	
Migrants	from	endemic	areas	arriving	in	high-income	countries	have	a	higher	risk	of	TB	than	
the	 autochthon	 population,	 especially	 in	 the	 first	 five	 years.105	 As	 the	 majority	 of	 TB	 in	
migrants	arises	 through	 the	 reactivation	of	 infections	acquired	overseas	and	developed	 in	
the	 first	 few	 years	 post	 entry,	 screening	 for	 LTBI	 in	 this	 population	 upon	 arrival	 may	 an	
essential	 element	 of	 any	 TB	 elimination	 strategy.105	 This	 group	 may	 be	 a	 hard-to-reach	
population,	 with	 low	 rates	 of	 returns	 to	 have	 TSTs	 read,	 thus	 an	 IGRA	 test	 might	 be	
preferred.	 The	 use	 of	 IGRAs	 can	 increase	 test	 completion	 rates,	 so	 control	 efforts	 should	
focus	on	those	most	likely	to	benefit	from	further	evaluation	and	treatment.	
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2.2.4.	Management	of	latent	tuberculosis	infection		
The	 treatment	 of	 LTBI	 has	 a	 long	 history,	 starting	 from	 the	 early	 studies	 of	 the	 1950s	
through	to	modern	trials	of	novel	combination	regimens	in	high-risk	populations.38	Drugs	for	
treating	 latent	 infection	 should	 possess	 sterilizing	 properties	 against	 dormant	
mycobacteria,106	as	such	is	the	status	of	bacteria	in	these	patients.	As	previously	described,	
the	very	 fact	 that	 isoniazid	 is	active	against	LTBI	 suggests	 that	at	 least	 some	replication	 is	
occurring,	as	this	drug	inhibits	the	synthesis	of	mycolic	acid,	required	by	the	mycobacterial	
cell	 wall	 during	 replication.	 Numerous	 randomised	 controlled	 trials	 and	 a	 handful	 of	
systematic	 reviews	 have	 demonstrated	 the	 safety	 and	 efficacy	 of	 isoniazid	 in	 the	 general	
population,60	 HIV	 infected,101	 anti-TNF	 recipients107	 and	 post-transplant	 patients108	 for	
preventing	TB	reactivation.	
Rifampicin,	 the	 second	 proven	 active	 drug	 for	 LTBI,	 is	 a	 well-known	 antibiotic	 with	
intracellular	 activity	 that	 inhibits	 the	 bacterial	 DNA-dependent	RNA	 polymerase	 and	 has	
been	 used	 against	 other	 bacterial	 infections	 in	 their	 latency	 period.	 Globally,	 it	 is	 most	
common	to	use	six	months	of	daily	 isoniazid	monotherapy	(dose	300	mg)	although	recent	
data	 suggest	 that	 four	 months	 of	 daily	 rifampicin	 (dose	 600	 mg),	 or	 three	 months	 of	
combined	therapy	with	both	antibiotics	(isoniazid	300	mg	plus	rifampicin	600	mg).	A	novel	
regimen	consisting	of	12	doses	of	a	weekly	 regimen	of	 rifapentin	 (900	mg)	and	high-dose	
isoniazid	(900	mg)	has	recently	been	described	as	effective,109	and	is	currently	used	in	the	
USA	under	directly	observed	therapy.	
The	three	common	treatment	regimens	are	generally	well	 tolerated.	Patients	must	always	
be	told	about	symptoms	that	may	indicate	the	development	of	adverse	effects	so	that	they	
seek	 care	 promptly.	 The	 most	 common	 life-threatening	 adverse	 event	 resulting	 from	
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isoniazid	is	liver	toxicity.	Not	only	is	a	clinical	assessment	needed,	but	liver	function	tests	are	
also	essential	 in	 the	 third	or	 fourth	week	of	 treatment,	 and	 then	 in	 the	 second	and	 third	
month,	 as	 well	 as	 in	 the	 instance	 of	 patients	 reporting	 hepatitis	 signs	 and	 symptoms.	
Biochemistry	 variations	 on	 alaninetransaminase	(ALT)	 and	aspartatetransaminase	(AST)	
precede	symptoms	as	indicators	of	liver	damage,	which	is	the	reason	for	testing	apparently	
healthy	 patients.	 Another	 frequent	 adverse	 event	 of	 isoniazid	 is	 peripheral	 neuropathy,	
which	can	easily	be	prevented	with	daily	pyridoxine.110	
Patients	 taking	 rifamycins	 can	 present	 flu-like	 symptoms	 in	 their	 first	week	 of	 treatment.	
This	 adverse	 event	 is	 more	 common	 in	 intermittent	 regimens	 (i.e.	 weekly	 doses).	
Hypersensitivity	 reactions	 are	more	 frequently	 related	 to	 rifamycins,	 although	 they	might	
also	be	caused	by	isoniazid.	These	reactions	are	mostly	seen	in	the	second	to	fourth	week	of	
treatment	 and	 consist	 of	 a	 rash	 and	 fever,	 ranging	 from	 harmless	 itching	 of	 the	 skin	 to	
severe	clinical	pictures	including	Stevens-Johnson	syndrome.		
Although	 the	 prevention	 of	 drug	 resistant	 TB	 cases	 is	 of	 great	 concern	 for	 clinicians	 and	
health	 authorities,	 there	 are	 no	 recommended	 regimens	 for	 LTBI	 treatment	 of	 those	
exposed	 to	MDR-TB	cases,	as	 there	are	no	 sterilizing	drugs	 for	dormant	bacilli	 apart	 from	
isoniazid	and	the	rifamycins.	Guidelines	advise	only	“watchful	waiting”	of	these	individuals	
to	assure	an	early	diagnosis	 in	case	of	 the	development	of	active	TB.38	Some	studies	have	
reported	 the	 experience	 of	 prophylactic	 treatment	 given	 to	 young	 children,	 who	 are	
household	 contacts	 of	MDR-TB	 cases.111	 This	 should	 always	 be	 supervised	 by	 a	 physician	
with	 knowledge	 and	 experience	 of	 MDR-TB	 prophylactic	 treatment,	 based	 on	 drug	
susceptibility	results	of	the	index	case.	
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For	 all	 LTBI	patients	diagnosed	within	a	 contact	 study,	 it	 is	mandatory	 for	 the	 clinician	 to	
check	the	drug	susceptibility	of	the	index	case	and	to	ensure	that	the	transmitted	bacteria	
are	likely	to	be	sensitive	to	the	chosen	LTBI	treatment	regimen.	
The	first	and	major	reason	for	treatment	failure,	and	thus	for	the	development	of	active	TB,	
is	 poor	 medication	 adherence.59	 Unfortunately,	 direct	 observation	 of	 each	 patient	 is	
unaffordable	 for	 most	 countries.	 LTBI	 treatments	 are	 lengthy	 and	 a	 close	 monitoring	 of	
subjects	 is	 required	 to	 ensure	 high	 treatment	 compliance.	 Several	 methods	 for	 checking	
treatment	 compliance	 have	 been	 validated:	 they	 include	 the	 Eidus-Hamilton	 test112	 and	
commercially	available	reactive	stripes	that	can	easily	detect	urine	metabolites	of	isoniazid.	
Checking	 the	 orange-coloured	 urine	 of	 subjects	 taking	 rifampicin	 may	 also	 be	 useful	 for	
adherence	control.	
	 	
	32	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
	 	
	 33	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
CONTEXT	OF	THE	INVESTIGATION;		
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In	 low-incidence	 TB	 settings,	 screening	 and	 prescription	 of	 preventive	 therapy	 in	
populations	 at	 risk	 of	 developing	 active	 tuberculosis	 represent	 the	 main	 workload	 in	 TB	
units.113	Healthy	individuals	with	recent	exposure	to	an	active	tuberculosis	case,	whether	in	
their	 household	 or	 their	 work	 environment	 (i.e.	 healthcare	 professionals),	 as	 well	 as	 the	
growing	group	of	patients	about	to	receive	immunosuppressive	drugs	constitute	the	largest	
part	of	the	collaboration	in	the	End	TB	Strategy.	Each	diagnosis	and	decision	for	treatment	is	
part	 of	 a	 tailored	 preventive	 strategy.	 With	 the	 same	 test	 results	 one	 individual	 might	
receive	treatment	and	another	might	not.	Age,	comorbidities,	type	of	exposure	and	type	of	
immunosuppression	 need	 to	 be	 balanced,	 and	 benefits	 must	 outweigh	 the	 risks	 of	
preventive	treatment.	The	prescription,	the	control	of	adherence,	and	the	rapid	detection	of	
adverse	events	are	all	equally	important	for	the	strategy	to	yield	results,	i.e.	to	achieve	high	
rates	of	treatment	completion.	
The	 Bellvitge	 TB	 Clinical	 Unit	 benefits	 from	 full-time	 staff,	 comprehensive	 protocols	 for	
different	 patients’	 profiles,	 and	 prospective	 gathering	 of	 epidemiological,	 diagnostic	 and	
outcome	data	from	all	evaluated	individuals.	The	staff	prioritizes	contact	investigation	in	all	
tuberculosis	 cases,	 and	 receives	 every	 patient	 prior	 to	 immunosuppression	with	 anti-TNF	
agents	 from	 Dermatology,	 Rheumatology	 and	 Gastroenterology	 Departments,	 as	 well	 as	
kidney	 transplant	 recipients	 as	 a	 part	 of	 their	 pre-transplant	 evaluation.	 Other	 kinds	 of	
immunosuppressed	patients	are	also	examined.	Preventive	therapy	is	prescribed,	if	needed,	
and	checked	in	the	outpatient	clinic.	
The	 current	 project	 was	 conceived	 in	 this	 fertile	 ground,	 seeded	 by	 a	 previous	 doctoral	
project	 in	 the	management	of	 LTBI	 in	 immunosuppressed	patients	 soon	after	 IGRAs	were	
implemented	in	our	centre	in	2006.114–116	
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TST	 has	 been	 the	 only	 method	 for	 diagnostic	 approach	 to	 tuberculosis	 infection	 for	 a	
hundred	 years,	 although	 sensitivity	 is	 less	 than	 70%	 in	 culture-proven	 active	 cases.117	 As	
there	 is	no	gold	standard	 for	LTBI	diagnosis,	 studies	aiming	 to	assess	 the	accuracy	of	new	
diagnostic	 tests	 for	 LTBI,	 are	 inexact.	 For	 this	 reason,	 the	WHO	developed	 a	 hierarchy	 of	
reference	 standards	 to	 assess	 the	 performance	 of	 IGRAs.118	 Direct	 comparison	 and	
agreement	tests	between	 IGRAs	and	tuberculin	have	been	explored	 in	several	settings	 for	
the	last	decade,	as	have	studies	assessing	sensitivity	and	specificity	and	correlation	of	IGRA	
results	and	exposure	gradient.119	 In	the	 last	years	several	cohorts	have	been	followed	and	
data	on	predictive	values	have	been	provided.120	
	
	
	
	
	
At	the	time	this	project	began,	there	was	little	information	on	longitudinal	and	prospective	
studies	 assessing	 IGRA	 results	 and	 patients’	 outcomes.	 Until	 then	 there	 had	 been	 no	
conclusive	 evidence-based	 recommendations,	 as	 no	 studies	 had	 used	 IGRAs	 in	 their	
Figure	6.	Hierarchy	of	reference	standards	used	to	assess	the	evidence	base.	Modified	
from	WHO,	2011118.		
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decision-making	 process	 to	 provide	 preventive	 therapy.	 The	 fact	 that	 IGRAs	 are	 currently	
recommended	 by	 international	 guidelines	 and	 societies	 as	 part	 of	 several	 diagnostic	
approaches	for	latent	TB	infection	diagnosis	under	low	quality	evidence,	contributes	to	non-
standardized	practices	around	epidemiologically	similar	countries.	
In	immunosuppressed	populations,	sensitivity	is	the	most	desirable	property	for	a	diagnostic	
test,	 so	 as	 not	 to	 leave	 any	 subject	 unprotected	 from	 tuberculosis	 reactivation.	 As	
mentioned	 previously,	 a	 former	 fellow	 published	 the	 assessment	 of	 QFT-GIT	 in	 different	
cohorts	of	immunosuppressed	populations.114–116	The	analysis	of	the	anti-TNF	cohort	in	our	
centre	before	the	implementation	of	QFT-GIT	led	to	a	modification	in	the	clinical	protocol	of	
LTBI	 screening,	 since	a	higher	 than	expected	prevalence	of	 LTBI	was	 found.	 It	was	almost	
50%,	higher	 than	the	estimated	“third	of	 the	global	population”.37	The	diagnostic	strategy	
was	then	modified	by	means	of	adding	QFT-GIT	and	simplifying	the	two-step	TST	to	a	single-
step	practice.		
A	 cohort	 of	 liver	 transplant	 candidates	 and	 hematopoietic	 stem	 cell	 transplant	 recipients	
was	 also	 evaluated	 for	 QFT-GIT	 performance	 in	 an	 observational	 study.114	 None	 of	 these	
patients	received	preventive	therapy,	as	treatment	decisions	relied	on	the	transplant	group,	
which	decided	that	the	risk	of	side	effects	were	too	great.	The	follow-up	period	allowed	the	
calculation	 of	 predictive	 values	 of	 both	 TST	 and	 QFT-GIT	 for	 the	 development	 of	 active	
disease	in	theses	populations.	
In	 healthy	 populations	 evaluated	 after	 recent	 exposure	 to	 an	 active	 case	 of	 tuberculosis,	
IGRAs	had	shown	a	high	NPV.62	However,	they	were	only	slightly	better	than	TSTs	in	terms	
of	 predicting	 development	 of	 subsequent	 active	 TB.	 This	 fact	 led	 to	 a	 shared	
disenchantment	after	the	initial	expectations	of	IGRA	tests.	In	this	project,	we	relied	on	the	
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true	benefit	that	IGRAs	could	add	to	the	screening	of	latent	TB	infection	by	better	selecting	
healthy	patients	at	 risk	 for	developing	TB.	 This	 solid	 conviction	 led	 to	 three	actions.	 First,	
IGRA	were	included	as	part	of	the	diagnostic	process	of	LTBI	in	BCG-vaccinated	contacts	of	
TB	at	the	Clinical	TB	Unit.	Second,	the	doctoral	candidate	elaborated	a	 literature	study	on	
the	ability	of	 IGRAs	to	reduce	the	number	of	people	considered	for	preventive	treatment.	
Third,	we	decided	to	test	our	hypothesis	through	a	clinical	trial.	
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HYPOTHESIS	
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Assumptions	
1.	 The	 higher	 the	 proportion	 of	 LTBI	 diagnosis	 among	 tested	 individuals,	 the	 better	 the	
strategy	for	preventing	development	of	active	tuberculosis.	For	this	reason,	a	two-step	TST	
practice	has	been	used	for	years,	and	is	still	recommended	in	several	guidelines.121	However,	
this	practice	poses	a	high	rate	of	false	positive	results,	especially	in	BCG-vaccinated	patients.	
2.	There	is	no	solid	evidence	on	the	best	strategy	for	diagnosing	LTBI.	IGRAs	exceed	TSTs	in	
diagnostic	 accuracy,	 and	 have	 been	 progressively	 assimilated	 into	 clinical	 practice,	 either	
replacing	 or	 accompanying	 TSTs.	 The	 lack	 of	 well-evidenced	 practices	 impedes	 the	
homogeneity	of	recommendations	and	guidelines.	
3.	 IGRAs	 could	 improve	 LTBI	 diagnosis	 strategy	 in	 both	 populations	 at	 risk	 for	 developing	
active	tuberculosis.	
3.1	Immunosuppressed	individuals:	IGRAs	can	improve	TST	sensitivity	in	this	high-risk	
population.	Maximum	sensitivity	 in	these	populations	 is	 foreseen,	as	they	pose	the	
highest	 risk	 for	 development	 of	 active	 tuberculosis.	 IGRAs	 have	 shown	 better	
diagnostic	performance	than	TSTs	in	such	settings.81	
3.2.	 Healthy	 subjects	 who	 have	 recently	 been	 exposed	 to	 an	 active	 case	 of	
pulmonary	or	laryngeal	tuberculosis:	IGRAs	can	improve	TST	specificity	in	this	setting.	
IGRAs	 have	 shown	 an	 almost	 100%	 NPV	 for	 developing	 tuberculosis.62	 Leaving	
negative-IGRA	 responders	without	preventive	 therapy	could	 reduce	 the	number	of	
individuals	 receiving	 treatment,	 without	 increasing	 the	 risk	 of	 subsequent	 active	
tuberculosis.	
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4.	 Diagnostic	 tests	 are	 of	 great	 importance	 for	 LTBI	 management.	 However,	 control	 of	
treatment	 adherence	 as	 well	 as	 adverse	 events,	 which	 are	 the	 clue	 for	 treatment	
completion,	and	thus	for	efficacy,	are	usually	overlooked.	
Hypothesis	
	
LTBI	management	is	a	crucial	component	of	tuberculosis	prevention	in	high-risk	individuals.	
A	global	 approach	 including	diagnosis	 and	 treatment	 completion	ensures	good	outcomes.	
Increasing	the	proportion	of	LTBI	diagnosis	does	not	imply	better	results;	on	the	contrary,	it	
could	lead	to	an	increase	in	unnecessary	treatments.	
	
1.	 In	 immunosuppressed	 individuals:	 The	 addition	 of	 an	 IGRA	 test	 might	 benefit	 the	
diagnostic	strategy	in	order	to	maximize	TST	sensitivity.		
	
2.	 In	recently	 infected	individuals	(contact	tracing	studies):	 Implementing	the	use	of	 IGRAs	
could	narrow	the	proportion	of	preventive	therapy	in	individuals	at	risk	of	developing	active	
tuberculosis,	without	increasing	its	risk.	
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AIMS		
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Global	aim:	
Improve	 the	 management	 of	 LTBI—particularly	 by	 the	 implementation	 of	 IGRAs—in	
populations	at	risk	of	developing	active	tuberculosis	
	
Specific	aims:	
1.	In	immunosuppressed	populations	
1.1	Candidates	to	anti-TNF	agents	
First,	to	assess	whether	a	comprehensive	latent	tuberculosis	screening	and	treatment	
program	can	prevent	anti-TNF–associated	tuberculosis.	
Second,	to	determine	whether	the	currently	recommended	two-step	TST	approach	can	be	
safely	replaced	by	a	single-step	TST	plus	QFT-GIT	screening	strategy	by	reducing	the	number	
of	patients	treated	without	increasing	the	risk	of	subsequent	active	tuberculosis.	
Third,	 to	 evaluate	 the	 need	 for	 systematic	 retesting	 in	 patients	 with	 negative	 latent	
tuberculosis	screening	at	baseline.	
	
1.2.	Transplant	candidates	
To	assess	the	usefulness	of	QFT-GIT	in	predicting	the	development	of	active	tuberculosis	in	
comparison	to	the	TST	in	patients	undergoing	liver	transplant	and	hematopoietic	stem	cell	
transplant.	
	
	
	
	46	
2.	In	recently	tuberculosis-infected	individuals	(contact	tracing)	
First,	 to	ascertain	whether	using	 IGRA,	either	 in	place	of	TST	or	 to	confirm	a	positive	TST,	
might	reduce	the	number	of	people	considered	for	preventive	treatment,	without	leading	to	
a	significant	increase	in	the	risk	of	subsequent	active	tuberculosis.	
Second,	to	determine	whether	the	use	of	QFT-GIT	as	a	confirmatory	test	of	the	TST	to	target	
preventive	 therapy	 in	 tuberculosis	 contacts	 might	 reduce	 the	 number	 of	 individuals	
receiving	 treatment	 without	 an	 increased	 risk	 of	 subsequent	 active	 tuberculosis,	 as	
compared	to	a	TST-based	strategy.	
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MATERIALS	AND	METHODS			 	
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1.	SETTING	
	
Since	 the	 foundation	 of	 the	 Infectious	 Diseases	 (ID)	 Department	 at	 Bellvitge	 University	
Hospital	 in	 1977,	 it	 has	 traditionally	 been	 admitting	 tuberculosis	 patients	 for	 isolation	
purposes.	On	discharge,	patients	were	systematically	 followed	up	by	 ID	staff	and	a	clinical	
nurse	at	a	single-tuberculosis	outpatient	clinic.	In	1988	the	Tuberculosis	Unit,	as	it	is	called	
today,	took	 its	first	steps,	aiming	to	avoid	unnecessary	admissions	of	tuberculosis	patients	
and	 to	 provide	 simple	 and	 efficient	 care	 to	 both	 patients	 and	 their	 contacts.	 The	 health	
district	where	 the	unit	 is	 located	established	a	protocol	 to	ensure	 the	prevention,	 control	
and	treatment	of	tuberculosis.	In	summary,	these	were	the	objectives	to	develop	this	New	
Plan	of	Tuberculosis	Control:	
	
1. Ensure	treatment	completion	of	TB	patients.	
2. Ensure	contact	investigation	and	preventive	therapy	indications.	
3. Standardize	of	the	TST	and	microbiological	procedures.	
4. Enhance	declaration	of	each	tuberculosis	case	to	the	Health	Department.	
5. Improve	adherence	to	tuberculosis	treatment	in	those	groups	at	risk	of	withdrawal.	
6. Screen	 latent	 and	 active	 tuberculosis	 in	 difficult	 to	 reach	 populations	 (homeless	
and	those	living	in	poverty	belts).	
7. 	Train	General	Practitioners	and	Clinical	Nurses	in	order	to	ensure	rapid	diagnoses	
of	active	TB	cases.	
8. Care	for	patients	in	special	situations:	people	living	with	HIV,	disease	with	resistant	
strains	or	patients	infected	with	non-tuberculous	mycobacteria.	
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The	 clinical	 activity	 at	 the	 TB	Unit	 has	 expanded	 since	 the	 first	 anti-TNF	 treatments	were	
prescribed	at	the	hospital.	In	2002	we	began	the	screening	of	LTBI	in	candidates	to	anti-TNF,	
in	collaboration	with	the	Rheumatology,	Dermatology	and	Gastroenterology	Departments.	
In	2006,	the	QuantiFERON®-TB	Gold	In-Tube	was	implemented	in	our	clinic,	initially	as	a	part	
of	 three	 research	 projects	 with	 liver	 and	 stem	 cell	 transplantation	 candidates,	 patients	
considered	for	anti-TNF	agents	and	HIV	patients.	After	the	study	projects,	we	began	to	use	
QFT-GIT	 in	 BCG-vaccinated	 contacts	 of	 TB,	 and	 after	 two	 years	 of	 positive	 experience	 in	
reducing	the	proportion	of	diagnoses	and	treatments	prescribed,	the	test	became	available	
to	 the	 rest	 of	 the	 hospital.	 In	 the	 last	 four	 years	 a	 new	 screening	 program	 for	 LTBI	 in	
candidates	for	kidney	transplantation	is	being	carried	out.	Also,	our	unit	acts	as	a	reference	
centre	for	MDR-TB	and	difficult-to-treat	mycobacterial	infections.	
	
2.	CLINICAL	PROTOCOL	FOR	LATENT	TUBERCULOSIS	INFECTION	AT	THE	TB	UNIT	
	
The	clinical	protocol	includes:	
2.1.	Baseline	assessment	
• Data	 gathering:	 demographics,	 comorbidities	 and	 treatment	 during	 the	 previous	
three	months,	previous	history	of	 tuberculosis	or	LTBI,	BCG	vaccination	status,	and	
past	risk	factors	for	tuberculosis,	description	of	the	current	risk	factor	for	developing	
active	TB.	
• Exclusion	of	active	tuberculosis	through	suggestive	symptoms	(fever,	cough,	weight	
loss,	and	drenching	sweats)	and	chest	X-ray.	
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2.2.	Diagnosis	of	latent	infection	
• Patients	who	have	already	been	diagnosed	or	have	radiographic	 findings	of	healed	
tuberculosis	 are	 assumed	 to	 have	 “past”	 LTBI	 and	 no	 immunodiagnostic	 tests	 are	
carried	 out.	 If	 previously	 treated,	 they	 do	 not	 undergo	 further	 evaluation.	 If	 not,	
preventive	therapy	is	offered.		
• In	 patients	 who	 have	 never	 been	 tested	 for	 tuberculosis	 infection,	 the	 TST	 is	
performed	by	the	Mantoux	method	using	2	TU	of	PPD	RT23	(Statens	Serum	Institute,	
Copenhagen,	Denmark)	 in	the	volar	aspect	of	the	forearm.	TST	is	administered	and	
assessed	 by	 two	 experienced	 nurses	 at	 the	 Tuberculosis	 Unit.	 When	 appropriate,	
QFT-GIT	 is	 performed	 before	 TST	 and	 in	 accordance	 with	 the	 manufacturer’s	
instructions.	
	
2.3.	Preventive	therapy	
All	newly	LTBI	diagnosed	patients	receive	six	months	of	isoniazid	treatment.	The	alternative	
regimen	 is	 four	 months	 of	 rifampicin.	 Patients	 about	 to	 receive	 preventive	 treatment	
receive	extensive	counselling	about	tuberculosis	 infection,	 its	treatment,	and	possible	side	
effects.	During	treatment,	patients	have	access	to	their	treatment	team	at	the	Tuberculosis	
Unit.	Reinforcement	visits	and	blood	test	monitoring	are	performed	at	months	1,	3	and	6.	
Adherence	to	isoniazid	is	assessed	by	detecting	isoniazid	metabolites	in	the	urine	with	the	
Eidus-Hamilton	test,112	and	adherence	to	rifampicin	is	assessed	by	checking	the	urine	colour.	
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3.	SCIENTIFIC	PRODUCTION		
The	 clinical	 studies	 included	 in	 this	 thesis	 comprise	 three	 longitudinal	 cohort	 studies,	 a	
systematic	 review	 and	 a	 clinical	 trial.	 The	 three	 observational	 studies	 are	 retrospective	
analyses	 of	 prospectively	 gathered	 data,	 recorded	 as	 part	 of	 the	 clinical	 assistance	 in	 the	
Tuberculosis	Unit.	
3.1.	Study	design		
Article	 1.	 Prevention	of	Anti–Tumour	Necrosis	 Factor–	Associated	 Tuberculosis:	 A	 10-Year	
Longitudinal	Cohort	Study	(Clin	Infect	Dis	2015;60:349-356).	
A	prospective	observational	cohort	study,	originally	designed	in	2005	aiming	to	evaluate	the	
efficacy	 of	 the	 comprehensive	 clinical	 program	 for	 tuberculosis	 prevention	 in	 patients	
receiving	 anti-TNF	 therapy.	We	 included	 consecutive	 patients	 between	 January	 2003	 and	
December	2013.	Three	periods	with	different	LTBI	diagnostic	strategies	and	their	outcomes	
during	a	 two-year	 follow-up	were	evaluated.	The	Ethics	Committee	of	Bellvitge	University	
Hospital	approved	the	study	(approval	number	PR235/11).	
	
Article	 2.	 Immunodiagnostic	 Tests’	 Predictive	 Values	 for	 Progression	 to	 Tuberculosis	 in	
Transplant	Recipients.	A	Prospective	Cohort	Study	(Transplant	Direct	2015;1:e12).	
A	prospective	cohort	 study	was	conducted	 to	assess	predictive	values	of	TST	and	QFT-GIT	
for	developing	active	TB	 in	 consecutive	 transplant	 candidates	between	 July	2008	and	 July	
2010;	 it	 was	 originally	 designed	 in	 2006	 to	 assess	 the	 usefulness	 of	 the	 QFT-GIT	 for	
predicting	 the	development	of	 active	TB	 in	 comparison	 to	 the	TST	 in	patients	undergoing	
liver	transplant	(LT)	and	hematopoietic	stem	cell	transplant	(HSCT).	These	patients	did	not	
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receive	preventive	therapy	as	their	treating	physicians	considered	that	risks	outweighed	the	
benefits	 of	 such	 prescription.	 The	 ethics	 committee	 of	 Bellvitge	 University	 Hospital	
approved	the	study	(approval	number	PR248/06).	
	
Article	3.	 Interferon-gamma	release	assays	versus	tuberculin	skin	test	 for	 targeting	people	
for	tuberculosis	preventive	treatment:	An	evidence-based	review	(J	 Infection	2013;66:381-
387)	
We	aimed	to	ascertain	whether	using	an	IGRA	either	in	place	of	TST	or	to	confirm	a	positive	
TST	 might	 reduce	 the	 number	 of	 people	 considered	 for	 preventive	 treatment,	 without	
leading	to	a	significant	increase	in	the	risk	of	subsequent	active	tuberculosis.		
This	 literature	 review	 ensured	 the	 hypothesis	 of	 the	 next	 two	 studies	 in	 contact	
investigation,	 taking	 advantage	 of	 the	 better	 specificity	 and	 NPV	 of	 IGRAs	 for	 targeting	
preventive	treatment.		
	
Article	4.	QuantiFERON®-TB	Gold	In-Tube	for	contact	screening	in	BCG-vaccinated	adults:	A	
longitudinal	cohort	study	(PloS	One;	under	review).	
A	 retrospective	 comparative	 study	 of	 two	 screening	 strategies	 for	 tuberculosis	 contact	
tracing	 (before	and	after	 the	 implementation	of	QFT-GIT	 in	BCG-vaccinated	 contacts)	was	
performed	 between	 January	 2006	 and	December	 2010.	 The	 study	was	 designed	 in	 2008,	
when	QFT-GIT	was	 added	 to	 the	 LTBI	 screening	 strategy	 in	 BCG-vaccinated	 contacts.	We	
hypothesized	 that	 using	 the	 QFT-GIT	 to	 target	 TB	 contacts	 would	 reduce	 the	 number	 of	
individuals	diagnosed	with,	and	treated	for,	TB	infection	compared	to	the	previous	TST-only	
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strategy,	 without	 an	 increased	 risk	 of	 active	 TB	 in	 the	 follow-up	 period.	 The	 Ethics	
Committee	of	Bellvitge	University	Hospital	approved	the	study	(PR269/11).	
	
Article	5.	QuantiFERON®-TB	Gold	 In-Tube	as	a	confirmatory	 test	 for	 tuberculin	skin	 test	 in	
tuberculosis	 contact	 tracing:	 A	 non-inferiority	 clinical	 trial	 (Annals	 of	 Internal	 Medicine;	
under	review)	
We	conducted	an	open-label,	multicentre,	randomised	trial,	to	test	the	non-inferiority	of	a	
two-step	strategy	with	the	tuberculin	skin	test,	followed	by	QuantiFERON®-TB	Gold	In-Tube	
as	a	confirmatory	test	(the	TST/QFT	arm)	to	the	standard	TST-alone	strategy	(TST	arm),	for	
targeting	 preventive	 therapy	 in	 household	 contacts	 of	 tuberculosis.	 Eight	 hundred	 and	
seventy-one	participants	from	12	Spanish	hospitals	were	randomized.	The	follow-up	period	
was	 24	months.	 The	 primary	 endpoint	was	 the	 development	 of	 tuberculosis,	with	 a	 non-
inferiority	 margin	 of	 1.5%.	 The	 Research	 Ethics	 Committee	 at	 each	 participating	 site	
approved	 the	 study	 protocol,	 with	 Bellvitge	 University	 Hospital	 acting	 as	 Research	 Ethics	
Coordinator	(ref	AC111/09).	
	
3.2.	Participants	and	follow-up		
As	 mentioned,	 consecutively	 evaluated	 patients	 for	 LTBI	 screening	 at	 the	 TB	 Unit	 were	
included	 in	 the	 cohort	 groups	 of	 anti-TNF	 recipients,	 transplant	 candidates	 or	 contact	
investigation,	if	they	met	the	inclusion	criteria	for	the	respective	analysis.	
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The	three	observational	studies	had	different	periods	of	follow-up:	24	months	for	the	anti-
TNF	cohort,	48	months	for	the	transplant	candidates	and	5	years	for	the	contacts	of	active	
TB.	We	checked	and	updated	the	final	outcomes	annually	until	 the	pre-established	period	
was	 completed.	 This	 update	 consisted	 of	 reviewing	 the	 medical	 charts	 and	 contacting	
patients	to	assess	their	vital	status	and	the	development	of	tuberculosis.	We	recorded	the	
type	 and	 length	 of	 anti-TNF	 therapy,	 date	 and	 drugs	 after	 transplantation	 and	 further	
contacts	with	TB	cases	for	each	study	respectively.	Patients	lost	to	follow-up	were	matched	
with	the	registry	of	tuberculosis	patients	at	the	Health	Department	of	Catalonia	to	ensure	
that	no	incident	cases	were	missed.	
As	for	the	clinical	trial,	all	adult	household	contacts	of	pulmonary	tuberculosis	patients	who	
were	 evaluated	 at	 any	 of	 the	 participating	 sites	 were	 invited	 to	 take	 part	 in	 the	 trial.	
Inclusion	and	exclusion	criteria	as	well	 as	 the	 schedule	of	appointments	were	 specified	 in	
the	protocol	(Annex).		
3.3.	Statistical	analyses		
	Each	 paper	 describes	 the	 ad-hoc	 statistical	 analysis	 in	 great	 detail.	 In	 general	 terms,	 the	
statistical	 analyses	 were	made	 with	 the	 SPSS	 (Statistical	 Package	 for	 the	 Social	 Sciences)	
software	(version	17	and	22).	Differences	between	groups	were	assessed	using	the	χ2	or	the	
analysis	of	variance	tests	if	≥2	groups	were	compared.	Student	t	test	and	Mann–Whitney	U	
nonparametric	test	compared	continuous	variables,	as	appropriate.	The	level	of	significance	
was	 fixed	 at	 α	 =	 5%,	 and	 confidence	 intervals	 (CIs)	 for	 differences	 in	 proportions	 were	
estimated	using	OpenEpi	software	version	2.3.1.122	The	incidence	of	active	tuberculosis	was	
expressed	as	the	incidence	density	rate	with	95%	CIs.	The	risk	of	tuberculosis	was	assessed	
by	 Cox	 proportional	 hazard	 regression	 analysis	 to	 assess	 the	 effect	 of	 covariates	 and	 the	
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differences	between	groups.		
As	 for	 the	 clinical	 trial,	 an	electronic	 case	 report	 form	 (eCRF)	was	designed	 in	Access	and	
built	with	an	online	database	 in	which	 the	 information	was	 recorded.	Randomisation	was	
stratified	by	centre	in	a	1:1	allocation	ratio,	using	a	computer-generated	randomisation	list	
integrated	into	the	eCRF.	Details	on	the	statistical	analysis	and	the	included	variables	can	be	
found	 in	 the	 trial	 protocol.	 The	 Clinical	 Trials	 and	 Statistical	 Unit	 at	 Bellvitge	 University	
Hospital-IDIBELL	downloaded	and	analysed	the	data	contained	in	the	electronic	case	report	
forms	(eCRF)	following	the	statistical	analysis	plan.	
4.	ETHICS		
In	 all	 clinical	 studies	 approval	 was	 obtained	 from	 the	 Ethical	 Committee,	 and	 written	
informed	consent	was	obtained	from	all	subjects.	
	
5.	FUNDING	AND	GRANTS		
The	 doctoral	 candidate	 received	 the	 following	 grants	 and	 funding	 during	 her	 research	
process:	
-Post-Residence	grant	from	Bellvitge	University	Hospital	(July	2009)	
-Grant	P-FIS	from	the	Insituto	de	Salud	Carlos	III	[PI10/00443]	
In	addition,	the	clinical	trial	“Comparison	of	two	strategies	for	therapeutic	decision-making	
in	 tuberculosis	 contact	 tracing:	 a	 standard	 strategy	based	on	 TST	 alone	 vs.	 TST	 combined	
with	QuantiFERON®-TB	Gold	 In-Tube	(QFT)”,	was	partially	supported	by	 Insitituto	de	Salud	
Carlos	III	–	Convocatoria	2009	de	Ayudas	para	el	fomento	de	la	traslación	de	la	aplicación	de	
medicamentos	de	uso	humano,	huérfanos	y	terapias	avanzadas	(Exp	TRA-126).	 	
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1. Immunosuppressed	population	
1.1	Patients	about	to	receive	anti-TNF	agents			 	
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M A J O R A R T I C L E
Prevention of Anti–Tumor Necrosis Factor–
Associated Tuberculosis: A 10-Year Longitudinal
Cohort Study
Laura Muñoz,1 Susana Casas,2 Xavier Juanola,3,4 Xavier Bordas,4,5 Concepcion Martinez,1 and Miguel Santin1,4; for the
Prevention of Anti-TNF–Associated Tuberculosis Study Team of Bellvitge University Hospital
1Department of Infectious Diseases, Bellvitge University Hospital–Institut d’investigació biomèdica de Bellvitge (IDIBELL), 2Department of Internal
Medicine, Hospital Dos de Maig, Consorci Sanitari Integral, 3Department of Rheumatology, Bellvitge University Hospital–IDIBELL, 4Clinical Sciences
Department, University of Barcelona, and 5Department of Dermatology, Bellvitge University Hospital–IDIBELL, Barcelona, Spain
Background. The extent to which anti–tumor necrosis factor (TNF)–associated tuberculosis can be prevented
is unclear, and there is no established guidance on the optimal screening strategy for latent tuberculosis (LTBI) in
patients about to start anti-TNF therapy. We aimed to determine the effectiveness of a comprehensive program for
the prevention of anti-TNF–associated tuberculosis, and to evaluate 3 LTBI screening strategies and the need for
retesting patients with negative results at baseline.
Methods. In total, 726 patients were screened prior to anti-TNF therapy using 1 of 3 diagnostic strategies over 3
consecutive periods: first, a 2-step tuberculin skin test (TST); second, a 2-step TST plus QuantiFERON-TB Gold In-
Tube test (QFT-GIT) (2-step TST/QFT); and third, a single-step TST plus QFT-GIT (TST/QFT). Infected patients
were offered preventive therapy. We assessed differences in the incidence of tuberculosis between anti-TNF exposed
and nonexposed patients, and between the 3 study periods.
Results. Tuberculosis developed during the first year in 2.85 per 1000 exposed patient-years (3/1052 patient-
years) and 1.77 per 1000 nonexposed patient-years (1/566 patient-years). No cases occurred beyond the first year
of treatment. LTBI diagnoses decreased with the single-step TST/QFT (26.5%) compared with the 2-step TST
(42.5%; P < .001) and 2-step TST/QFT (38.5%; P = .02); the incidence of tuberculosis among exposed patients did
not change significantly across the 3 periods (2.63/1000, 3.91/1000, and 2.4/1000 patient-years, respectively).
Conclusions. Although anti-TNF–associated tuberculosis can be reduced, some risk remains during the first
year of therapy. Neither the 2-step TST nor systematic retesting after negative baseline testing is justified.
Keywords. tuberculosis; latent tuberculosis infection; anti-TNF; QuantiFERON-TB Gold In-Tube; IGRAs.
Biological agents, particularly tumor necrosis factor–α
antagonists (anti-TNF), have dramatically improved
the clinical course of patients with immune-mediated
inflammatory diseases (IMIDs). However, their introduc-
tion has been associated with an increase in the risk of
tuberculosis. The reported incidence of tuberculosis
ranges from 24.4 cases per 100 000 in the United States
to 522 cases per 100 000 in Spain, reflecting the differ-
ent tuberculosis burdens of each region [1, 2]. Differ-
ences have also been related to the type of anti-TNF,
with the monoclonal antibodies infliximab and adali-
mumab posing the greatest risk [3, 4].
Anti-TNF–associated tuberculosis mainly occurs due
to the reactivation of a latent tuberculosis infection
(LTBI) [5]. Consequently, screening and treatment for
LTBI before starting anti-TNF therapy are essential
for preventing tuberculosis reactivation [6], and its ef-
fectiveness has been proved in the BIOBADASER
(Spanish Society of Rheumatology Database on Biologic
Products) group [7]. Nonetheless, tuberculosis still oc-
curs, leading to questions regarding the effectiveness
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of current clinical practice. Although incomplete protection has
been attributed to poor compliance with the guidelines [8], the
suboptimal diagnostic tests, poor adherence with preventive
therapy, and incidental new infection may also be contributing
factors [8–10].
The best diagnostic strategy for LTBI prior to anti-TNF ther-
apy remains a matter of debate. The only evidence on the effec-
tiveness of preventive measures so far is based on screening with
a 2-step tuberculin skin test (TST) [7]. However, although the
2-step TST approach increases the detection of remote infection,
it may also increase the false-positive rate, leading to a greater
number of unnecessary preventive treatments. The ex vivo
interferon-γ release assays (IGRAs) may overcome the limita-
tions of the TST [11, 12]. However, it remains unclear whether
or not they should be used and how best to implement them.
This is reflected in differences in national guidelines [6, 13–20].
It is also unclear if patients who tested negative for LTBI before
starting anti-TNF therapy should undergo systematic reassess-
ment. Despite being advocated [21–23], there is no supporting
evidence for this practice.
In this study we aimed to answer 3 main questions. First, to
what extent can anti-TNF–associated tuberculosis be prevented
by a comprehensive LTBI screening and treatment program?
Second, can the 2-step TST approach be replaced by a single-
step TST plus QuantiFERON-TB Gold In-Tube (QFT-GIT)
screening strategy? Third, is systematic retesting necessary for
patients with negative baseline LTBI screening?
METHODS
Study Design, Setting, and Participants
A prospective observational cohort study was conducted be-
tween January 2003 and December 2013, at the Tuberculosis
Unit of Bellvitge University Hospital, Barcelona, Spain.
Consecutive patients with IMIDs needing anti-TNF agents
and referred for LTBI assessment between January 2003 and
December 2011 were eligible for the study. Follow-up data
were collected up to 31 December 2013. Diagnostic results from
the first 214 patients were published in a previous study on the
performance of QFT-GIT in anti-TNF candidates [24].
Clinical Program and Interventions
Screening for LTBI followed a preestablished clinical protocol,
as follows: Baseline assessment included demographics, the
type and duration of IMID, and treatment during the previous
3 months. Comorbidities, previous history of tuberculosis or
LTBI, BCG vaccination status, and risk factors for tuberculosis
were also collected. To rule out active tuberculosis, all patients
had a chest radiograph done and were asked for specific symp-
toms of active tuberculosis ( fever, cough, weight loss, and
drenching sweats). If there was evidence of radiographic signs
or suggestive symptoms of active tuberculosis, respiratory spec-
imens were collected for smear and culture. The decision on
whether to start anti-TNF was postponed until a firm diagnosis
of the current respiratory process was obtained.
As for diagnosis of LTBI, patients who had already been di-
agnosed or had radiographic findings of healed tuberculosis
were assumed to have “past” LTBI and no immunodiagnostic
tests were carried out. If previously treated, they did not under-
go further evaluation. If not, preventive therapy was offered.
The whole diagnostic assessment of LTBI, including immuno-
diagnostic tests, was carried out among asymptomatic patients
with normal chest radiograph and no previous testing for tuber-
culosis infection. Those with a positive result in any immunodi-
agnostic test were diagnosed as being “new” LTBI. We changed
the diagnostic strategy twice over the study period as new evi-
dence on the field became available.
We defined 3 consecutive periods in which 3 different
diagnostic strategies were applied. In the first period (January
2003–October 2006), a 2-step TST strategy was followed:
either an induration of ≥5 mm in the first test or an increase
of ≥5 mm in the second test was considered positive [25]. In
the second period (November 2006–May 2008), QFT-GIT
was added to the previous 2-step TST, and a LTBI diagnosis
was established based on positive TST or QFT-GIT results. In
the third period (June 2008–December 2010), the strategy was
simplified to a single-step TST and QFT-GIT.
The TST was performed by the Mantoux method using 2 U of
purified protein derivative RT23/0.1 mL (Statens Serum Institut,
Copenhagen, Denmark) in the volar aspect of the forearm. TST
was administered and assessed by 2 experienced nurses at the
Tuberculosis Unit. QFT-GIT was performed before TST and
in accordance with the manufacturer’s instructions [24]. LTBI
screening was not repeated in patients with negative results at
baseline.
In all newly LTBI diagnosed patients, a 9-month isoniazid
treatment schedule was recommended. Rifampin for 4 months
was used as the alternative regimen. Patients about to receive
preventive treatment received extensive counseling about tuber-
culosis infection, its treatment, and the possible adverse events.
During treatment, patients had access to their treating team at
the Tuberculosis Unit. Reinforcement visits and blood test
monitoring were performed at months 1, 3, 6, and 9. Adherence
to isoniazid was assessed by detecting isoniazid metabolites in
the urine with the Eidus–Hamilton test [26], and adherence to
rifampin was assessed by checking the color of the urine. Anti-
TNF treatment was postponed until completion of at least 4
weeks of therapy for LTBI.
Main Outcome Measures
We aimed to achieve at least 24 months of follow-up, and
checked and updated the final outcomes annually until 31
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December 2013. This update consisted of reviewing the medical
charts and contacting patients to assess their vital status, the
development of tuberculosis, and the type and length of anti-
TNF therapy. Patients lost to follow-up were matched with
the registry of tuberculosis patients at the Health Department
of Catalonia to ensure that no incident cases were missed [27].
Data Analysis
We defined 2 cohorts according to anti-TNF therapy exposure:
patients who received anti-TNF agents at any time since screen-
ing (exposed) and patients who did not (nonexposed). Candi-
dates who were not prescribed any anti-TNF agents contributed
person-time to the nonexposed cohort. Patients who received at
least 1 dose of anti-TNF therapy were included in both groups:
the time from the date of screening (date S) to the first dose of
anti-TNF (date D) represented the person-time attributable to
the nonexposed cohort (date S–D); from date D onward, they
contributed person-time to the exposed cohort (Figure 1).
The effectiveness of the program was assessed by comparing
the tuberculosis incidence rates of both the exposed and nonex-
posed cohorts. For risk estimation purposes, patients were cen-
sored after 2 years from date D (exposed cohort) or date S
(nonexposed cohort), as previous studies had defined the highest
risk of tuberculosis reactivation during the first 2 years of expo-
sure [1, 4]. Early censoring causes included death, development
of tuberculosis, or loss to follow-up, whichever came first.
Differences between groups were assessed using the χ2 or the
analysis of variance tests if ≥2 groups were compared. Student t
test and Mann–Whitney U nonparametric test compared contin-
uous variables, as appropriate. The level of significance was fixed
at α = 5%, and confidence intervals (CIs) for differences in pro-
portions were estimated using OpenEpi software version 2.3.1
[28]. The incidence of active tuberculosis was expressed as the
incidence density rate with 95% CIs. The risk of tuberculosis
was assessed by Cox proportional hazard regression analysis to
assess the effect of covariates and the differences between groups
(exposed, nonexposed, and exposed in different periods). Agree-
ment between TST and QFT-GIT was calculated using the
Cohen kappa coefficient (κ). Statistical analyses were performed
with SPSS statistical software (version 17.0, SPSS Institute Inc,
Chicago, Illinois) and the VassarStats website [29].
Ethical Considerations
The ethics committee of Bellvitge University Hospital approved
the study (approval number PR235/11).
RESULTS
Characteristics of the Cohort
During the study period, 726 patients were referred for evalua-
tion. Changes in the characteristics of the cohort over the 3
periods are shown in Supplementary Table 1. Five hundred
forty-two patients (74.7%) started at least 1 course of anti-
TNF treatment at some point during the study period. No
cases of active tuberculosis were diagnosed at baseline.
Diagnosis of LTBI and Preventive Therapy According to the Study
Period
Overall, among 726 screened patients, 34 (12.7%) were excluded
from the final analysis of differences in LTBI prevalence. Reason
Figure 1. Models for calculating time at risk in the exposed and nonexposed cohort. Abbreviation: TNF, tumor necrosis factor.
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for exclusion included past LTBI (n = 26) and incomplete diag-
nostic strategy (n = 8). Comparison between periods was finally
restricted to 692 patients who had undergone complete evalua-
tion according to the study protocol (Figure 2).
The prevalence of new LTBI diagnoses over the study period
was 34.2% (237/692). There were no significant differences be-
tween the first and second periods (42.5% and 38.5%, respective-
ly; P = .37), but a notable decrease was observed in the third
period (26.5%; P < .02) (Figure 3). Five of 473 (1.1%) QFT-GIT
tests yielded indeterminate results.
Of the 237 newly diagnosed patients, 226 (95.4%) were treated
for LTBI. The proportions of patients on preventive therapy were
41%, 38.5%, and 24% in first, second, and third period, respec-
tively (P < .01). Specifically, 212 patients (93.8%) were treated
with isoniazid for 9 months, and 14 (6.2%) were treated with ri-
fampin for 4 months. During treatment, 11 (5.2%) patients on
isoniazid developed liver toxicity necessitating treatment termina-
tion. Of these, 6 completed LTBI therapy with rifampin, but 5 did
not because they no longer required anti-TNF therapy. Overall,
221 (97.8%) patients completed a full course of treatment.
Impact of BCG Vaccination on the Diagnosis of LTBI
We conducted a stratified analysis by the BCG vaccination sta-
tus for differences in prevalence of LTBI, and obtained 3 main
findings. First, the prevalence of positive TST results was higher
in BCG-vaccinated than in non-BCG-vaccinated patients
(41.8% and 27.8%, respectively; P < .01), whereas there were
nonsignificant differences in the prevalence of positive QFT-
GIT results between the 2 groups (20.1% and 16.9% for BCG-
vaccinated and non-BCG-vaccinated patients, respectively;
P = .39) (Table 1).
Second, the concordance between TST and QFT-GIT was
lower in BCG-vaccinated than in nonvaccinated patients (κ = 0.36
and 0.67, respectively; Table 2). BCG vaccination was predictive of
discordant results (positive TST/negative QFT-GIT) after making
adjustments for sex, age, type of IMID, and previous immunosup-
pressive treatment (odds ratio [OR], 4.0 [95% CI, 2.24–7.26]).
Third, BCG vaccination was found to be independently associated
with the booster effect (OR, 2.54 [95% CI, 1.25–5.16]), as was age
<65 years (OR, 7.92 [95% CI, 1.05–59.9]).
Development of Active Tuberculosis
After a median observation of 5.47 years (interquartile range,
3.67–7.91), representing 3985 patient-years, 54 (7.4%) patients
were lost to follow-up and 41 (5.6%) died. Causes of death were
as follows: respiratory infection and failure having excluded tu-
berculosis by culture results or necropsy (n = 8), cancer (n = 7),
cardiovascular events (n = 14), sepsis (n = 9), end-stage liver
disease (n = 1), and renal failure (n = 1).
During the entire follow-up period, 4 patients (0.6%) born in
Spain and without specific risk factors for tuberculosis developed
active disease. Three were receiving anti-TNF treatment: 2 had
Figure 2. Flowchart of patients referred for evaluation and included in the final analysis. aDiagnosis out of protocol: 8 patients were only evaluated with
tuberculin skin test (TST): 1 of 5 patients in the second period and 3 patients in the third period were diagnosed with LTBI based only on a positive TST.
Abbreviations: LTBI, latent tuberculosis; QFT-GIT, QuantiFERON-TB Gold In-Tube; TB, tuberculosis.
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negative LTBI tests and developed culture-confirmed pulmonary
and disseminated tuberculosis, respectively, in the first year on
treatment; the remaining patient received a 4-month course of
rifampin and developed pleural tuberculosis 3 months after the
LTBI therapy. The fourth patient developed pleural tuberculosis
in the first year after negative LTBI screening and had never re-
ceived anti-TNF agents (Supplementary Table 2).
At the 2-year follow-up, the incidence of active tuberculosis
was 2.47 cases per 1000 patient-years (95% CI, .79−5.97 per
1000 patient-years) for the whole cohort. Comparison between
exposed and nonexposed cohorts found no significant differ-
ences (2.85/1000 and 1.77 cases/1000 patient-years, respective-
ly; P = .74; Table 3).
After adjusting for sex, age, type of anti-TNF, tuberculosis
risk factors, and baseline immunosuppressant agents, anti-
TNF treatment was not associated with a higher risk of
developing tuberculosis (relative risk, 1.02 [95% CI, .11–
9.85]). In addition, differences in risk between periods for pa-
tients exposed to anti-TNF agents were not significant (P = .94).
DISCUSSION
We report the results of a comprehensive clinical program for
tuberculosis prevention in patients receiving anti-TNF therapy.
The key findings can be summarized as follows: (1) although
anti-TNF–associated tuberculosis can be prevented, certain
risk remains in the first year of therapy; (2) the single-step
TST plus QFT-GIT strategy offered a substantial reduction in
LTBI treatment proportion compared with the 2-step TST-
based strategies; and (3) the systematic periodic retesting of pa-
tients for LTBI does not appear to be needed following negative
testing prior to anti-TNF therapy.
Table 1. Prevalence of Latent Tuberculosis by Tuberculin Skin Test and QuantiFERON-TB Gold In-Tube According to BCG Vaccination
Status
Test BCG Vaccinated no./No. (%; 95% CI) Non-BCG Vaccinated no./No. (%; 95% CI) P Value
Overall TST 82/196 (41.8; 35.2–48.8) 138/496 (27.8; 24.1–31.9) <.01
1st TST 66/196 (33.7; 27.4–40.6) 106/496 (21.4; 18–25.2) <.01
2nd TST 16/52 (30.8; 20.0–44.3) 32/225 (14.2; 10.3–19.4) <.01
QFT-GIT 32/159 (20.1; 14.6–27.0) 53/314 (16.9; 13.1–21.4) .39
Abbreviations: BCG, Bacillus Calmette-Guerin; CI, confidence interval; no./No., number of patients with positive results/number of patients on whom the test was
carried out; QFT-GIT, QuantiFERON-TB Gold In-Tube; TST, tuberculin skin test.
Figure 3. Prevalence of latent tuberculosis (LTBI) in 692 patients according to the 3 study periods. Bars denote the overall proportion of LTBI, and the
individual contribution of the first tuberculin skin test (TST), second TST, and QuantiFERON-TB Gold In-Tube (QFT-GIT), respectively.
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Our findings showed that the incidence of tuberculosis
among patients exposed to anti-TNF agents was comparable
to that of nonexposed patients. However, 3 of the 4 tuberculosis
cases diagnosed during the study period occurred in the ex-
posed cohort before the completion of the first year on anti-
TNF treatment. Two of them had no evidence of LTBI infection
at baseline, which strongly suggests reactivation of undetected
LTBI. Recently, a large study evaluating golimumab targeted pa-
tients for preventive therapy based on TST plus QFT-GIT. In
this study, 0.3% of patients with negative baseline results for
both tests developed tuberculosis during the first year of
follow-up [10]. These findings are in accordance with our re-
sults, showing that anti-TNF–associated tuberculosis can be
greatly reduced, but not completely prevented [30].
The single-step TST plus QFT-GIT strategy used in the last
period led to a substantial reduction in the proportion of pa-
tients put on preventive treatment as compared to the previous
2-step TST approaches, without increasing tuberculosis inci-
dence. The reduction is even more striking if the epidemiology
profile of the cohort in the last period is taken into account.
Because a larger proportion of patients came from tuberculo-
sis-endemic countries, a higher prevalence of LTBI might be ex-
pected. Thus, this decrease was likely the result of avoiding the
false-positive diagnoses linked to the 2-step TST practice. This
assumption is supported by several findings. There was poor
agreement between QFT-GIT and the second TST (more dis-
cordant results with positive TST and negative QFT-GIT) in
comparison with the first TST. In addition, there was an inde-
pendent association between BCG vaccination and both second
TST positivity (boosting effect) and discordant results (TST
positive/QFT-GIT negative).
As for the use of IGRAs, 11.8% of patients diagnosed with
LTBI in the present study were only identified by QFT-GIT,
which represented a 13.4% increase in the overall diagnoses.
Conversely, considering QFT-GIT as the only diagnostic meth-
od in the third period would have supposed a further reduction
in LTBI diagnoses of 41.6%. However, the major concern when
using only IGRAs is the potential risk of developing tuberculo-
sis in TST responders with a negative IGRA test. Five recent
studies have assessed the risk of tuberculosis in anti-TNF can-
didates in whom LTBI diagnosis and the decision for treatment
was based on IGRAs regardless of the TST results [22, 31–34].
None of the 136 patients with a negative IGRA and positive TST
developed tuberculosis after 1 year minimum follow-up. None-
theless, in a large international study of anti-TNF candidates, 2
of 150 patients with TST positive/QFT-GIT negative results de-
veloped active tuberculosis. To note, both patients were from
high-prevalence tuberculosis countries [35, 36].
Our data do not support the systematic periodic retesting of
patients with negative screening results at baseline. After a medi-
an follow-up of almost 5 years, no tuberculosis cases occurred be-
yond the first 12 months of anti-TNF therapy. Furthermore,
periodic TST would increase the number of false-positive results,
particularly in BCG-vaccinated patients. Concerning IGRAs,
Zwerling et al described unexpectedly high conversion rates in
healthcare workers without either conversion with the TST or ex-
posure to a known source of tuberculosis, suggesting that these
apparent conversions may not reflect new tuberculosis infections
[37]. As a consequence, the indiscriminate retesting of patients
with negative LTBI tests at baseline may lead to further unneces-
sary treatments. In view of our results, retesting should be based
on individual risk assessment for tuberculosis infection.
Table 2. Concordance Between Tuberculin Skin Test and
QuantiFERON-TB Gold In-Tube
Test
BCG
Vaccinated
Non-BCG
Vaccinated
QFT-GIT with 1st TST (n = 468)
No. 159 309
Agreement, % (95% CI) 75 (67–81) 91 (87–94)
κ (95% CI) 0.38 (.23–.53) 0.69 (.58–.79)
QFT-GIT with 2nd TST (n = 117)
No. 27 90
Agreement, % (95% CI) 78 (57–91) 86 (76–92)
κ (95% CI) 0.13 (0–.56) 0.30 (.02–.59)
QFT-GIT with either 1st or 2nd TST (n = 468)
No. 159 309
Agreement, % (95% CI) 73 (65–80) 90 (86–93)
κ (95% CI) 0.36 (.22–.51) 0.67 (.57–.78)
Five patients with indeterminate QFT-GITwere excluded from the concordance
analysis.
Abbreviations: BCG, Bacillus Calmette-Guerin; CI, confidence interval; QFT-
GIT, QuantiFERON-TB Gold In-Tube; TST, tuberculin skin test.
Table 3. Incidence of Active Tuberculosis During the First 2
Years of Follow-up
Population
Observation
Period, Patient-
years
Cases of
Tuberculosis
Incidence Rate
/1000 Patient-
years (95% CI)
P
Value
Whole cohort
(n = 726)
1616.5 4 2.47 (.79–5.97)
Nonexposed 565.5 1 1.77 (.09–8.7) .74*
Exposed 1051.4 3 2.85 (.73–7.77)
1st period
(n = 194)
380.1 1 2.63 (.13–13.0) .94**
2nd period
(n = 130)
255.5 1 3.91 (.20–19.3)
3rd period
(n = 218)
415.9 1 2.40 (.12–11.9)
Abbreviation: CI, confidence interval.
* Difference between exposed and nonexposed cohort.
** Difference between 3 periods in exposed patients.
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The main strengths of our research are the homogeneity of
the series and the long follow-up assessment period. Patients
were prospectively enrolled and evaluated under the same clin-
ical program for prevention of tuberculosis. In contrast to other
series, our results cannot be biased by diverse diagnostic and
treatment strategies and underreporting. Tuberculosis preven-
tive therapy was instituted and controlled by the evaluating
team at the Tuberculosis Unit, where active measures are sys-
tematically taken to promote and control adherence to preven-
tive therapy, as described elsewhere [38]. Our study, however,
has limitations that deserve further comment. First, the esti-
mates of tuberculosis incidence are not precise due to the
small number of events. Second, 54 patients were lost to fol-
low-up, and some cases of active disease may have been missed
in this group. However, underestimation is unlikely as they were
lost after a median follow-up of 3 years. Third, 2 of the 4 active
tuberculosis cases were not culture confirmed. Although their
clinical features made tuberculosis the most likely cause of
their disease, the final diagnosis could not be proved.
In summary, 3 relevant conclusions can be drawn from this
study. First, although anti-TNF–associated tuberculosis can be
greatly reduced, a certain risk remains during the first year of
treatment. Second, the 2-step TST approach for LTBI screening
prior to anti-TNF therapy is no longer justified. Third, system-
atic periodic retesting for LTBI in patients with negative test re-
sults prior to anti-TNF therapy is not required.
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Immunodiagnostic Tests’ Predictive Values for
Progression to Tuberculosis in Transplant
Recipients
A Prospective Cohort Study
Laura Muñoz, MD,1,6 Aina Gomila, MD,1 Susana Casas, PhD,2 José Castellote, PhD,3 Montserrat Arnan, PhD,4
Antoni Rafecas, PhD,5 and Miguel Santin, PhD1,6
Background. Little is known about the predictive value for progression to tuberculosis (TB) of interferon-γ release assays and
how they compare with the tuberculin skin test (TST) in assessing the risk of TB infection in transplant recipients.Methods.We
screened 50 liver transplant (LT) and 26 hematopoietic stem cell transplant (HSCT) recipients with both QuantiFERON-TB
Gold In-tube (QFT-GT) and TSTand prospectively followed them for amedian of 47months without preventive chemoprophylaxis.
Results. In the LT cohort, 1 in 22 (4.5%) QFT-GT–positive patients developed posttransplant TB, compared with none of the
QFT-GT–negative patients. In the HSCT cohort, none of the 7 QFT-GT–positive patients developed TB, whereas 1 case (5.3%)
progressed to active TB among the 19QFT-GT-negative patients. Comparable results were obtainedwith the TST: in the LT group,
1 of 23 TST-positive and none of the 27 TST-negative patients developed TB; and in the HSCT group, none of the 8 TST-positive
and one of the 18 TST-negative patients progressed to active TB.Conclusions. In this cohort of transplant recipients, the pos-
itive predictive value of QFT-GT for progression to active TB was low and comparable to that of TST. Although the risk of devel-
oping TB in patients with negative results at baseline is very low, some cases may still occur.
(Transplantation Direct 2015;1:e12; doi: 10.1097/TXD.0000000000000520. Published online 1 April 2015)
Transplant recipients are at increased risk for tuberculosis(TB) compared to the general population,1 although its
risk varies with the type of transplant and the endemic TB
burden.2-4 In low-prevalence regions, transplant-associated
TBmostly arises from the reactivation of a latent TB infection
(LTBI), which can be effectively prevented with proper treat-
ment.5 Therefore, guidelines strongly recommend screening
and treatment for LTBI for transplant candidates.1,6,7
The tuberculin skin test (TST) has been the reference
method for targeting TB chemoprophylaxis. However, its
low sensitivity in immunosuppressed patients and its limited
ability to identify patients at higher risk of reactivation com-
promise its reliability in transplant candidates. These limita-
tions, together with the prevailing lack of awareness of the
risk of active TB and a fear of isoniazid toxicity,8 make phy-
sicians not offer universal LTBI treatment in this population.
The T cell–based interferon-γ release assays (IGRAs) have
been increasingly used for detecting LTBI in many clinical
scenarios. Although published data suggest that IGRAs
might perform better than TST in immunocompromised pa-
tients, such as transplant candidates,9 little is known about
their ability to predict posttransplant TB.10-14Received 29 November 2014. Revision requested 22 February 2015.
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This study aimed to assess the usefulness of the Quanti -
FERON-TB Gold In-tube (QFT-GT) for predicting the devel-
opment of active TB in comparison to the TST in patients
undergoing liver transplant (LT) and hematopoietic stem cell
transplant (HSCT) in a low-TB burden setting (17.3 per
100,000 population).15
MATERIALS AND METHODS
We performed a prospective cohort study to evaluate the
performance of TST and QFT-GT for detecting LTBI in con-
secutive candidates to LT and HSCT between July 2008 and
July 2010 at Duran i Reynals and Bellvitge University Hospi-
tals in Barcelona (Spain). All patients provided written in-
formed consent before enrolment, and the ethics committee
approved the study.
Transplant candidates were referred to the TB unit for clin-
ical assessment and were asked to enrol after active TB had
been excluded. In accordance with current guidelines, we
followed a symptom-driven diagnostic workup for ruling
out active TB in our cohort. All patients were screened for re-
spiratory and had a chest x-ray performed. Because all our
patients were asymptomatic and there were no concerning
radiographic findings, no microbiologic testing was neces-
sary to evaluate for active TB infection.
Experienced staff took a blood sample for QFT-GT test-
ing, and TST was administered immediately after. For the
TST, any induration 5 mm or greater was considered posi-
tive.7 If the TST result was negative, another TST was ad-
ministered within a week to assess any booster effect. After
testing, patients were referred back to their treating phy-
sicians, who decided whether to treat them or not. In LT
candidates, the risk of liver toxicity was considered to out-
weigh the potential benefit of chemoprophylaxis regardless
of the TSTor QFT-GT results. The lack of specific guidelines
and the priority of treating a hematologic malignance also
meant no LTBI treatment for patients in the HSCT cohort.
By December 31, 2013, we checked on the statuses of pa-
tients by reviewing their medical charts and contacting their
physicians. We focused on transplant procedure and the de-
velopment of active TB and death. A definitive TB diagnosis
was defined as the isolation of Mycobacterium tuberculosis
complex in clinical samples, or a positivemolecular test result
and response to specific treatment. The incidence of active TB
was calculated both as a cumulative incidence and as a den-
sity incidence (events per person-year) with 95% confidence
intervals (95%CI). The positive/negative predictive values
for TB progression for each test were defined as the propor-
tion of patients with positive/negative results who did/did
not develop TB within the follow-up period, respectively.
RESULTS
The initial cohort included 90 patients with end-stage liver
disease and 27 patients with hematologic malignancies that
were considered for LT and HSCT, respectively. However,
of the patients with end-stage liver disease scheduled for
LT, 24 died before transplantation, 16 improved without
LT, and 50 (55.6%) eventually received LT by the follow-up
date. All 27 patients with hematologic malignancies received
HSCT but we excluded 1 candidate because he was screened
for LTBI after transplantation.
The baseline characteristics of both cohorts are summa-
rized in Table 1. The prevalence of LTBI according to the
TABLE 1.
Baseline Characteristics of Liver and Hematopoietic Stem Cell Transplant Recipients
Baseline Characteristics Liver Transplant, n = 50 (%) Hematopoietic Stem Cell Transplant, n = 26 (%) P
Age: median (IQR), y 57.5 (51-64) 52.0 (39-60) <0.01
Male sex 38 (76) 8 (30.8) <0.01
Spanish born 45 (90) 23 (88.5) 0.56
Risk factors for TB 5 (10.0) 4 (15.4) 0.37
Birth/residence in a high-prevalence country 2 (4.0) 3 (11.5) 0.22
Exposure to active TB 2 (4.0) 1 (3.8) 0.73
Occupational exposure 1 (2.0) — —
Immunosuppressive treatment in the previous 6 months 3 (0.06) 24 (92.3) <0.01
BCG scar 15 (30.0) 8 (30.8) 0.95
Primary reason for transplant
Alcoholic or hepatitis virus cirrhosis 24 (48.0) — —
Hepatocellular carcinoma 20 (40.0) — —
Other liver diseases 6 (12.0) — —
Acute leukemia — 6 (23.1) —
Lymphoma — 10 (38.5) —
Multiple myeloma — 8 (30.8) —
Others — 2 (7.6) —
TST result
Positive 23 (46.0) 8 (30.8) 0.2
Negative 27 (54.0) 18 (69.2) 0.2
QFT-GT result
Positive 22 (44.0) 7 (26.9) 0.15
Negative 26 (52.0) 19 (73.1) 0.08
Indeterminate 2 (4.0) — —
BCG indicates Bacillus Calmette-Guerin.
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QFT-GTwas 44% and 26.9% in the LT and HSCT cohorts,
respectively; 2 patients in the LT (2.6%) had indeterminate
results due to low production upon stimulation with phyto-
hemagglutinin. Regarding TST, 23 patients (46%) in the liver
cohort and 8 (30.8%) in the HSCT cohort presented with
positive reactions. Correlation of LTBI tests' results and tra-
ditional TB risk factors are shown in Table 2. Median time
from LTBI screening and transplantation was 15 days (inter-
quartile range [IQR], 8-23).
The LT cohort was followed up for a median of 47.5
months (IQR, 35.0-53.9) after transplantation, over which
period, 7 patients died, none was lost to follow-up, and
1 patient developed TB (incidence rate, 0.6 per 100 person-
years; 95%CI, 0.3-28.3). Hewas a 67-year-oldmanwith he-
patocellular carcinoma and positive QFT-GT and TST at
baseline, who presented with abdominal pain and anorexia
11 months after an orthotopic LT. A computed tomography
scan showed an ileocecal mass and a subsequent biopsy con-
firmed granulomatous inflammation. Culture from colonic
and liver biopsies yielded Mycobacterium tuberculosis com-
plex, and he made a complete recovery after a 9-month regi-
men of rifabutin, isoniazid, and levofloxacin.
The HSCT cohort was followed up for a median of
47.51 months (IQR, 27.0-57.5), and of the 26 participants,
7 patients died, 2 were lost to follow-up (after 113 and
370 days), and 1 patient developed TB (incidence rate, 1.1 per
100 person-years; 95% CI, 0.05-5.4). This patient was a
46-year-old woman who had tested negative for TST and
QFT-GT before receiving an allogeneic HSCT for acute leu-
kemia. Three months after transplantation, she developed
multiple organ dysfunction, which was attributed to pro-
gression of the leukemia. She died 15 days after being ad-
mitted to the intensive care unit. A skin biopsy culture re-
vealed infection with M. tuberculosis complex. Table 3
shows the incidence rates for TB and the predictive values
for progression to TB according to each diagnostic test.
DISCUSSION
This study aimed to determine the ability of the QFT-GT
to predict the development of active TB in patients undergo-
ing LTand HSCT. Our findings reveal a poor positive predic-
tive value of QFT-GT for progression, which is comparable
to that of the TST. Only 1 (4.5%) QFT-GT-positive patient
among LT recipients, and none of the QFT-GT-positive
HSCTrecipients, developed TBwithin 3.5 years of transplan-
tation. However, the risk of developing active TB among
QFT-GT-negative patients was minimal.
To our knowledge, only 4 studies have reported the inci-
dence of active TB in solid organ transplant recipients
screened with IGRAs.10-13 The incidence of TB in IGRA-
positive patients could only be assessed in 2 that did not offer
preventive therapy.10,11 Kim et al10 reported 4 cases of TB
among 71 T-SPOT.TB-positive patients in a prospective co-
hort of 272kidney transplant recipients,whereas Lange et al11
found no cases of active TB among 25 QFT-GT-positive solid
organ transplant recipients. Furthermore, no cases of TB
occurred among the combined 409 IGRA-negative trans-
plant patients in these retrospective studies. On the con-
trary, in their series of 633 and 87 patients, Jeong et al13
and Theodoropoulos et al12 described 1 (1.1%) and 2
(0.3%) cases of TB in QFT-GT–negative transplant patients,
respectively. Although there is limited data available on
IGRAs in HSCT recipients,11,14 these also report low posi-
tive and very high negative predictive values for progression
to active TB.
A recent study assessed the TST and both IGRAs to iden-
tify patients at risk for TB in different groups of immunocom-
promised patients in Europe.16 Although it included a large
number of solid organ transplant and HSCT recipients, both
LTBI tests were carried out after the transplant procedure.
Their results, including a high unexpected rate of indetermin-
ate results, are therefore not comparable with the present study.
There is no consensus on whether TST or IGRAs should
be used to assess the risk of transplant-associated TB and ulti-
mately prevent it.6 This uncertainty may be linked to the scar-
city of longitudinal data of simultaneous screening with both
tests, together with the inability of either test to predict the
development of active TB.16-18 In our study, incidence of
TB and predictive values for TB progression either in the LT
cohort or the HSCT cohort did not differ significantly with
the 2 tests. Although 2 series of kidney andHSCT patients re-
ported a higher incidence of TB in IGRA-positive than in
TST-positive patients, the differences were not statistically
significant.10,14 These results are consistent with those re-
ported in a previous meta-analysis, in which IGRAs showed
a modest, but higher positive predictive value for TB prog-
ression than the TSTwith and without risk stratification.17
TABLE 2.
Correlation of QFT-GT and TST Testing and Traditional TB Risk Factors for Both Cohorts
Liver Transplant Candidates HSCT Candidates
QFT-GT QFT-GT
Pos Neg Indet Global Pos Neg Indet Global
TST Positive 18a 4 1 23 5 3 0 8
No. Risk F 21,2 21,4 — 12 11 —
Negative 4 22 1 27 2 16b 0 18
No. Risk F — 22,3 — — 21 —
Global 22 26 2 50 7 19 0 26
a Case 1: a 67-year-old Spanish man developed disseminated TB 387 days after LT (and 532 days after LTBI screening). He had no specific TB risk factors and had tested positive for TST and QFT while awaiting
liver transplantation for hepatocellular carcinoma.
b Case 2: a 46-year-old Spanish woman developed disseminated TB 100 days after HSCT (and 116 days after LTBI screening). He had tested negative for both TST and QFT. She had no specific risk factors for TB.
The reason for practicing an unrelated allogeneic bone marrow transplant was an acute leukemia.
Indet, indeterminate. No. Risk F: Number of patients with risk factors for TB, as described: being born in a high-prevalence TB country1, previous TB close contact2, health worker3, (ex-) intravenous drug user4.
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The major advantage of IGRAs over the TST in healthy
people in low-prevalence settings is that it can reduce the num-
ber of people considered for preventive chemotherapywithout
increasing the risk of subsequent active TB.19 Although this
characteristic cannot be applied to immunocompromised pa-
tients, in whom IGRAsmay not save LTBI diagnostics as com-
pared with TST, the negative predictive value of IGRAs for
progression to active TB is consistently high in this popula-
tion, and probably better than that of the TST.17
Therefore, with the current data available, the choice of
TST or IGRAs for screening transplant candidates should
be based on the expected specificity in each setting, opera-
tional factors, logistics, patients' preferences, and cost; and
always keeping in mind that a negative result does not rule
out the future risk of developing TB.16
The main limitation of our study is the small sample size
and the low progression rate during follow-up, both of which
preclude an accurate estimation of the incidence and predic-
tive values for progression to active TB.
In conclusion, the rate of posttransplant TB among QFT-
GT-positive patients was both low and comparable to that
of the TST in this cohort of LT and HSCT recipients. Our re-
sults add to the evidence that IGRAs are poor at predicting
the development of active TB in transplant recipients.
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Summary Objectives: To assess whether Interferon-g release assays (IGRAs) reduce the
number of people considered for tuberculosis (TB) preventive treatment without increasing
subsequent active disease.
Methods: Longitudinal studies with both tuberculin skin test (TST) and IGRAs were identified
through a PubMed search. Reductions in diagnosis of TB infection and increases in incident
TB in people considered not infected, using IGRAs either instead of TST or as a confirmatory
test (two-step approach), were assessed.
Results: In comparison with TST alone, the pooled reductions in diagnosis of TB infection ob-
tained with IGRAs were 16.7% and 5.8% at 5 and 10 mm cut-offs respectively, and 24.5% and
12.4% at 5 and 10 mm respectively with the two-step approach. Compared with TST alone, in-
cident TB among people considered not infected increased with the two-step approach (0.94%
with T-SPOT!.TB and 1.1% with QuantiFERON!-TB Gold In-Tube) in one of seven studies in high-
income countries. In middle- and low-income countries, two of four studies presented in-
creases (0.08 and 0.03 per 100 patient-years respectively) with the two-step approach.
Conclusions: In high-income countries, the use of IGRAs, either instead of TST or as confirma-
tory test reduces the number of people considered for preventive treatment, without a signif-
icant risk of subsequent active disease.
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Introduction
The detection and treatment of latent tuberculosis in-
fection (LTBI) is an important component of the tubercu-
losis (TB) elimination strategy worldwide.1 This is
particularly so in low burden TB countries, in which most
new cases occur due to reactivation of a past acquired in-
fection.2 However, while the effectiveness of this practice
has been demonstrated,3,4 the number of people who must
be treated to prevent a single TB case is disproportionally
high because of the low ability of the tuberculin skin test
(TST) to predict development of active TB.5e7 Furthermore,
the long treatment duration and occurrence of adverse
events, as well as the need for regular monitoring during
treatment, frequently lead to suboptimal adherence to
treatment and low completion rates.8
T-cell-based interferon-g release assays (IGRAs) arose as
a promising alternative to the old TST. Unfortunately,
despite their higher specificity9 and better association
with risk factors for acquisition of Mycobacterium tubercu-
losis infection,10 their accuracy for predicting the develop-
ment of active TB is low e at best, only slightly better than
TST.6,7 In a systematic review (SR) by Rangaka et al.,6 com-
pared with test-negative results, the incidence rate ratio
(IRR) for incident TB was 2.11 (95%CI 1.29e3.46) for IGRA-
positive and 1.60 (95%CI 0.94e2.72) for TST-positive at
10 mm cut-off. In another SR, Diel et al.7 found a positive
predictive value of 2.7% (95%CI 2.3e3.2) for IGRAs and
1.5% (95%CI 1.2e1.7) for TST. Nevertheless, since the pro-
portion of positive results obtained with IGRAs is usually
lower than with TST, and considering the very low risk of
developing TB with a negative test,6,7 their use may still
be preferable, since they substantially reduce the number
of people put on treatment.
We aimed to ascertain whether using an IGRA either in
place of TST or to confirm a positive TST might reduce the
number of people considered for preventive treatment
without leading to a significant increase in the risk of
subsequent active TB.
Methods
This systematic review was conducted in accordance with
the PRISMA statement.11
Search strategy and study selection
We searched PubMed for relevant original articles, using
a pre-established combination of terms: “tuberculosis”,
“QuantiFERON-TB”, “T-SPOT.TB”, “interferon-gamma as-
say”, “predictive value”, “incident tuberculosis” and “tu-
berculin skin test”, as listed in titles, abstracts or text
words. The search was limited to studies in humans
published in English or Spanish between January 1, 2005
and May 31, 2012. We also reviewed citations of the original
and review articles, and guidelines for additional refer-
ences. We selected longitudinal studies of healthy or
immunosuppressed individuals, adults or children, in which
patients were screened for LTBI with TST and an IGRA
(commercial available tests [QuantiFERON!-TB Gold In-
Tube (QFT-GIT) and T-SPOT!.TB] or in-house developed
Elispot) either together or as a confirmatory test of a posi-
tive TST result, which also provided results on incident TB
in people left untreated. We excluded studies with the
old version of the ELISA assay (QuantiFERON!-TB Gold),
studies in which IGRAs were not performed according to
the manufacturer’s instructions, and studies presenting
non-original data, conference abstracts, editorials, reviews
and guidelines.
Quality assessment
We checked the quality of the studies with the QUADAS
check list,12 and a modified Newcastle-Ottawa scale for
non-randomized observational studies,13 adapted from
Rangaka et al.6
Data extraction
The two authors (L.M. and M.S.) independently in duplicate
conducted the study selection and compiled the data using
a standardized data extraction sheet. Discrepancies were
resolved by discussion and consensus. The following data
were recorded: author, date of the study and year of
publication, country, design (prospective/retrospective),
population of the study, prevalence of BCG vaccination,
IGRA evaluated (ELISA, Elispot, in-house, commercial), cut-
off for positivity of TST, TST and IGRA results, development
of incident active TB and length of follow-up.
Data synthesis and analysis
We looked at the reduction in the proportion of individuals
diagnosed with TB infection and the increase in rates of
incident active TB by using an IGRA either as alternative to
TST or as a confirmatory test (two-step approach) with
respect to the standard practice (TST alone). To do so, we
compared the number of diagnoses of TB infection with TST
(TST-positive), with IGRAs (IGRA-positive) and with TST
followed by an IGRA (TST-positive/IGRA-positive). Reduc-
tion in diagnosis of TB infection with IGRAs was represented
by the subset of individuals with discordant TST-positive/
IGRA-negative results. Increases in rates of active TB with
the alternative approaches to TST alone would be repre-
sented by individuals with a negative IGRA who developed
TB during the follow-up, and who would have been
captured by TST.
Rates of incident TB are given as presented in the
original papers, either as cumulative incidence or person-
years incidence rates (density incidence). The results of
both outcomes were stratified for countries income status
according to the World Bank Classification.14 Pooled esti-
mates were only obtained for reduction in diagnosis of TB
infection by either alternative to TST alone (IGRA instead
of TST or as a confirmatory test of TST) according to the
TST cut-off for positivity (5 or 10 mm). Overall pooled esti-
mates were precluded by the distinct cut-offs used for TST.
A random-effects synthesis model meta-analysis was used
to pool the effect across the studies. Heterogeneity was
quantified by the I2 statistic. The analyses were performed
with MetaAnalyst software.15
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Results
Characteristics of the studies
Of the 131 citations identified, 11 were eligible for the
analysis (six studies with QFT-GIT,16,18,20,21,23,26 two with
commercial T-SPOT.TB,19,25 two with in-house Elispot,22,24
and one that included both QFT-GIT and T-SPOT.TB17)
(Fig. 1 and Table 1 of the supplementary material). For
the study including QFT-GIT and T-SPOT.TB,17 results of
the two tests were reported separately. In two studies,16,17
an IGRA was performed as a confirmatory test in individuals
with positive TST. Seven studies were conducted in high-in-
come,16e21,23 three in middle-income countries,22,25,26 and
one in a low-income country.24 Five studies followed up TB
case contacts,16e18,22,24 three followed up patients with
immune-mediated inflammatory diseases (IMID) screened
prior to anti-TNF therapy,19,20,23 one followed up a cohort
of patients with silicosis,25 one followed up a cohort of asy-
lum seekers,21 and one followed up adolescents in a high-
burden TB area.26 Preventive treatment was offered to in-
dividuals with a positive IGRA regardless of TST result, in six
studies16,18e21,23; to individuals with positive TST in
two,22,25 and no treatment in three.17,24,26 For the two
studies in which TSTwas used as the diagnostic test to insti-
tute preventive treatment, the group of individuals who re-
fused it was the subset of our analysis (untreated
individuals with negative TST and positive TST/negative
IGRA).22,25
Five studies met the 14 quality indicators,16,18,22,24,25
and the other six met all but one.17,19e21,23,26 As for the as-
sessment of incident TB, length of follow-up was adequate
in most cases (at least two years in eight studies16e18,22e26)
and the samples evaluated were representative of the pop-
ulation at risk in all the studies. However, the quality was
constrained by the lack of independent blind assessment,
incorporation of either IGRA or TST into the reference stan-
dard for the diagnosis, and the low proportion of culture-
confirmed diagnoses of TB cases. Five studies stated the
time period elapsed from screening to diagnosis of active
disease to define incident TB17,21,24e26 (three months in
Figure 1 Flowchart for study selection.
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two studies, two months in two, and from day 0 in one
other), and six did not report it.17e20,22,23 However, of
these six studies, the cases recorded occurred after three
months in three studies, and no cases occurred in the other
three (Table 2, supplementary material).
Prevalence of LTBI according to TST and IGRA
results
Prevalence of LTBI with TST was higher than with IGRAs in
eight of the nine studies in which the two tests were
performed in all patients.18e22,24e26 In the other study, con-
ducted in a high-income country with IMID patients,23 IGRA
yielded a slightly higher rate of positive results than TST
(Table 3, supplementary material).
Overall, using an IGRA test to screen TB infection would
have achieved a reduction in diagnosis rates of TB in-
fection, either by replacing TST (nine studies18e26 with a to-
tal of 9304 patients) or as a confirmatory test for TST (11
studies16e26 with a total of 11,996 patients) (Tables 1 and
2). The pooled reduction in the diagnosis by using an IGRA
in place of TST varied according to the TST cut-off used
(pooled 16.7% [95%CI 0.6e32.8; I2 Z 98.6%], and 24.5%
[95%CI 13.0e36.1; I2Z 97.9%] when IGRA was used instead
of TST and as a confirmatory test respectively using a 5 mm
cut-off, and 5.8% [95%CI "4.1 to 15.8; I2 Z 54.8%], and
12.4% [95%CI 4.0e20.9; I2Z 90.9%] when IGRA was used in-
stead of TST and as a confirmatory test respectively using
a 10 mm cut-off).
Incident active TB in individuals without TB
infection according to the TST and IGRA results
To assess whether the reduction in the diagnosis of TB
infection and the secondary increase in the number of
individuals left untreated might lead to a rise in rates of
subsequent active TB, we looked at the development of
active disease in people considered non-infected by any of
the three screening approaches (TST, IGRA in place of TST,
and IGRA as a confirmatory test for TST).
High-income countries
Increase in incident TB was assessed in seven stud-
ies,16e21,23 which included 4560 individuals (2616 had a neg-
ative TST result, 1458 of 2179 who had undergone the test
had a negative IGRA result, and 3533 had either a negative
TST or a positive TST/negative IGRA result). There was
a slight increase in the incidence of subsequent active TB
with the TST/IGRA approach in one study17 (0.94% and
1.1% with T-SPOT.TB and QFT-GIT respectively) with re-
spect to TST (Table 3). In this study, conducted in the Neth-
erlands17 with immigrant TB contacts born in high burden
countries, both IGRAs were only performed in individuals
with a positive TST result. This approach missed two indi-
viduals using T-SPOT.TB, and three individuals using QFT-
GIT who developed active TB during a two-year follow-up
period, and who would have been considered infected by
the TST result. The contacts who later developed active
TB had their IGRA test performed shortly after the diagnosis
of the index case (5, 19 and 34 days for the three patients
with negative QFT-GIT, and 5 and 34 days for the two pa-
tients with negative T-SPOT.TB), and the test was not re-
peated later. There was no increase in incident TB in the
other six studies.16,18e21,23
Middle- and low-income countries
Increase in incident TB was assessed in four studies,22,24e26
which included 7586 individuals (3714 had a negative TST
result, 4049 had a negative IGRA result, and 4645 had either
a negative TST or a positive TST/negative IGRA result).
There was a slight increase in incident TB with the TST/
IGRA approach in two of the four studies (Table 4).24,26 In
one of them, conducted in TB contacts in the Gambia,24
the two-step approach would have missed four individuals
who were later diagnosed with active TB, and who would
have been considered infected by the TST result, which
represented an increase of 0.08 per 100 pyrs. The other
Table 1 Prevalence of TB infection with IGRAs either in place of TST or as a confirmatory test compared to TST alone. High-
income countries.
Reference (Year) Population TST cut-off Reduction in diagnosis of TB infection (%; 95%CI)a
IGRA vs TST TST/IGRA vs TST
Song16 (2007) TB case-contacts #10 mm NA 67 (3.7; 1.5e5.9)
Kik17 (2009)b TB case-contacts #5 mm NA 118 (27.3; 20.7e33.4)
Kik17 (2009)c TB case-contacts #5 mm NA 167 (38.6; 32.3e44.4)
Diel18 (2010) TB case-contacts #5 mm 410 (45.5; 41.4e49.4) 412 (45.7; 41.4e49.4)
Laffite19 (2009) Anti-TNF candidates #10 mm 10 (21.7; 3.3e38.4) 10 (21.7; 3.3e38.4)
Garcovich20 (2011) Anti-TNF candidates #5 mm 3 (6.8; "7.3 to 21.3) 3 (6.8; 0e19.9)
Chang23 (2011) Anti-TNF candidates #10 mm "1 (1.2; "14.4 to 16.7) 16 (19.3; 5.0e32.5)
Harstad21 (2010) Asylum seekers #6 mm 178 (22.0; 17.3e26.6) 208 (25.7; 21.0e30.2)
TBZ tuberculosis; TSTZ Tuberculin Skin Test; IGRAZ Interferon Gamma Release Assay; QFT-GITZ QuantiFERON-TB Gold In-tube; T-
SPOTZ T-SPOT.TB; TST/IGRA denotes sequential approach (positive TST followed by IGRA as a confirmatory test); NAZ not applicable
(IGRA performed only to individuals with positive TST); TNF Z tumor necrosis factor.
a Reduction in the number of diagnoses of TB infection by using an IGRA test either in place of TST (IGRA vs TST) or as a complementary
test for a positive TST result (TST/IGRA vs TST), as alternative strategies to TST alone.
b With T-SPOT.
c With QFT-GIT.
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study, which involved adolescents in South Africa,26 found
a slight rise in rates of subsequent active TB with the
TST/IGRA approach (0.03 per 100 pyrs).
Discussion
In this systematic review we assessed whether using IGRAs
either in place of TST or to confirm its positivity might
reduce the number of diagnoses of latent TB, and therefore
considered for preventive treatment, without increasing
the risk of incident active TB. The available evidence,
although scarce, strongly suggests that in immunocompe-
tent people in high-income countries IGRAs can replace TST
or being used as a confirmatory test to reduce the number
of people considered for preventive treatment, without
increasing subsequent active disease. In the Netherlands
study17 the two IGRAs missed some few recently exposed
close contacts who later developed TB. However, they
were administered only once, and shortly after the diagno-
sis of the index case; since IGRAs have a “window period”
after exposure, like TST,27 it is plausible that the contacts
with initial negative IGRA results would have been captured
if the test had been repeated a few weeks later.
Which of the two alternative approachese IGRA either in
place of TSTor as a confirmatory teste is better for screening
people at risk is a matter of debate. In immunocompetent
individuals, in whom TST sensitivity is roughly comparable to
that of the IGRAs, a two-step approach may be appropriate.
Table 2 Prevalence of TB infection with IGRAs either in place of TST or as a confirmatory test compared to TST alone. Middle-
and low-income countries.
Reference (Year) Population TST cut-off Reduction in diagnosis of TB infection (%; 95%CI)a
IGRA vs TST TST/IGRA vs TST
Hill24 (2008) TB case-contacts #10 mm 53 (3.2; "0.1 to 6.5) 230 (14.0; 10.8e17.1)
Bakir22 (2008) TB case-contacts #5 mm 47 (16.4; 9.4e23.2) 73 (25.4; 19.2e31.2)
Leung25 (2010) Patients with silicosis #5 mm 10 (4.1; "4.4 to 12.6) 37 (15.4; 6.6e23.8)
Mahomed26 (2011) Adolescents with no prior TB #5 mm 225 (4.3; 2.4e6.2) 511 (9.7; 7.8e11.6)
TB Z tuberculosis; TST Z Tuberculin Skin Test; IGRA Z Interferon Gamma Release Assay; T-SPOT Z T-SPOT.TB; QFT-
GIT Z QuantiFERON-TB Gold In-tube; TST/IGRA denotes sequential approach (positive TST followed by IGRA as a confirmatory test).
a Reduction in the number of diagnoses of TB infection by using an IGRA test either in place of TST (IGRA vs TST) or as a complementary
test for a positive TST result (TST/IGRA vs TST), as alternative strategies to TST alone.
Table 3 Incident TB in individuals considered not infected according to the TST and IGRA results. High-income countries.
Reference
(Year)
Population Follow-up Incident TB in individuals without
TB infection n/N (Incidence)a
Increase in incidenceb
TST
(TST-ve)
IGRA
(IGRA -ve)
TST/IGRA
(TST-ve and
TSTþve/IGRA-ve)
IGRA vs TST TST/IGRA
vs TST
Song16 (2007) TB case-contacts 2 yrs 10/1556
(0.6%)
N.A. 10/1623 (0.6%) N.A. No
Kik17 (2009)c TB case-contacts 2 yrs 0/94 N.A. 2/212 (0.94%) N.A. Yes (0.94%)
Kik17 (2009)d TB case-contacts 2 yrs 0/94 N.A. 3/261 (1.1%) N.A. Yes (1.1%)
Diel18 (2010) TB case-contacts Up to 4 yrs 2/346
(0.6%)
0/750 2/756 (0.3%) No No
Garcovich20
(2011)
Anti-TNF
candidates
1 yr 0/39 0/44 0/42c No No
Chang23 (2011) Anti-TNF
candidates
2 yrs 0/65 0/64 0/64 No No
Laffite19 (2009) Anti-TNF
candidates
1.5 yrs 0/28 0/38 0/38 No No
Harstad21 (2010) Asylum seekers 23e32
months
0/394 0/562 0/601 No No
n/N Z cases of incident TB/individuals considered not infected by each of the three approaches; TST Z tuberculin skin test;
IGRAZ interferon-gamma release assays; QFT-GITZ QuantiFERON-TB Gold In-tube; T-SPOTZ T-SPOT.TB; TST/IGRA denotes sequential
approach (positive TST followed by IGRA as a confirmatory test); N.A. Z Not applicable; TNF Z tumor necrosis factor.
a Cumulative incidence (%) or incidence rate per 100 pyrs.
b Increase in incidence among individuals considered not infected by using an IGRA test either in place of TST (IGRA vs TST) or as a com-
plementary test for a positive TST result (TST/IGRA vs TST), as alternative approaches to TST alone.
c With T-SPOT.
d With QFT-GIT.
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After an initial TST, an IGRA would reduce the number of
individuals considered for preventive treatment and follow-
up. The lower the expected rate of infection in the
population screened, the more cost-effective this strategy
will be. In contrast, in populations with an expected high
prevalence of infection, it is likely that replacing TSTwith an
IGRA may be safe and more cost-effective.
In immunosuppressed populations, the present review
identified three small longitudinal studies with IMID patients
screened for LTBI before starting anti-TNF agents,19,20,23 in
which none of 29 patients with positive TST/negative IGRA
andnoneof 146with negative IGRA, regardless of TSTresults,
had developed active TB after at least 12 months of follow-
up. These results, though promising, should be confirmed in
larger cohort studies. As the initial TST in immunosuppressed
patients may miss some individuals who would not have the
chanceofbeing capturedby the IGRA, the two-stepapproach
may not be an appropriate strategy in these patients. Our
review did not identify any similar studies in HIV-infected
patients. However, the high negative predictive value of
QFT-GIT reported in a large cohort28 suggests that IGRAs
could replace TST for detecting latent infection in HIV-
seropositive people.
Results obtained for high-income countries are not
applicable to low-income high TB burden settings. In two
large cohorts in the Gambia24 and South Africa,26 a propor-
tion of individuals who later developed active TB were
missed by using an IGRA in place of TST or in a two-step
fashion. The results of this analysis, together with the mod-
est predictive value of IGRAs, which does not add meaning-
ful contribution to TST, and the high TB burden favoring re-
infection, bear out the recommendations of the World
Health Organization (WHO), which advise against the use
of IGRAs for identifying people at risk in these settings.29
Therefore, implementation of IGRAs in constrained-
resource settings for screening people at risk of developing
active TB should be based on operational factors and cost
rather than on clinical benefits.
This systematic review has limitations. First, most
studies have important shortcomings related to the longi-
tudinal assessment of the development of active TB.
Moreover, in two studies, there was a self-selection bias
due to the fact the cohort of analysis comprised people who
refused preventive treatment. Second, the limited data on
immunosuppressed people precludes drawing any firm
conclusions regarding these populations.
In summary, IGRAs substantially reduce the number of
diagnoses of TB infection, and therefore, the number of
people considered for preventive treatment. Among TB
contacts in high-income settings, using an IGRA in place of
TST or as a confirmatory test does not increase the risk
of subsequent active TB. Among immunosuppressed
patients, replacing TST with an IGRA may be appropriate.
However, more evidence is needed because of the limited
available evidence. In low-income high TB burden coun-
tries, there is an increase in the incidence of active TB
among people with negative IGRA compared to those with
negative TST, which argues against the use of IGRAs in these
settings.
Appendix A. Supplementary material
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.jinf.2012.12.005.
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Abstract  
 
Objective. To assess the utility of QuantiFERON®-TB Gold In-tube (QFT-GIT) for targeting 
preventive therapy in BCG-vaccinated contacts of tuberculosis (TB), based on its high 
specificity and negative predictive value for development of TB. 
Methods. We compared two screening strategies for TB contact tracing in two consecutive 
periods: the tuberculin skin test (TST) period, when all contacts were screened with the TST 
alone; and the QFT-GIT period, when BCG-vaccinated contacts underwent TST and QFT-
GIT. Diagnosis of TB infection among BCG-vaccinated contacts relied on TST ≥5 mm in the 
TST period, while in the QFT-GIT period either a positive QFT-GIT or a TST ≥15 mm was 
required.  
Measurements and main results. Six hundred and sixty-one contacts were compared. In the 
QFT-GIT period there was a reduction in diagnoses of TB infection (77.4% vs. 51.2%; p 
<0.01) and preventive therapy prescribed (62.1% vs. 48.2%; p = 0.02) among the 290 BCG-
vaccinated contacts. After a median follow-up of 5 years, cumulative incidences of TB were 
0.62 and 0.29 in the TST and QFT-GIT periods respectively (p = 0.59). 
Conclusions. In BCG-vaccinated TB contacts, the addition of QFT-GIT safely reduced TB 
diagnosis and treatment rates without increasing the risk of subsequent active TB.  
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Introduction 
Detection and treatment of recently infected people is an essential measure of tuberculosis 
(TB) control in low-prevalence countries [1]. Up to approximately ten years ago, the 
diagnosis of TB infection relied exclusively on the tuberculin skin test (TST). A positive TST 
response indicates infection with Mycobacterium tuberculosis indirectly, by measuring the 
delayed-type hypersensitivity response to the intradermal injection of a mixture of wall 
antigens, the so-called PPD (purified protein-derivate), which is shared by many 
mycobacteria species and the Bacillus Calmette–Guérin (BCG) strain [2]. The main 
limitations of the TST for targeting preventive therapy among the contacts of patients with 
pulmonary TB (TB contacts) are its low specificity and poor ability to identify those likely to 
develop active disease [3]. Thus, a high number of TB contacts need to be treated to prevent a 
case of TB in clinical practice. 
By contrast to the TST, the interferon-γ release assays (IGRAs), the in vitro 
immunodiagnostic tests based on M. tuberculosis complex-specific antigens, have no cross-
reactivity with the BCG-vaccine strains and most non-tuberculous mycobacteria [4-6]. After 
more than a decade, evidence indicates that, at best, the ability of these tests to predict the 
development of TB is only a little better than that of the TST [7, 8]. Nevertheless, IGRAs 
yield fewer positive results than TST, are more specific, and have shown a high negative 
predictive value for better selecting those immunocompetent individuals who will not 
develop TB; thus, their use for targeting TB contacts for preventive therapy, especially in 
BCG-vaccinated subjects, may still be preferable to TST and also more cost-effective [9].  
In 2007, the QuantiFERON®-TB Gold In-tube (QFT-GIT) test was implemented in our 
center. Shortly after, our TB Unit modified its internal protocol for contact tracing by adding 
the QFT-GIT to the ongoing TST-based strategy for screening and informing treatment 
decisions in BCG-vaccinated contacts of TB. Here, we report our experience with this 
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practice. We hypothesized that using the QFT-GIT to target TB contacts would reduce the 
number of individuals diagnosed with, and treated for, TB infection compared with the 
previous TST-only strategy without an increased risk of subsequent active TB.  
 
Methods 
 
Design, setting, and study population 
A retrospective comparative study of two screening strategies for TB contact tracing was 
performed at the TB Unit of a teaching hospital for adults in Barcelona (Spain) between 
January 2006 and December 2010. The Ethics Committee of Bellvitge University Hospital 
approved the study (PR269/11). 
We included immunocompetent contacts older than 15 years who had no history of TB 
infection and whose index case had culture-proven non-MDR pulmonary TB. As part of 
routine clinical practice, medical histories, BCG-vaccination status (vaccine scar), treatment, 
adverse events and adherence to therapy had been gathered prospectively.  
 
Screening strategies and preventive therapy 
We compared two consecutive 30-month periods: TST period (January 2006 to May 2008), 
and QFT-GIT period (June 2008 to December 2010). In both periods, active TB was ruled 
out through symptom-guided interview and chest X-ray. In the TST period there was no 
difference in contact management regarding BCG-vaccination status: the screening was 
performed with TST, and non-responders underwent a second test after the window period (8 
weeks). Preventive therapy was prescribed if TST was ≥5 mm by 48–72 hours after 
administration. In the QFT-GIT period, two different strategies were used according to BCG-
vaccination status. While non-BCG contacts were screened only with TST, as in the TST-
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period, BCG-vaccinated contacts were simultaneously screened using both the QFT-GIT 
assay and the TST. In this group preventive therapy indication was established by either a 
positive QFT-GIT assay or a TST result ≥15 mm. If the QFT-GIT assay was negative and the 
TST was <15 mm, a second QFT-GIT assay was performed 8 weeks later. Treatment 
regimens included 6–9 months of treatment with isoniazid (INH) as the first-choice option, or 
4 months with rifampicin (RMP) or 3 months with RMP plus INH as alternative regimens. 
While on treatment, contacts had regular appointments at the TB unit. There, both blood tests 
for monitoring liver function and adherence assessments were carried out. The latter included 
the Eidus-Hamilton test [10] for those taking INH and the simple checking of urine color for 
those on rifampicin. 
 
Follow-up 
In 2015, the vital status and development of TB were checked among all contacts by 
retrospective review of the electronic medical records of both the Hospital and local primary 
care services, which were available online. If no data were available for the last 6 months or 
before the contact completed at least 5 years of follow-up, individuals were contacted by 
phone and briefly interviewed using a pre-designed questionnaire form. If the contact was not 
reachable, they were considered lost to follow-up. Contacts were censored at the time of 
active TB diagnosis, death, loss to follow-up, or after 5 years of follow-up, whichever came 
first. 
 
 
Data Analysis 
Incidence was given as the density of incidence (TB cases per person-time). Continuous 
variables were presented as medians (interquartile ranges) and compared with the Student t 
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test or the Mann–Whitney U rank test, as appropriate. Differences in categorical variables 
were assessed with the χ2 test. All statistical analyses were two-tailed, and a p-value <0.05 
was considered statistically significant. Analyses were performed with IBM® SPSS® Statistics 
for Macintosh, Version 22.0 (IBM Corp., Armonk, NY; released 2013) and the OpenEpi 
software (Open Source Epidemiologic Statistics for Public Health) [11]. 
 
Results 
 
During the study period, 1395 contacts of 360 index cases were evaluated, and 661 were 
included in the analysis (321 in the TST period and 340 in the QFT-GIT period). The 
selection of eligible contacts is summarized in Fig 1, and the baseline characteristics of the 
cohort by study period is shown in Table 1. The QFT-GIT period included a higher 
proportion of foreign-born individuals (p <0.01), close contacts (p <0.01), and BCG-
vaccinated subjects (p = 0.01).  
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Figure 1. Chart of the contacts included  
 
 
 
TB: tuberculosis; HIV: human immunodeficiency virus; MDR: multi-drug resistant; ESRD: end-stage renal 
disease; TST: tuberculin skin test; NTM: Non-tuberculous mycobacteria  
a12 and 6 patients in the first and second period, respectively. 
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Table 1. Baseline characteristics and immunodiagnostic test results by study period 
 
 TST period 
(n= 321) 
QFT-GIT period 
(n= 340) 
 
p 
Gender, man; n (%) 151 (47.0) 157 (46.2) 0.82 
Age; median (IQR) 37 (25.5-48.5) 33.5 (21-46) 0.08 
Foreign-born; n (%) 72 (22.4) 148 (43.5) <0.01 
    -Latin America; n (% of foreign-born) 40 (55.6) 94 (63.5) -- 
    -North Africa 9 (12.5) 22 (14.9) -- 
    -Sub-Saharan Africa  1 (1.4) 15 (10.2) -- 
    -India/Pakistan 1 (1.4) 12 (8.1) -- 
    -South-East Asia 3 (4.2) 2 (1.4) -- 
    -Eastern Europe 18 (25) 3 (2) -- 
Close contacta; n (%) 170 (53.0) 222 (65.3) <0.01 
Index case with positive smear; n (%) 229 (71.3) 228 (67.1) 0.24 
BCG-vaccination; n (%) 124 (38.6) 166 (48.8) 0.01 
1st TST-positive; n (%) 194 (60.4) 168 (49.4) <0.01 
TB infection diagnosis; n (%) 223 (69.5) 184 (54.1) <0.01 
     BCG-vaccinated 96/124 (77.4) 85/166 (51.2) <0.01 
     Non-BCG-vaccinated 127/197 (64.5) 99/174 (56.9) 0.14 
Preventive therapy prescribed; n (%) 186 (57.9)  171 (50.3) 0.05 
 
IQR: interquartil range, BCG: Bacillus Calmette-Guérin, TST: tuberculin skin test. 
a Exposure to the index case was stratified as close (household or daily ≥6 hours of exposure), frequent (daily <6 
hours of exposure), and occasional (no household or daily exposure, and <2 hours of exposure each time). 
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TB Infection diagnosis and preventive therapy  
Regarding diagnosis, 407 of 661 contacts (61.6%) were diagnosed with TB infection 
according to the definition in each period (69.5% in the TST period and 54.1% in the QFT-
GIT period; p <0.01). Of the 290 BCG-vaccinated contacts in both periods, 181 (64.5%) were 
diagnosed with TB infection (77.4% in the TST period and 51.2% in the QFT-GIT period; p 
<0.01). Table 2 shows the results of both tests for TB infection diagnosis in the 166 BCG-
vaccinated patients in the QFT-GIT period. As for the 371 non-BCG contacts, 226 (60.9%) 
were diagnosed with TB infection, with no significant differences between periods (64.5% in 
the TST period and 56.9% in the QFT-GIT period; p = 0.14).  
 
Table 2. TST and QFT-GIT results of BCG-vaccinated patients in the second period 
 QFT-GIT  
Positive Negative 
TST Positive 55 
(40 (73%) patients with TST ≥15 mm) 
44 
(21 (48%) patients with TST ≥15 mm) 
99 
Negative 9 58 67 
 64 102 166 
 
TST: tuberculin skin test; QFT-GIT: QuantiFERON®-TB Gold In-Tube. 
 
While there was a higher proportion of diagnosis of TB infection among BCG-vaccinated 
contacts than among non-BCG-vaccinated contacts in the TST-period (77.4% and 64.5% 
respectively; p = 0.01), there was no such difference in the QFT-GIT period, when TB 
infection was diagnosed in 51.2% and 56.9% of BCG-vaccinated and non-BCG-vaccinated 
contacts respectively; p = 0.29) (Fig 2).  
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Figure 2. Proportion of TB infection diagnosis by study period and BCG-vaccination 
status 
 
 
 
As regards treatment, 357 courses of preventive treatment were prescribed. There were 50 
contacts diagnosed with TB infection that were not recommended treatment: 37 (16.6%) and 
13 (7%) in the TST and QFT-GIT-periods respectively. Eight contacts refused treatment. The 
most common regimen was 6-month INH (n = 275), followed by INH for 9 months (n = 47), 
rifampicin for 4 months (n = 19), and combination therapy with INH-RMP for 3 months (n = 
8). Among the 330 INH-based regimens, 19 individuals (5.8%) developed toxicity and 
required drug withdrawal; 14 of them (73.7%) completed treatment with RMP. Overall, 290 
(81.2%) contacts completed a whole course of treatment (77.9% and 87.1% in the TST and 
QFT-GIT periods, respectively).  
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Development of active tuberculosis 
The outcomes of the 661 contacts are shown in Table 3. Information was retrievable from the 
electronic medical records for 616 (93.2%) individuals, and another 45 (6.8%) were 
contacted by phone.  
 
Table 3. Final disposition and incidence of active TB by study period 
 TST period 
(N = 321) 
QFT-GIT period  
(N = 340) 
p 
Dieda 11 13 0.79 
Lost to follow-up before 5 years 
Median follow-up, years (IQR) 
14 
3.5 (2.0-4.2) 
54 
3.6 (2.7-4.4) 
<0.01 
0.5 
Follow-up (5 years maximum) 
   Median (IQR), years 
   Patient-years 
 
5 (N.A) 
1581.84 
 
5 (4.9-5.0) 
 1595.15 
 
Incident TB cases 2 1 0.96 
Cumulative incidence, % 0.62 0.29 0.59 
Density of incidence,   
(TB cases x 1 000 p-years (95%CI)) 
1.26 (0.21-4.18) 0.63 (0.03-3.09) 0.62 
 
TB: tuberculosis. TST: tuberculin skin test; QFT-GIT: QuantiFERON®-TB Gold In-Tube. N.A: non-applicable.a 
Died of non-TB related causes.  
 
Over the median follow-up period of 5 years, three contacts developed active TB: two 
screened in the TST period and one screened in the QFT-GIT period. Table 4 shows their 
main features.  
 
  
	100	
Table 4. Descriptive features of the TB cases diagnosed during the follow-up period 
 
 TST period QFT-GIT period 
Time from the first TB 
infection screening (years) 
4.5 4.2 3.3 
Description and relationship 
with the index case 
Man, 51 
Spanish 
BCG-vaccinated 
Occasional 
relationship  
Woman, 22 
Bolivian 
BCG-vaccinated 
Close contact  
Woman, 26 
Spanish  
Not-BCG-vaccinated  
Close contact  
TB infection screening Negative TST and 
booster.  
No TB infection. 
No treatment. 
Positive TST (16 mm).  
TB infection diagnosis and 
treatment 
Positive TST (13 mm); 
switched from negative 
after the window period) 
TB infection diagnosis and 
treatment 
Risk factor for developing TB  No risk factors Abandoned preventive 
treatment in the first month 
(pregnancy)  
Lack of adherence to 
treatment (6-month 
isoniazid) 
Form of TB Pulmonary 
Upper lobes. 
Pulmonary  
Upper lobes. 
Pulmonary 
Upper lobes. 
 
BCG: Bacillus Calmétte-Guerin; IC: Index case; TST: tuberculin skin test; TB: tuberculosis.  
 
Discussion 
 
The results of this observational study support our hypothesis that the use of QFT-GIT for 
targeting BCG-vaccinated TB contacts for preventive therapy is as effective as a TST-based 
strategy for preventing subsequent development of TB, while allowing a substantial reduction 
of treatment prescriptions. 
In 2008, we found that we were treating a huge proportion of BCG-vaccinated individuals 
(three out of every four contacts), and therefore decided to update the screening strategy. In 
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June of that year we introduced the QFT-GIT assay as part of our routine assessment of 
BCG-vaccinated TB contacts, in line with current knowledge at that time. Despite the 
conservative approach of treating close contacts with TST ≥15 mm and negative QFT result, 
we attained a significant reduction of 26% in TB diagnoses among BCG-vaccinated contacts, 
without increasing the risk of active TB. This outcome is consistent with the findings of 
longitudinal studies in other countries with low and intermediate incidences of TB and high 
vaccination rates [12-14]. Although the effect of BCG vaccination on the TST’s specificity 
should not last over 10 years if BCG was received in infancy, as it used to until 1978 in Spain, 
and BCG would unlikely have a major influence in TST results in adults [15], obvious 
differences have been reported to date in TST results and BCG vaccination status [16]. 
In a German study of close contacts of smear-positive TB patients (n = 954), of the 495 
BCG-vaccinated contacts who were TST-positive, 83% were ≥5 mm and 31% were ≥10 mm, 
while only 17% had a positive QFT-GIT assay result [12]. After at least two years of follow-
up, none of the 413 TST-positive/QFT-GIT-negative untreated contacts had developed active 
TB. In a French study of 687 TB contacts, of the 300 TST-positive contacts (≥10 mm), only 
106 (35%) had positive QFT-GIT results [13]. Two contacts developed active TB after 3 
years, one of whom had a discordant TST-positive/QFT-GIT-negative result (negative 
predictive value for the QFT-GIT assay of 99.8%). In another retrospective study from South 
Korea, which included 1826 high-school student contacts, of the 270 TST-positive contacts 
(≥10 mm), 203 (75%) had positive QuantiFERON-Gold (QFT-G) results, but none of the 67 
TST-positive/QFT-G-negative untreated contacts progressed to active TB [14]. Conversely, a 
Dutch study, which included foreign-born close contacts of smear-positive TB patients with 
high BCG-vaccination rates (81%), showed that using the QFT-GIT assay for preventive 
therapy decision, resulted in three missed contacts who had positive TST results and 
subsequently progressed to active TB [17]. However, in that study, QFT-GIT was performed 
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only once, and shortly after the diagnosis of the index case. Therefore, it is plausible that 
these cases could have been captured if retested a few weeks later. 
Despite the reported differences, the results of the present and the three previous studies 
indicate that the QFT-GIT assay is safe for targeting preventive therapy to fewer contacts. As 
for cost-effectiveness in contact screening, the benefits of applying QFT-GIT as either a 
confirmatory test or in place of the TST is also currently unknown. Some heath economic 
models have explored this issue. Given the similar sensitivities of QFT-GIT and TST for TB 
infection in immunocompetent individuals and the higher specificity of QFT-GIT, despite its 
higher testing costs, some models indicate that IGRA-based strategies might be the most 
cost-effective option when a high pre-test probability is expected (>59%) [18]. However, in 
cases where the estimated probability is lower, performing the QFT-GIT only in TST-
positive contacts would probably be most cost-effective, as it would significantly reduce the 
number of QFT-GIT tests, and thus the overall testing costs. In our study, the BCG-
vaccinated group in the second period increased from 38% to almost half the cohort of 
contacts; the saving of 26% of preventive therapies, blood tests and follow-up visits, as well 
as the avoidance of unnecessary risk, justify the change in the protocol. 
The present study also provides two relevant findings related to the screening and treatment 
of TB infection among contacts. First, there was a non-negligible TB prevalence of 2.3% at 
the time of the first appointment in the TB Unit among the 770 individuals with a recent 
infection in our cohort (12 and 6 patients in each period, respectively); indeed, this confirms 
the importance of contact tracing for finding new cases and providing early treatment to 
avoid TB transmission [19]. Second, a remarkably high proportion of individuals (81.2%) 
completed a full course of preventive therapy without serious adverse events. In 5% of cases, 
foreseeable liver toxicity was detected early and reversed by prompt drug withdrawal. Our 
experience confirms that high completion rates are possible when well-trained staff deliver 
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comprehensive health education about treatment and toxicity following systematic interviews 
and providing written information [20].  
Although the single-center design might theoretically be considered a limitation, in fact it is 
one of the main strengths of the study because it guarantees the homogeneity of the series. 
Since contacts were prospectively evaluated under the same clinical program, our results 
were not biased by diverse diagnosis and treatment strategies. Indeed, it was the evaluating 
team who treated the index cases and their contacts, prescribed preventive therapy, 
systematically took active measures to promote and control adherence to treatment, and 
looked for the follow-up of the contacts. While there are larger cohorts, they usually come 
from regional databases or the fusion of several databases coming from regions with different 
TB prevalence, with different diagnostic and therapeutic approaches and no complete data on 
BCG-vaccination [21]. This paper provides well-documented evidence on the secure saving 
of unnecessary treatments of TB contacts after the implementation of an IGRA. Although 
differences in LTBI diagnosis could be attributed to a difference in the cut-off of the TST (5 
mm in the first period and 15 mm in the second), QFT-GIT contributed in the decision-
making by means of its high negative predictive value [7].  
The other strength of the study is the long-term assessment for TB development. These five 
years of follow-up include the highest risk period for developing active TB after being 
infected, which has been classically established in two years [22]. Had we chosen a two-year 
period, we would have missed the three new cases of TB.  
Despite its strengths, this study also has limitations that deserve further comment. First, the 
retrospective design: development of active TB was evaluated by passive monitoring of 
contacts, who were assessed by reviewing clinical charts and phone interviews. This may 
have resulted in some missed cases of active disease, although specific features of TB (lack 
of mention in clinical notes equals lack of active TB) and the fact that active cases would 
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have been referred to our Centre do make this unlikely. Moreover, we did a cross-match with 
the contacts in our cohort and the detection-system of new TB cases in Catalonia from 2006 
to 2015. Second, there were differences in the follow-up at 5 years, probably because of the 
high proportion of immigrants in the second period (45.9%), who went back to their countries 
as a consequence of the economic crisis in our country. However, the mean follow-up period 
was almost 4 years (3.99; SD 1.08), which means that most of the high-risk period of 
developing TB was passed before leaving Spain. Third, there were very few contacts that 
progressed to active in both periods; as a consequence, wide confidence intervals impaired a 
proper comparison of TB incidence between the two periods. Fourth, since we did not 
genotype the causative strain of the three “assumed” cases of incident secondary TB, we 
cannot exclude the possibility of reinfection by a different strain.  
In conclusion, the results of this study add evidence on the benefit of implementing QFT-GIT 
to target BCG-vaccinated contacts for preventive therapy. This approach reduces exposure to 
unnecessary treatment without increasing the risk of subsequent active TB. Prospective 
cohort studies with health economic data are needed to determine whether this strategy is 
suitable and cost-effective for the management of non-BCG-vaccinated contacts, and other 
risk groups for active TB.   
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Research	in	context	
Evidence	before	this	study:	Some	observational	studies	have	shown	that,	compared	to	the	tuberculin	skin	test	
(TST),	 interferon-γ	 release	 assays	 (IGRA)	may	 reduce	 the	 number	 of	 diagnoses	 of	 tuberculosis	 infections	 in	
people	at	risk.	However,	so	far	there	is	no	reliable	evidence	to	confidently	base	preventive	therapy	on	IGRAs.	
As	 a	 consequence,	 there	 are	 large	 discrepancies	 in	 guidelines	 and	 position	 statements	 for	 their	 use	 across	
epidemiologically	similar	settings.		
Added	value	of	this	study:	This	is	the	first	clinical	trial	comparing	two	diagnostic	strategies,	with	and	without	
an	IGRA,	for	targeting	preventive	therapy	in	contact	investigations	of	tuberculosis.	This	trial	demonstrates	that	
a	 two-step	 strategy	 of	 TST	 confirmed	 by	 QFT-GIT	 allows	 avoiding	 a	 significant	 proportion	 of	 unnecessary	
preventive	 treatments,	 without	 increasing	 the	 risk	 of	 subsequent	 active	 disease	 in	 household	 contacts	 of	
tuberculosis.	
Implications	of	all	available	evidence:	The	results	of	this	trial	support	previous	evidence	on	the	higher	accuracy	
of	 IGRAs	 over	 TSTs,	 and	 reassure	 their	 use	 for	 targeting	 preventive	 therapy	 in	 contact	 investigations	 of	
tuberculosis	in	low-incidence	settings.		 	
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SUMMARY	
Background.	Interferon-γ	release	assays	have	better	specificity	than	the	tuberculin	skin	test	
(TST)	 for	 the	diagnosis	of	 tuberculosis	 infection	and	high	negative	predictive	value	 for	 the	
development	of	tuberculosis	disease.	We	hypothesized	that	a	sequential	strategy	using	TST	
followed	by	confirmation	with	the	whole-blood	interferon-γ	release	assay	QuantiFERON®-TB	
Gold	 In-Tube	 (QFT-GIT)	 would	 narrow	 the	 target	 population	 for	 preventive	 therapy	 in	
contact	tracing	of	tuberculosis	without	increasing	the	risk	of	subsequent	active	disease.		
Methods.	We	 conducted	 an	 open-label,	 randomized	 trial,	 to	 test	 the	 non-inferiority	 of	 a	
two-step	strategy	with	the	tuberculin	skin	test	 followed	by	QFT-GIT	as	a	confirmatory	test	
(the	 TST/QFT	 arm)	 to	 the	 standard	 TST-alone	 strategy	 (TST	 arm)	 for	 targeting	 preventive	
therapy	 in	 healthy	 household	 adult	 contacts	 of	 tuberculosis	 in	 12	 Spanish	 hospitals.	
Randomisation	was	stratified	by	centre	in	a	1:1	allocation	ratio,	using	a	computer-generated	
randomization	list.	The	primary	endpoint	was	the	development	of	tuberculosis	in	a	two-year	
period	of	follow-up,	with	a	non-inferiority	margin	of	1.5	percentage	points.	We	performed	
both	 intention-to-treat	 and	 per-protocol	 analysis.	 This	 study	 was	 registered	 with	
Clinicaltrials.gov,	number	NCT01223534.	
Findings.	 From	 September	 23rd,	 2010	 to	 February	 3rd,	 2014	 a	 total	 of	 871	 contacts	were	
randomized.	 There	 were	 79	 dropouts;	 792	 and	 492	 individuals	 were	 included	 in	 the	
intention-to-treat	and	per-protocol	analyses,	respectively.	Four	contacts	in	the	TST	arm	and	
two	in	the	TST/QFT	arm	developed	tuberculosis.	In	the	modified	intention-to-treat	analysis,	
this	accounted	for	0.99%	in	the	TST	arm	and	0·51%	in	the	TST/QFT	arm	(-0.48%	difference;	
97.5%	 confidence	 interval	 [CI],	 -0.90%	 to	 1.86%);	 in	 the	 per-protocol	 analysis,	 the	
corresponding	 rates	were	 1.67%	 and	 0.82%	 in	 the	 TST	 and	 TST/QFT	 arms,	 respectively	 (-
0.85%	difference;	97.5%	CI,	−1.43%	to	3.14%).	Of	 the	792	contacts	analysed,	65.3%	 in	 the	
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TST	arm	and	42.2%	in	the	TST/QFT	arm	were	diagnosed	with	tuberculosis	 infection	(23.1%	
difference;	97.5%	CI,	16.4%	to	30.0%).		
Interpretation.	 In	low-incidence	settings,	screening	household	contacts	with	the	tuberculin	
skin	test	and	using	QFT-GIT	as	a	confirmatory	test	is	not	inferior	to	TST-alone	for	preventing	
active	tuberculosis,	allowing	a	safe	reduction	of	preventive	treatments.		
Funding.	 This	 is	 an	 investigator-initiated	 trial.	 The	 study	was	 supported	 by	 a	 competitive	
grant	 of	 the	 Spanish	 Government.	 AlereTM,	 the	 Spanish	 distributor	 of	 QFT-GIT	 (Cellestis	
Limited,	currently	owned	by	Qiagen)	provided	the	participating	centres	with	QFT-GIT	blood-
collecting	tubes.		
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Introduction	
According	 to	 the	World	 Health	 Organization	 (WHO),	 tuberculosis	 (TB)	 tops	 the	 causes	 of	
death	 from	 infectious	diseases	worldwide.1	While	prompt	diagnosis	and	proper	 treatment	
are	essential	 to	 tackle	 the	TB	epidemic	 in	high-incidence	settings,	an	additional	 important	
measure	 for	TB	control	 in	 low-incidence	countries	 is	 treating	 latently-infected	people	who	
are	 at	 risk	 of	 developing	 active	 disease.1	 Recently	 acquired	 TB	 infection,	 from	 individuals	
with	 infectious	 pulmonary	 disease,	 is	 known	 to	 pose	 a	 high	 risk	 of	 progression	 to	 active	
disease.2	 Therefore,	 tracing	 the	 contacts	 of	 patients	 with	 pulmonary	 TB	 has	 become	 the	
central	 intervention	 for	 identifying	 and	 treating	 recently	 infected	 people,	 and	 ultimately	
preventing	the	development	of	new	cases	of	TB.3	Unfortunately,	because	of	the	low	ability	
of	 the	 tuberculin	 skin	 test	 (TST)	 to	predict	active	TB,	 this	practice	 requires	 treating	a	high	
number	of	at-risk	people	to	prevent	a	single	case	of	disease.4,5	
T-cell-based	interferon-gamma	release	assays	(IGRAs)	were	first	developed	a	decade	ago,	at	
which	 time	 they	 represented	 a	 promising	 alternative	 to	 the	 TST;	 however,	 they	 too	 are	
limited	by	their	poor	ability	to	predict	future	active	TB,	being	only	slightly	better	than	TST	at	
best.6–8	 Although	 this	 dampened	 initial	 expectations,	 IGRAs	may	 still	 be	 preferable	 to	 the	
TST	because	they	may	reduce	the	number	of	contacts	put	on	treatment	without	increasing	
subsequent	active	TB.7	Although	supported	by	several	longitudinal	studies	in	low-incidence	
settings,9–11	the	true	benefit	of	the	IGRA-based	screening	strategies	over	the	standard	TST-
based	strategy	has	not	been	demonstrated	in	randomized	clinical	trials.	
In	 this	 clinical	 trial,	 we	 assessed	 the	 non-inferiority	 to	 traditional	 testing	 of	 a	 sequential	
strategy	 using	 the	 TST	 followed	by	 confirmation	with	 the	QuantiFERON®-TB	Gold	 In-Tube	
(QFT-GIT)	test	when	targeting	preventive	therapy	in	household	contacts	of	patients	with	TB.	
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We	hypothesized	that	such	a	strategy	should	narrow	the	target	population	compared	with	
the	standard	TST-based	strategy,	without	increasing	the	risk	of	subsequent	active	TB.	
	
Methods	
Study	design	
The	OPTIMIST	study	(Clinicaltrials.gov	number:	NCT01223534)	was	an	investigator-initiated,	
randomized,	open-label,	controlled	clinical	trial	that	we	conducted	at	12	public	hospitals	in	
Spain.	The	aim	of	 the	study	was	 to	 test	 the	non-inferiority	of	a	sequential	 strategy	of	TST	
followed	 by	 QFT-GIT	 as	 a	 confirmatory	 test	 against	 a	 standard	 TST-alone	 strategy	 when	
targeting	preventive	therapy	for	household	contacts	of	patients	with	TB.	
The	trial	was	conducted	in	accordance	with	the	Declaration	of	Helsinki,	and	was	reported	in	
agreement	with	the	key	methodological	items	of	the	CONSORT	(Consolidated	Standards	of	
Reporting	 Trials)	 statement.	 The	 research	 ethics	 committee	 at	 each	 participating	 site	
approved	 the	 study	 protocol,	 with	 Bellvitge	 University	 Hospital	 acting	 as	 Research	 Ethics	
Coordinator	 (ref	 AC111/09).	 The	 study	 Protocol	 can	 be	 found	 online	 (Supplementary	
material).	
Participants	
Participants	 were	 considered	 eligible	 if	 they	 were	 healthy	 adult	 household	 contacts	 of	
patients	 with	 pulmonary	 or	 laryngeal	 TB	 and	 if	 they	 provided	 written	 informed	 consent.	
Contacts	whose	 index	 case	 finally	 had	either	no	 culture-confirmed	TB	or	 a	multi-resistant	
strain	were	withdrawn	from	the	study.	Exclusion	criteria	 included	any	 immunosuppressive	
conditions	and	previous	diagnosis	of	TB	infection.		
Randomisation		
Participants	were	randomly	allocated	to	either	a	TST-alone	strategy	(the	TST	arm)	or	a	two-
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step	TST/QFT-GIT	strategy	 (the	TST/QTF	arm).	Randomisation	was	stratified	by	center	 in	a	
1:1	allocation	ratio,	using	a	computer-generated	randomization	list	integrated	into	the	eCRF.	
None	of	the	investigators	could	access	the	list.		
Procedures	
Participants	 allocated	 to	 the	 TST/QFT	 arm	were	 first	 tested	with	 TST,	 and	 responders	 (≥5	
mm)	underwent	a	QFT-GIT	test	for	confirmation.	Diagnosis	of	TB	infection	was	based	on	the	
QFT-GIT	result.	By	contrast,	diagnosis	of	TB	infection	was	based	only	on	the	TST	result	in	the	
TST	 arm.	 Participants	 with	 negative	 TST	 or	 QFT-GIT	 results,	 who	 had	 been	 tested	 two	
months	 before	 the	 last	 contact	 with	 the	 index	 case,	 also	 underwent	 a	 second	 test	 eight	
weeks	later	(Figure	1).	All	contacts	diagnosed	with	TB	infection	were	given	isoniazid	300	mg	
daily	 for	 six	months,	 or	 rifampicin	 600	mg	 daily	 for	 four	months	 if	 they	 did	 not	 tolerate	
isoniazid	 or	 if	 the	 related	 index	 case’s	 culture	 yielded	 an	 isoniazid-resistant	 strain.	
Adherence	was	measured	at	each	appointment	as	follows:	by	detection	of	N-acetyl	isoniazid	
in	 the	urine,	using	 the	Eidus-Hamilton	 test,12	 for	 isoniazid;	by	 the	orange	color	of	urine	 in	
case	of	 rifampicin;	and	by	 returned	pill	 count	 in	each	visit.	Development	of	active	TB	was	
assessed	 by	 clinical	 evaluation	 and	 chest	 x-ray	 at	 24	 months.	 When	 there	 was	 clinical	
suspicion	of	TB,	 respiratory	 samples	were	 taken	 for	 smear	 stain	and	culture,	 and	chest	 x-
rays	were	taken.	Follow-up	visits	were	scheduled	twice	a	year	for	two	years,	irrespective	of	
whether	participants	received	preventive	therapy.	
Outcomes	
The	primary	study	endpoint	was	the	proportion	of	contacts	developing	active	TB	during	the	
24	 months	 after	 randomization.	 Diagnosis	 of	 active	 TB	 was	 considered	 definitive	 if	
Mycobacterium	tuberculosis	was	 isolated	 in	clinical	samples,	highly	probable	 if	 there	were	
compatible	clinical	data	and	a	positive	molecular	test	in	respiratory	samples	or	sterile	fluids	
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without	positive	culture,	or	probable	if	there	were	suggestive	clinical	and	radiographic	signs	
without	microbiological	 confirmation	and	a	 favorable	 response	 to	specific	 therapy.	Strains	
of	 secondary	 TB	 cases	were	matched	with	 those	 of	 their	 index	 case	 through	MIRU-VNTR	
(Mycobacterial	 Interspersed	Repetitive	Units-Variable	Number	of	Tandem	Repeats),	which	
was	performed	by	amplifying	the	24	MIRU-VNTR	loci	as	described	elsewhere.13	
The	secondary	endpoint	was	the	proportion	of	contacts	diagnosed	with	TB	infection.	
The	safety	and	tolerability	of	preventive	therapy	were	assessed	on	the	basis	of	symptoms	or	
signs	 during	 treatment	 (clinical	 assessment	 and	blood	 tests	 at	 baseline	 and	 after	 1	 and	 3	
months	of	treatment,	and	whenever	patients	presented	with	new	symptoms	suggestive	of	
drug	toxicity).	
Statistical	analysis	
We	designed	the	trial	to	assess	the	non-inferiority	of	the	TST/QFT	arm	with	respect	to	the	
TST	arm	for	preventing	development	of	active	TB.	Non-inferiority	was	defined	as	the	upper	
limit	 of	 the	 one-sided,	 97.5%	 confidence	 interval	 (CI)	 of	 the	 difference	 in	 TB	 incidence	
between	the	TST/QFT	and	the	TST	arms,	being	less	than	1.5	percentage	points.	Based	on	an	
expected	 0.5%	 risk	 of	 progression	 to	 active	 disease	 within	 the	 first	 two	 years	 after	 the	
randomization,	348	patients	was	the	number	of	contacts	required	in	each	group	to	achieve	
a	 power	 of	 80%	 to	 demonstrate	 the	 non-inferiority	 hypothesis.	 To	 account	 for	 a	 possible	
20%	patient	loss	to	follow-up	in	each	group,	we	planned	to	enroll	870	contacts	overall.	This	
sample	size	was	also	sufficient	to	detect	a	minimum	expected	effect	size	of	10%	reduction	in	
the	proportion	of	TB	infection	diagnosis,	assuming	a	TST	positive	rate	of	45%.	
Pre-specified	 subgroup	 analyses	 were	 performed	 according	 to	 Bacillus	 Calmette-Guérin	
(BCG)	 vaccination	 status.	We	added	 a	 post-hoc	 analysis	 to	 improve	 the	 expression	of	 the	
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savings	 in	unnecessary	 treatments	 from	one	 strategy	 to	another,	which	was	expressed	as	
the	 number	 needed	 to	 screen	 (NNS).	 This	 measure	 was	 an	 estimate	 of	 the	 number	 of	
contacts	needed	to	be	screened	in	the	TST/QFT	arm	to	avoid	one	unnecessary	treatment	in	
the	 TST	 arm.	 Thus,	 it	 is	 the	 reciprocal	 of	 the	 absolute	 risk	 reduction	 (1/absolute	 risk	
reduction)	of	being	diagnosed	with	TB	infection.	
We	 performed	 both	modified	 intention-to-treat	 and	 per-protocol	 analyses.	 The	modified	
intention-to-treat	 population	 included	 all	 participants	 who	 completed	 the	 allocated	
diagnostic	strategy	and	had	at	least	one	follow-up	assessment.	The	per-protocol	population	
was	restricted	to	participants	who	adhered	to	the	clinical	trial	instructions	as	established	in	
the	 protocol	 in	 terms	 of	 preventive	 therapy	 completion,	 proven	 adherence	 and	 schedule	
punctuality.	The	protocol	specified	an	 interim	analysis	 two	years	after	the	 inclusion	of	the	
400th	 patient,	 and	we	 established	 that	 the	 trial	would	 stop	 if	 the	 lower	 97.5%	 CI	 for	 the	
estimated	 incidence	 of	 TB	 was	 strictly	 to	 the	 left	 of	 the	 non-inferiority	 margin.	 After	
reviewing	 the	 interim	 analysis,	 the	 data	 and	 safety	monitoring	 committee	 recommended	
continuing	the	study	as	planned.		
The	 baseline	 characteristics	 and	 outcome	 measures	 were	 compared	 by	 the	 χ2test	 for	
categorical	 variables,	 and	 Student	 t-test	 or	 nonparametric	 Mann-Whitney	 U	 test	 for	
continuous	 variables,	 as	 appropriate.	 The	 incidence	 of	 active	 TB	 was	 reported	 as	 the	
cumulative	incidence	and	incidence	rate	(per	100,000	person-years).	All	Statistical	analyses	
were	carried	out	with	R	(version	3.2.5	for	Windows).		
An	 independent	 data	monitoring	 committee,	 the	 Central	 Clinical	 Research	Unit	 in	 Clinical	
Trials	(UCICEC)	had	access	to	all	data	and	oversaw	the	trial.	The	Clinical	Trials	and	Statistical	
Unit	at	Bellvitge	University	Hospital-IDIBELL	downloaded	and	analyzed	the	data	contained	in	
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the	electronic	case	report	forms	(eCRF)	following	the	data	analysis	plan.	
Role	 of	 the	 funding	 source.	AlereTM,	 the	Spanish	distributor	of	QFT-GIT	 (Cellestis	 Limited,	
currently	 owned	 by	 Qiagen)	 provided	 the	 participating	 centers	 with	 QFT-GIT	 blood-
collecting	tubes,	but	had	no	role	in	the	design	of	the	trial,	data	analysis,	or	interpretation	of	
the	results.	
Results	
From	 September	 23,	 2010	 to	 February	 3,	 2014	we	 enrolled	 871	 subjects	 in	 the	 study:	 of	
these,	438	were	allocated	to	the	TST	arm	and	433	were	allocated	to	the	TST/QFT	arm.	After	
excluding	 79	 (9.1%)	 participants,	 792	 (90.9%)	were	 included	 in	 the	modified	 intention-to-
treat	analysis,	and	482	 (55.3%)	qualified	 for	 the	per-protocol	analysis.	The	study	ended	 in	
February	2016	when	the	last	recruited	patient	attended	the	last	follow-up	visit.	The	flow	of	
patients	through	the	study	is	shown	in	figure	2.		
Both	arms	were	well	balanced	in	terms	of	baseline	demographic	characteristics,	relationship	
with	the	index	case,	and	clinical	features	of	the	index	cases	(Table	1).	
During	the	follow-up	period,	six	contacts	developed	active	TB,	four	in	the	TST	arm	and	two	
in	 the	 TST/QFT	 arm.	 All	 six	 cases	 occurred	 before	 the	 sixth	 month	 from	 their	 baseline	
appointment.	Full	details	of	the	TB	cases	are	provided	in	Table	2.	By	the	modified	intention-
to-treat	 analysis,	 the	 cumulative	 incidences	 of	 active	 TB	were	 0.99%	 (97.5%	 CI,	 0.34%	 to	
2.85%)	and	0.51%	(97.5%	CI,	0.12	 to	2.17)	 in	 the	TST	and	 the	TST/QFT	arms,	 respectively,	
giving	a	difference	in	the	TB	incidence	rate	of	−0.48	(97.5%	CI,	−0.90	to	1.86).	The	results	of	
the	per-protocol	 analysis	were	 consistent	with	of	 the	modified	 intention-to-treat	analysis,	
giving	 a	 cumulative	 incidence	 of	 active	 TB	 of	 1.67%	 (97.5%	 CI,	 0.58	 to	 4.76)	 and	 0.82%	
(97.5%	CI,	0.19	to	3.45)	in	the	TST	and	the	TST/QFT	arms,	respectively;	the	difference	in	TB	
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incidence	rate	was	−0.85	(97.5%	CI,	−1.43	to	3.14)	 (Figure	3	and	Table	3).	Three	of	the	six	
active	 TB	 cases	 in	 the	 trial	 were	 culture-confirmed,	 and	 MIRU-VNTR	 based	 genotyping	
analysis	 showed	 identical	patterns	between	 their	 isolates	and	 those	 from	 their	 respective	
index	cases.	
In	 the	 modified	 intention-to-treat	 analysis,	 TB	 infection	 was	 diagnosed	 in	 263	 of	 403	
contacts	(65.3%)	in	the	TST	arm,	and	164	of	389	contacts	(42.2%)	in	the	TST/QFT	arm,	giving	
a	 difference	 of	 23.1%	 (95%	 CI,	 16.4%	 to	 30.0%).	 In	 the	 per-protocol	 analysis,	 155	 of	 239	
(64.9%)	and	104	of	243	(42.8%)	were	diagnosed	with	TB	 infection	 in	the	TST	and	TST/QFT	
arms	respectively,	giving	a	difference	of	22.1%	(95%	CI,	13.5%	to	30.9%).	
We	included	869	subjects	in	the	safety	analysis.	There	were	54	adverse	events	in	49	patients	
(28	and	21	for	the	TST	and	TST/QFT	arms	respectively;	p=0.4).	Regarding	the	429	subjects	
who	 were	 given	 preventive	 therapy,	 42	 (9.8%)	 experienced	 treatment-related	 adverse	
events,	the	most	frequent	being	liver	toxicity	related	to	isoniazid	(28	events;	6.8%).	Details	
of	these	adverse	events	are	provided	in	the	Supplementary	Appendix,	Table	S1.	
The	 analysis	 stratifying	 for	 BCG-vaccination	 status	 showed	 a	 difference	 in	 TB	 infection	
diagnoses	 (between	the	TST	and	the	TST/QTF	arms)	of	34.5%	(95%	CI,	22.5%	to	46.5%)	 in	
BCG-vaccinated	contacts,	and	19.5%	(95%	CI,	10.9%	to	28.0%)	among	non-BCG-vaccinated	
contacts	 in	 the	 modified	 intention-to-treat	 analysis.	 The	 corresponding	 data	 for	 the	
difference	between	the	two	arms	in	the	per-protocol	analysis	were	31.9%	(95%	CI,	16.9%	to	
47.0%)	 among	BCG-vaccinated	 contacts	 and	18.9%	 (95%	CI,	 7.77%	 to	 30.1%)	 among	non-
BCG-vaccinated	 contacts	 (Figure	 4).	 After	 adjusting	 for	 contagiousness	 of	 the	 index	 case	
(sputum	smear	status	and	cavitation	on	chest	x-ray),	time	(cumulative	hours	per	week),	and	
degree	of	exposure	(intimate	versus	frequent)	as	covariates,	assignation	to	the	TST/QFT	arm	
remained	 as	 an	 independent	 predictor	 of	 reduction	 in	 the	 proportion	 of	 diagnosed	 TB	
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infections	(Tables	4-5).	
In	the	modified	intention-to-treat	analysis,	for	every	five	contacts	screened	in	the	two-step	
TST/QFT	arm,	one	unnecessary	treatment	could	be	avoided	(NNS=5	([1/(0.65	–	0.42)=	4.38]).	
If	only	the	BCG-vaccinated	population	was	considered,	the	NNS	would	fall	to	3	([1/	(0.79	–	
0.44)=	2.86])	(Supplementary	Appendix;	Figure	S1)	
	
Discussion	
In	 this	 trial,	 we	 demonstrated	 that	 using	 the	 QFT-GIT	 as	 a	 confirmatory	 test	 following	 a	
positive	TST	for	targeting	preventive	therapy	in	household	TB	contacts	is	not	inferior	to	TST-
alone	strategy	for	the	prevention	of	subsequent	active	TB,	while	it	provides	the	advantage	
of	reducing	the	number	of	preventive	treatments.		
According	to	the	WHO,	detection	and	treatment	of	TB	infection	by	contact	investigation	to	
identify	recently	exposed	people	is	a	main	goal	of	the	global	strategy	to	eliminate	TB	in	low-
incidence	countries	by	2035.14	Therefore,	optimizing	the	screening	strategies	and	promoting	
compliance	with	 preventive	 therapy	 schemes	 is	 essential.	 Since	 their	 introduction,	 IGRAs	
have	been	increasingly	used	for	screening	adult	TB	contacts.	However,	a	lack	of	compelling	
evidence	for	their	superiority	over	TST	has	led	to	a	diversity	in	the	recommendations	given	
in	guidelines	and	position	statements;	instead,	these	have	relied	on	reasons	other	than	the	
evidence-based	 balance	 between	 the	 benefits	 and	 harms	 of	 the	 tests	 and	 strategies.15–20	
Some	guidelines	favor	the	use	of	either	the	TST	or	IGRA,15,16,18	whereas	others	recommend	
primary	testing	with	the	TST,	and	only	retesting	TST	reactors	with	an	IGRA.17,19,20	
The	 two-step	 approach,	 aimed	 at	 reducing	 false-positive	 TST	 results	—especially	 in	 BCG-
vaccinated	 individuals—	 is	 supported	 by	 both	 observational	 studies10,21–23	 and	 favorable	
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cost-effectiveness	 analyses	 in	 low-incidence	 countries.24–26	 A	 large	 German	 study	 which	
tested	close	contacts	of	TB,	showed	a	substantial	reduction	in	the	number	of	diagnoses	of	
TB	infection	with	QFT-GIT	(17%)	compared	with	the	TST	at	10	mm	cut-off	(31%),	and	none	of	
the	untreated	contacts	with	TST-positive	and	QFT-GIT-negative	results	developed	TB	after	at	
least	two	years	of	follow-up.21	Similarly,	35%	of	TST-positive	contacts	in	a	French	study	had	
a	positive	QFT-GIT,	 and	only	one	contact	 (0.2%)	with	a	TST-positive	and	QFT-GIT-negative	
result	developed	active	TB	after	three	years	of	follow-up.23	In	a	study	of	TB	contacts	in	high	
school	students	in	South	Korea,	the	addition	of	QFT-Gold	(QFT-G)	as	a	confirmatory	test	for	
the	TST	reduced	the	number	of	preventive	treatments,	with	none	of	the	TST-positive/QFT-
G-negative	 contacts	 progressing	 to	 active	 disease.22	 In	 a	 Dutch	 study	 using	 an	 IGRA	 to	
confirm	TST	results,	three	of	nine	foreign-born	contacts	who	subsequently	developed	active	
TB	were	missed	by	the	QFT-GIT	 (they	were	TST-positive	but	QFT-GIT-negative).10	Now,	 for	
the	 first	 time,	 a	 randomized	 controlled	 clinical	 trial	 provides	 solid	 evidence	 showing	 the	
benefit	 of	 including	 IGRA	 tests	 to	 avert	 over-diagnosis	 and	 avoidable	 treatments	 when	
testing	adult	contacts	of	patients	with	TB	in	a	low-incidence	setting.	Our	results	showed	that	
for	 every	 five	 contacts	 screened	with	 the	 two-step	 strategy,	 one	 unnecessary	 preventive	
treatment	 could	 be	 avoided.	 This	 benefit	 was	 achieved	 not	 only	 in	 the	 subset	 of	 BCG-
vaccinated	contacts,	in	which	it	may	be	expected,	but	also	among	non-vaccinated	contacts.	
Indeed,	 several	 analyses,	 including	 those	 of	 contacts	 with	 the	 highest	 risk	 profiles	 (i.e.	
intimate	contacts	of	smear-positive	 index	cases	who	presented	with	cavitation	on	chest	x-
ray),	 still	 showed	a	 significant	 reduction	 in	 the	proportion	of	 TB	 infection	diagnosis	when	
screened	with	the	two-step	approach.	
Our	results	provide	reassurance	that	using	QFT-GIT	in	TB	contact	tracing	is	effective	and	safe.	
However,	we	have	not	established	whether	this	is	the	most	convenient	strategy	or	whether	
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the	QFT-GIT	should	entirely	replace	TST	in	terms	of	cost-effectiveness.	In	the	setting	of	well-
selected	 high-risk	 contacts,	which	 implies	 a	 high	 estimated	pre-test	 probability,	 screening	
with	the	QFT-GIT	alone	might	be	amore	cost-effective	option,	despite	the	higher	unit	cost.	
Conversely,	 if	 there	 is	 a	 low	 pre-test	 probability,	 performing	 the	QFT-GIT	 in	 TST	 reactors	
would	probably	be	most	convenient	because	this	strategy	would	reduce	the	overall	number	
of	QFT-GIT	tests,	and	therefore,	testing	costs.	
Our	 trial	 has	weaknesses	 that	 deserve	 further	 comment.	 First,	we	did	 not	 include	 a	 third	
arm	of	 screening	with	 the	QFT-GIT	alone,	which	would	have	helped	us	 to	establish	either	
using	QFT-GIT	as	a	confirmatory	test	or	replacing	the	TST	is	better	strategy.	Unfortunately,	
the	necessary	size	of	the	sample	was	prohibitive	and	could	not	be	achieved	in	a	reasonable	
period.	Second,	the	two-year	observational	period	may	have	been	insufficient	to	assess	the	
real	 risk	 of	 developing	 TB.	 Indeed,	 this	 is	 a	 common	 limitation	 of	 most	 contact-tracing	
studies	 looking	at	 the	 risk	of	TB	development.	However,	because	 the	 first	 two	years	after	
recent	 exposure	 constitute	 the	 period	 of	 highest	 risk,2	 our	 results	 are	 comparable	 with	
previous	observational	studies.	
We	 concluded	 that	 in	 low-incidence	 settings	of	 TB,	 using	QFT-GIT	 to	 confirm	positive	 TST	
reactors	 allows	 a	 significant	 reduction	 of	 TB	 infection	 diagnoses	 and	 preventive	 therapy	
prescriptions	without	increasing	the	risk	of	active	disease.	
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Tables	
 
Table	1.	Baseline	characteristics	of	participants	and	relationship	with	their	index	cases	
	 Intention-to-treat	population	 Per-protocol	population	
	 TST	arm	
(n=403)	
TST/QFT	arm	
(n=389)	
TST	arm	
(n=239)	
TST/QFT	arm	
(n=243)	
Participant	characteristics	 	 	 	 	
Gender,	male;	n	(%)	 181	(44.9)	 169	(43.4)	 105	(43.9)	 108	(44.4)	
Age,	years;	median	(IQR)	 39.4	
(30.2–54.0)	
39.5	
(30.3–53.2)	
40.4	
(30.5–54.5)	
42.0	
(31.1–56.5)	
Spanish	origin;	n	(%)	 306	(75.9)	 292	(75.1)	 197	(82.4)	 202	(83.1)	
BCG-vaccination*;	n	(%)	 114	(28.3)	 108	(27.8)	 76	(31.8)	 72	(29.6)	
Index	case	data	 	 	 	 	
Cavitation	on	X-ray;	n	(%)	 208	(51.6)	 210	(54.0)	 123	(51.0)	 139	(56.7)	
Smear-positive	sputum;	n	(%)	 313	(77.7)	 295	(75.8)	 171	(71.0)	 179	(73.1)	
Weeks	since	symptom	onset;	
median	(IQR)	
8	(4–15)	 8	(4–16)	 8	(4–13)	 10	(4–20)	
Contact	characteristics	 	 	 	 	
Intimate;	n	(%)	 249	(61.8)	 226	(58.1)	 158	(65.6)	 146	(59.6)	
Daily	contact	>12	h/d;	n	(%)	 121	(30.0)	 110	(28.3)	 84	(35.2)	 78	(32.1)	
Days	of	exposure;	median	(IQR)	 108.0	
(59.0–170.0)	
121.0	
(74.0–180.0)	
121.0	
(74.0–174.0)	
127.0	
(87.5–183.5)	
	
*Missing	data	on	BCG-vaccination	status	(16	and	22	subjects	in	the	TST	and	TST/QFT	arms	respectively.	
IQR:	 Interquartile	 range;	 TB:	 tuberculosis;	 BCG:	 Bacillus	 Calmette-Guérin;	 TST:	 tuberculin	 skin	 test.	 QFT-GIT:	
QuantiFERON®-TB	Gold	In-Tube.TST	arm:	TB	infection	diagnosis	relies	on	TST	results	exclusively.	TST/QFT	arm:	TB	
infection	 diagnosis	 relies	 on	 QFT-GIT	 results	 in	 TST	 positive	 contacts	 (confirmatory	 test),	 or	 in	 a	 negative	 TST
Table	2.	Description	of	the	active	tuberculosis	cases	developed	during	the	study	period	
	
	 TST	arm	 TST/QFT	arm	
Sex,	Age	(years)	 Woman,	31	 Woman,	20	 Man,	60	 Woman,	38	 Man,	56	 Man,	41	
TB	infection	at	screening	 Positive	TST	 Positive	TST	 Negative	TST	 Negative	1stTST	 Negative	1stTST	 Negative	1stTST	
Preventive	therapy	(PT)	 Isoniazid	6	m*	 Isoniazid	3	m*	 No	 No	 No	 No	
Time	from	screening	(days)	 304	
(4	months	after	PT)	
91	
(While	on	PT)	
182	
	(Scheduled	visit)	
60	
(Window	period)	
60	
(Window	period)	
60	
(Window	period)	
Type	of	TB	 Pleural	 Pleural	 Pulmonary	 Pulmonary	 Pulmonary	 Pulmonary	
Tests	at	active	TB	diagnosis	 N.A	 N.A	 Negative	
	TST	and	QFT-GIT	
Positive	
TST	
Positive	
	TST	and	QFT-GIT	
Positive	
	TST	and	QFT-GIT	
Diagnosis	
	
Definitive	
Sputum	culture†	
	
Probable	
Lymphocytic	
exudative	pleural	
effusion	with	normal	
ADA	activity.	
Response	to	TB	
treatment	
Definitive	
Sputum	culture†	
	
Definitive	
Sputum	culture†	
	
Probable	
Response	to	TB	
treatment	
Probable	
Response	to	TB	
treatment	
	
*months.	†In	 the	 three	culture-confirmed	cases	of	 tuberculosis,	MIRU-VNTR	genotyping	showed	the	 involvement	of	 the	same	strain	as	 their	 respective	 index	cases.	TB:	
tuberculosis;	TST:	tuberculin	skin	test.	QFT-GIT:	QuantiFERON®-TB	Gold	In-Tube.	TST	arm:	TB	infection	diagnosis	relies	on	TST	results	exclusively.	TST/QFT	arm:	TB	infection	
diagnosis	relies	on	QFT-GIT	(QuantiFERON®-TB	Gold	In-Tube)	results	 in	TST	positive	contacts	(confirmatory	test),	or	 in	a	negative	TST;	ADA:	adenosine	deaminase;	MIRU-
VNTR:	Mycobacterial	Interspersed	Repetitive	Units-Variable	number	tandem	repeats;	N.A:	non	applicable.	
Table	3.	Participants’	disposition	and	development	of	active	disease	at	the	end	of	the	
study	
	
	
	 Intention-to-treat	population		 Per-protocol	population	
	 TST	arm	
(n=403)	
TST/QFT	arm	
(n=389)	
TST	arm	
(n=239)	
TST/QFT	arm	
(n=243)	
Follow-up	(days);	median	
(IQR)	
735.0	(720.0–
791.0)	
735.0	(727.0–
773.0)	
735.0	(728.0–
755.0)	
735.0	(729.0–
749.0)	
Dead	 2	 3	 0	 0	
Lost	to	follow-up	 67	 45	 -	 -	
Active	TB	 4	 2	 4	 2	
Cumulative	incidence	 0.99	(0.34–
2.85)	
0.51	(0.12–2.17)	 1.67	(0.58–4.76)	 0.82	(0.19–3.45)	
Incidence	rate	(n	x	
100,000	p/y)	
505.5	(110.6–
954.5)	
252.1	(21.1–
629.8)	
820.0	(180.4–
1557.8)	
405.5	(33.9–
1012.8)	
	
IQR:	Interquartile	range;	TB:	tuberculosis;	TST:	tuberculin	skin	test.	TST	arm:	TB	infection	diagnosis	relies	
on	TST	results	exclusively.	TST/QFT	arm:	TB	infection	diagnosis	relies	on	QFT–GIT	(QuantiFERON®-TB	Gold	
In-Tube)	results	in	TST	positive	contacts	(confirmatory	test),	or	in	a	negative	TST.	
	
Table	4.	Variables	associated	with	diagnosis	of	tuberculosis	infection	in	household	contacts	of	pulmonary	tuberculosis	
	
	 Intention-to-treat	population	 Per-protocol	population	
Variable	 Unadjusted	 Adjusted	 Unadjusted	 Adjusted	
OR	 CI95%	 OR	 CI95%	 OR	 CI95%	 OR	 CI95%	
Allocation	to	the	TST/QFT	arm	 0.39	 0.29–0.52	 0.37	 0.26–0.50	 0.41	 0.28–0.58	 0.37	 0.25–0.56	
Index	case	with	positive	sputum	smear		 2.53	 1.81–3.58	 2.28	 1.55–3.38	 2.94	 1.95–4.48	 2.68	 1.67–4.33	
Index	case	with	cavitation	on	chest	X-ray	 2.04	 1.54–2.71	 1.71	 1.24–2.36	 2.02	 1.41–2.91	 1.54	 1.0–2.36	
Intimate	contact	with	the	index	case	 1.59		 0.83–1.89	 1.71	 1.24–1.98	 1.69	 1.17–2.46	 1.79	 1.19–2.72	
Symptomatic	weeks	of	the	index	case		
4-11	vs.	<4	weeks	
>11	vs.	<4weeks	
	
1.25	
1.77	
	
0.83–1.89	
1.14–2.76	
	
1.27	
1.64	
	
0.82–1.98	
1.01–2.66	
	
1.53	
1.62	
	
0.97–2.44	
1.02–2.58	
	
1.39	
1.48	
	
0.85–2.30	
0.90–2.47	
	
TST:	tuberculin	skin	test.	QFT-GIT:	QuantiFERON®-TB	Gold	In-Tube.	OR:	Odds	Ratio.	CI:	Confidence	interval.	
TST/QFT	arm:	TB	infection	diagnosis	relies	on	QFT-GIT	(QuantiFERON®-TB	Gold	In-Tube)	results	in	TST	positive	contacts	(confirmatory	test),	or	in	a	negative	TST.	 	
Table	5.	Differences	in	diagnosis	of	tuberculosis	infection	between	TST	and	TST/QFT	arms	stratified	for	risk		
	
High	risk	group*	 	
	 Intention-to-treat	Population		 Chi-Square	test	 Per-protocol	Population		 Chi-Square	test	
ARM	 TST	arm	 TST/QFT	arm	 	 p	 TST	arm	 TST/QFT	arm	 	 p	
Diagnosis	of	TB	infection	 89	 64	 153	 	 53	 44	 97	 	
No	TB	infection	 28	 42	 70	 	 15	 22	 37	 	
	 117	 106	 223	 0.014	 68	 66	 134	 0.18	
Non-High	risk	group	
	 Intention-to-treat	Population		 Chi-Square	test	 Per-protocol	Population		 Chi-Square	test	
ARM	 TST	arm	 TST/QFT	arm	 	 p	 TST	arm	 TST/QFT	arm	 	 p	
Diagnosis	of	TB	infection	 174	 100	 274	 	 102	 60	 162	 	
No	TB	infection	 112	 183	 295	 	 69	 117	 186	 	
	 286	 283	 569	 0.00	 171	 177	 348	 0.00	
 
High-risk	 group	 incudes	 intimate	 contacts	 of	 index	 cases	 with	 both	 cavitary	 lesions	 and	 positive	 smear	 sputum.TB:	 tuberculosis;	 TST:	 tuberculin	 skin	 test.	 QFT-GIT:	
QuantiFERON®-TB	Gold	In-Tube;	TST/QFT	arm:	TB	infection	diagnosis	relies	on	QFT-GIT	(QuantiFERON®-TB	Gold	In-Tube)	results	in	TST	positive	contacts	(confirmatory	test),	
or	in	a	negative	TST.		
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Figures	
 
Figure	1.	Overview	of	the	diagnostic	strategies	
	
TST:	tuberculin	skin	test.	QFT-GIT:	QuantiFERON®-TB	Gold	In-Tube.	
*	Negative	responders	were	tested	again	(after	eight	weeks)	so	as	to	avoid	the	window	period.	Only	if	
their	first	appointment	was	after	two	months	of	their	last	contact	with	the	index	case	was	there	no	need	
for	a	second	test.	
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Figure	2.	Study	enrolment,	randomization,	and	follow-up	of	991	participants	assessed	
	
TB:	 tuberculosis.	 TST	 arm:	 TB	 infection	 diagnosis	 relies	 on	 TST	 results	 exclusively.	 TST/QFT	 arm:	 TB	
infection	diagnosis	 relies	 on	QFT-GIT	 (QuantiFERON®-TB	Gold	 In-Tube)	 results	 in	 TST	positive	 contacts	
(confirmatory	test),	or	in	a	negative	TST.	
*	Two	subjects	(one	per	arm)	were	randomized	twice.	The	real	number	of	contacts	to	be	assessed	is	869.	
 
  
		 991	Contacts	were	assessed	for	eligibility		
120	Were	excluded		
	
49	Did	not	meet	inclusion	criteria		
60	Declined	to	participate		
11	Other	reasons	
239	were	included	in	the	per-protocol	
analysis	
	
403	were	included	in	the	modified		
intention-to-treat	analysis	
438	Were	allocated	to	the	TST	arm	
389	were	included	in	the	modified		
intention-to-treat	analysis	
	
433	Were	allocated	to	the	TST/QFT	arm	
243	were	included	in	the	per-protocol	
analysis	
	
871	Underwent	randomization	
35	were	excluded	
	
11	Major	protocol	
violations*	
6	Withdrawal	criteria	(2	
without	TB	confirmation	
of	the	index	case)	
18	Unfinished	diagnostic	
processes	
	
44	were	excluded		
	
9	Major	protocol	
violations*	
7	Withdrawal	criteria	(2	
without	TB	confirmation	
of	the	index	case)	
28	Unfinished	diagnostic	
processes	
	
164	were	excluded	
	
65	Lost	to	follow-up		
97	Minor	protocol	violations	
- 1	diagnostic	process	
- 81	missed	>2	visits	
- 5	rejected	treatment	
- 6	no	treatment	completion	due	
to	adverse	events	
- 4	no	proof	of	adherence		
2	Died	
	
146	were	excluded	
	
42	Lost	to	follow-up	
98	Minor	protocol	violations	
- 1	diagnostic	process	
- 90	missed		>2	visits	
- 4	rejected	treatment	
- 1	no	treatment	completion	due	to	
adverse	events	
- 5	no	proof	of	adherence		
3	Died	
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Figure	3.	Differences	in	tuberculosis	incidence	between	TST	and	TST/QFT	arms	by	
both	modified	intention-to	treat	and	per-protocol	analyses		
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Figure	4.	Proportion	of	participants	with	tuberculosis	infection	per	arm	in	the	
modified	intention-to-treat	population	(A)	and	in	the	per-protocol	population	(B)	
 
 
BCG:	Bacillus	Calmette-Guérin.	TST	arm:	Tuberculin	Skin	Test	arm.	 	TST/QFT	arm:	 two-step	Tuberculin	
Skin	Test,	followed	by	QuantiFERON®-TB	Gold	In-Tube,	as	a	confirmatory	test.	
	
*	Differences	between	arms	for	both	modified	 intention-to-treat	and	per-protocol	analyses	 (Global	p<	
0.001;	BCG-vaccinated	p<	0.001,	and	Non-BCG-vaccinated	p=	0.001).		
 
Figure	4A.		
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Figure	4B.	
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Figure	S1	Risk	of	diagnosis	of	TB	infection	and	active	disease	in	both	arms.		
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Figure	S2:		
A.	Contacts	included	in	both	arms	by	intention-to	treat	analysis	
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B.	Contacts	included	in	both	arms	by	per-protocol	analysis	
	
	
	
	
	
	
The	numbers	in	brackets	represent	the	number	of	contacts	that	underwent	a	second	test.	The	ones	who	
did	not	have	a	test	repeated	had	already	exceeded	the	window	period	when	that	test	was	carried	out.	
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In	 low-incidence	 countries	 as	 a	whole,	 the	main	 contribution	 to	 the	End	TB	 strategy	
consists	 of	 proper	 screening	 and	 LTBI	 treatment	 for	 individuals	 at	 higher	 risk	 for	
developing	 active	 tuberculosis.113	 Unfortunately,	 until	 now	 diagnostic	 tests	 are	 not	
accurate	 enough	 to	 select	 which	 individuals	 are	 at	 higher	 risk	 of	 developing	 active	
tuberculosis.	 Clearly	 defined	 groups	 have	 been	 defined	 as	 the	 riskiest,	 but	 not	 all	
individuals	 in	 those	 groups	 would	 develop	 tuberculosis	 if	 left	 untreated,	 moreover,	
treating	them	all	would	not	imply	zero-risk	for	subsequent	active	development	of	the	
disease.	It	is	not	only	important	to	detect	new	cases	of	LTBI.	Preventive	therapy	should	
be	completed	in	order	to	be	effective.	Currently	available	treatments	are	lengthy,	not	
free	from	side	effects,	and	require	compulsory	appointments	to	check	adherence	and	
tolerance	 for	 the	 treatment	 to	 be	 safe	 and	 effective.	While	 less	 toxic	 and	 easier	 to	
adhere	and	complete	regimens	are	under	investigation,	making	the	most	of	available	
tests	can	also	enhance	better	management	of	latent	tuberculosis	infections.	
The	aim	of	this	dissertation	is	to	improve	diagnostic	strategies	in	each	risk	group.	Two	
different	 groups	 and	 different	 strategies	 have	 been	 considered:	 immunosuppressed	
individuals	 in	 which	 higher	 sensitivity	 is	 preferred,	 and	 healthy	 subjects	 after	 being	
exposed	to	Mycobacterium	tuberculosis	complex,	in	which	specificity	is	preferable.	
As	for	groups	with	 impaired	 immunity,	the	observational,	 longitudinal	study	to	check	
the	results	of	our	modified	IGRA-containing	protocol	of	LTBI	diagnosis	in	candidates	to	
anti-TNF	agents	showed	three	main	results.	First,	anti-TNF–associated	tuberculosis	can	
be	greatly	reduced	when	a	comprehensive	protocol	for	screening	and	treating	LTBI	is	
applied,	although	a	certain	risk	remains	during	the	first	year	of	treatment.	Second,	this	
risk	 is	 not	 related	 to	 a	 lack	 of	 sensitivity	 in	 diagnostic	 tests.	 On	 the	 contrary,	 we	
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discourage	 the	 use	 of	 a	 two-step	 TST-strategy	 as	 a	 way	 to	 increase	 the	 number	 of	
diagnosis,	 although	 that	 is	what	 the	Spanish	guidelines	 currently	 recommend.	 In	our	
series,	 an	 independent	 association	 between	 BCG	 vaccination	 and	 both	 second	 TST	
positivity	(boosting	effect)	and	discordant	results	(TST	positive/QFT-GIT	negative)	was	
found,	suggesting	that	the	second	test	increased	false	positive	results.	The	withdrawal	
of	 a	 second	 TST	 offered	 a	 substantial	 and	 safe	 reduction	 in	 LTBI	 diagnosis	 and	
treatment	as	compared	to	the	previous	two-step	TST-based	strategies,	with	no	more	
risk	 of	 subsequent	 active	 tuberculosis.	 Third,	 the	 systematic	 periodic	 retesting	 of	
patients	for	LTBI	does	not	appear	to	be	needed	following	negative	testing	prior	to	anti-
TNF	 therapy.	 This	 common	 question,	 shared	 by	 most	 clinicians,	 had	 until	 now	
remained	unsolved	in	the	literature.	
Regarding	another	group	of	 immune-impaired	patients,	we	 reported	 the	 results	of	 a	
small	cohort	of	 liver	transplant	candidates	and	 individuals	waiting	for	haematological	
stem	cell	 transplantation,	with	a	 log	follow-up	period.	We	were	able	to	calculate	the	
predictive	 values	 of	 both	 TST	 and	 QFT-GIT,	 as	 no	 patient	 was	 offered	 preventive	
treatment,	 according	 to	 the	 indications	 of	 the	 transplant	 team.	 The	 rate	 of	 post-
transplant	tuberculosis	among	QFT-GIT-positive	patients	was	both	low	and	comparable	
to	that	of	the	TST	in	this	cohort.	Our	results	added	to	the	evidence	that	IGRAs	are	poor	
at	predicting	the	development	of	active	tuberculosis	in	transplant	recipients,	as	did	the	
previous	 four	 reports	 of	 transplant	 individuals	 tested	with	 IGRAs	 at	 the	 time	 it	 was	
published.	Therefore,	with	the	currently	available	data,	the	choice	of	TSTs	or	IGRAs	for	
screening	 transplant	 candidates	 should	be	based	on	 the	 expected	 specificity	 in	 each	
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setting,	operational	factors,	logistics,	patients'	preferences,	and	cost;	always	keeping	in	
mind	that	a	negative	result	does	not	rule	out	the	future	risk	of	developing	tuberculosis.	
As	for	the	other	group	at	risk,	people	recently	exposed	to	an	active	case	of	tuberculosis,	
we	 confirmed	 our	 hypothesis	 of	 the	 safe	 reduction	 of	 preventive	 treatments	 when	
QFT-GIT	is	added	to	the	diagnostic	strategy.	First,	our	experience	at	the	TB	Unit	after	
the	 introduction	 of	 QFT-GIT	 to	 test	 BCG-vaccinated	 contacts	 showed	 a	 significant	
reduction	of	diagnoses	and	thus	preventive	treatments	as	compared	to	the	immediate	
previous	period.	A	remarkably	high	proportion	of	 individuals	 (>80%)	completed	a	full	
course	 of	 preventive	 therapy	 without	 serious	 side	 effects.	 Our	 experience	 confirms	
that	high	completion	rates	are	possible	when	well-trained	staff	deliver	comprehensive	
health	education	about	treatment	and	toxicity.	Second,	we	tested	the	same	hypothesis	
in	a	 large	multicentre	clinical	 trial,	 the	OPTIMIST	study.	We	demonstrated	 that	using	
the	QFT-GIT	 as	 a	 confirmatory	 test	 following	 a	 positive	 TST	 for	 targeting	 preventive	
therapy	in	household	tuberculosis	contacts	is	not	inferior	to	TST-alone	strategy	for	the	
prevention	of	subsequent	active	disease,	while	 it	provides	the	advantage	of	reducing	
the	 number	 of	 preventive	 treatments.	 For	 the	 first	 time,	 a	 randomized	 controlled	
clinical	trial	has	provided	solid	evidence	showing	the	benefit	of	including	IGRA	tests	to	
avert	over-diagnosis	and	avoidable	treatments	when	testing	adult	contacts	of	patients	
with	TB	in	a	low-incidence	setting.	This	benefit	was	achieved	not	only	in	the	subset	of	
BCG-vaccinated	contacts,	in	which	it	may	be	expected,	but	also	among	non-vaccinated	
contacts.	
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The	 Optimist	 Study	 has	 contributed	 to	 the	 reinforcement	 and	 creation	 of	 highly	
specialized	TB	Units,	well	trained	in	contact	tracing	studies	of	TB	in	Spain,	which	is	an	
undeniable	added	value	of	this	trial.	
These	results	are	expected	to	remodel	the	Spanish	guidelines	and	include	IGRAs	in	the	
recommendations	of	contact	tracing	studies	of	tuberculosis.	Other	settings	with	similar	
epidemiologic	profile	may	also	benefit	from	these	outcomes.	Although	some	societies	
and	 institutions	 have	 already	 implemented	 IGRAs	 in	 their	 day-to-day	 practice,	 these	
results	 may	 encourage	 those	 who	 still	 have	 not	 to	 add	 IGRAs	 to	 LTBI	 screening	
protocols,	as	there	is	now	strong	evidence	of	their	benefits.	
This	 dissertation	 has	 several	 limitations	 that	 deserve	 comment.	 First,	 diagnostic	
properties,	 especially	 predictive	 values,	 are	 closely	 related	 to	 the	 target	 disease’s	
prevalence	in	each	setting.	Different	regions	may	not	benefit	from	this	LTBI	approach,	
mainly	 if	 a	 high	pre-test	 probability	 is	 expected.	 Second,	 a	 proper	 cost-effectiveness	
analysis	 might	 be	 needed	 in	 each	 type	 of	 risk-population	 to	 demonstrate	 the	
superiority	of	 IGRA-based	 strategies	on	a	 large	 scale.	 Third,	 our	 cohort	of	 transplant	
recipients	was	small	and	very	few	cases	of	active	tuberculosis	developed,	so	incidence	
rates	 showed	 huge	 confidence	 intervals.	 Moreover,	 liver	 transplant	 recipients	
constitute	the	less	immunosuppressed	group	of	solid-organ	transplantations;	thus,	our	
results	cannot	be	extrapolated	to	kidney,	heart	and	lung	transplant	recipients.	
Several	questions	 remain	 to	be	addressed	 in	 further	 research.	The	cost-effectiveness	
of	 each	 strategy	needs	 to	be	assessed	ahead	of	 implementation.	Other	 clinical	 trials	
comparing	 results	 after	 IGRA-based	 decisions	 in	 other	 risk	 groups	will	 be	 needed	 in	
order	 to	establish	good	quality	evidence	 for	 the	 implementation	of	 IGRAs.	Countries	
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with	different	epidemiologic	profiles	may	need	their	own	trials	to	better	ascertain	the	
best	 strategy	 in	 terms	 of	 efficacy	 and	 cost-effectiveness.	 The	 new-generation	 QFT-
GIT77	and	new-TST	(C-Tb)93	may	need	to	be	tested	in	high-risk	populations,	not	only	to	
compare	 its	 performance	 with	 QFT-GIT	 and	 T-SPOT.TB,	 but	 also	 to	 make	 decisions	
based	on	its	results	so	as	to	achieve	patient-important	outcomes.	
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The	 results	 of	 these	 studies	 provide	 significant	 evidence	 on	 the	 benefits	 of	 several	
IGRA-including	 diagnostic	 strategies	 in	 populations	 at	 risk	 for	 developing	 active	
tuberculosis.	 Such	 gain	 is	 achieved	 by	 safely	 avoiding	 unnecessary	 preventive	
treatments	through	a	better	targeting	of	individuals	at	risk.	
	
First,	in	patients	about	to	receive	anti-TNF	agents:	
1. Anti-TNF-associated	 tuberculosis	 can	 be	 greatly	 reduced	 through	 a	
comprehensive	 clinical	 program.	 However,	 a	 certain	 risk	 remains	 during	 the	
first	year	of	treatment.	
2. The	two-step	TST	approach	for	 latent	tuberculosis	 infection	screening	prior	to	
anti-TNF	 therapy	 signifies	 a	 substantial	 increase	 in	 the	 proportion	 of	 LTBI	
diagnoses	 and	 treatment	 prescriptions,	 with	 no	 effect	 on	 the	 incidence	 of	
subsequent	 active	 tuberculosis.	 Therefore,	 this	 strategy,	 which	 is	 currently	
recommended	in	the	Spanish	guidelines,	is	no	longer	justified.	
3. Systematic	periodic	retesting	 for	 latent	 tuberculosis	 infection	 in	candidates	to	
anti-TNF	agents	with	negative	LTBI	test	results	at	baseline	is	not	required.	
	
Second,	in	liver	and	HSCT	transplant	receptors:	
The	rate	of	post-transplant	tuberculosis	among	QFT-GIT	positive	patients	was	both	low	
and	comparable	to	that	of	the	TST	in	this	cohort	of	liver	transplant	and	haematological	
stem	 cell	 transplantation	 recipients.	 Therefore,	 the	 choice	 of	 TSTs	 or	 IGRAs	 for	
screening	 transplant	 candidates	 should	be	based	on	 the	 expected	 specificity	 in	 each	
setting,	operational	factors,	logistics,	patients'	preferences,	and	cost.	
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Third,	in	healthy	individuals	with	recent	exposure	to	active	tuberculosis:	
The	use	of	QuantiFERON®-TB	Gold	In-Tube	to	confirm	positive	TST	reactors	allows	for	a	
significant	 reduction	 of	 tuberculosis	 infection	 diagnoses	 and	 preventive	 therapy	
prescriptions,	without	increasing	the	risk	of	active	disease,	in	low-incidence	settings	of	
tuberculosis.	
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ABBREVIATIONS		
	
AE	 Adverse	event	
AEMPS	 Agencia	Española	del	Medicamento	y	Productos	Sanitarios	
AR		 Adverse	reaction	
BCG	 Bacillus	Calmette-Guérin	
CRF	 Case	Report	Form	
EC	 Ethics	Committee	
ICF	 Informed	Consent	Form	
ICH	 International	Conference	of	Harmonisation	
IFN	 Interferon	
ITT	 Intention-to-treat	
LTBI	 Latent	tuberculosis	infection	
IGRAs	 IFN-gamma	release	assays	
MTC	 Mycobacterium	tuberculosis	complex	
NTM	 Non-tuberculous	mycobacteria	
PCR	 Polymerase	Chain	Reaction	
PI	 Principal	Investigator	
PIS	 Participant/	Patient	Information	Sheet	
PP	 Per-protocol		
PPD	 (tuberculin)	Purified	Protein	Derivate	
QFT	 QuantiFERON®-TB	Gold	In-Tube	
SAE	 Serious	Adverse	Event	
SSI	 Statens	Serum	Institute	
TB	 Tuberculosis	
TST	 Tuberculin	Skin	Test	
TU	 Tuberculin	Unit	
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PARTICIPANTS:	PRINCIPAL	INVESTIGATORS	AND	CENTRES	
	
Hospital	Universitari	de	Bellvitge,	IDIBELL		
Sponsor	and	Investigator	Coordinator:	Miguel	Santín	(Head	of	the	Tuberculosis	Unit)	
Hospital	Universitari	de	Bellvitge,	IDIBELL.	Servicio	de	Enfermedades	Infecciosas		
Av/	Feixa	Llarga	s/n.	08907	L'Hospitalet.	Barcelona.	Phone:	93	260	76	25	
	
Reference	Ethics	Committee:	
CEIC	 Hospital	 Universitari	 de	 Bellvitge;	 Unitat	 de	 Recerca.	 Av/Feixa	 Llarga	 s/n.	 08907	
L’Hospitalet	de	Llobregat	(Barcelona)	
	
Hospital	General	Universitario	Gregorio	Marañón	
Principal	investigator:	Mº	Jesús	Ruiz	Serrano	(Microbiology	Department)			
Hospital	General	Universitario	Gregorio	Marañón-	Laboratorio	de	Microbiología	
C/	Doctor	Esquerdo,	46.	28007	Madrid.	Phone	91	586	84	54	
	
Hospital	Universitario	de	Canarias	
Principal	investigator:	María	Lecuona	Fernández	(Microbiology	Department)	
Hospital	Universitario	de	Canarias-	Laboratorio	de	Microbiología	
Carretera	La	Cuesta-Taco	s/n.	38320	La	Laguna	(Tenerife).	Phone	92	267	90	71	
	
Corporació	Sanitària	Parc	Taulí	
Principal	investigator:	Mateu	Espasa	(Microbiology	Department)	
Corporació	Sanitària	Parc	Taulí-	Servei	de	Microbiologia.	
C/	Parc	Taulí	S/N.	08208	Sabadell	(Barcelona).	Phone:	93	745	84	48	
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Hospital	Sant	Joan	de	Déu	
Principal	investigator:	Jordi	Esplugas	Abós	(Pneumology	Unit)		
Hospital	Sant	Joan	de	Déu-	Servicio	de	Medicina	Interna	
Mancomunitats	Comarcals	1-3.	08760	Martorell	(Barcelona).	Phone	93	774	20	20		
	
Hospital	de	Mendaro	
Principal	investigator:	Alberto	Mº	García-Zamalloa	(Internal	Medicine	Department)		
Hospital	de	Mendaro-	Servicio	de	Medicina	Interna	
Barrio	de	Mendarozabal	s/n.	20850	Mendaro	(Gipuzkoa).	Phone	94	331	31	21	
	
Hospital	Universitario	Virgen	Macarena	
Principal	investigator:	Ángel	Domínguez	Castellano	(Infectious	Diseases	Unit).	
Hospital	Universitario	Virgen	Macarena.	Servicio	de	Medicina	Interna	
Avda.	Dr.	Fedriani	s/n.	41073	Sevilla.	Phone	95	501	86	36	
	
Hospital	Universitario	Reina	Sofía	
Principal	investigator:	José	María	Kindelan	Jaquotot	(Infectious	Diseases	Department).		
Hospital	Universitario	Reina	Sofía-	Servicio	de	Enfermedades	Infecciosas		
Av	Menéndez	Pidal	s/n.	14004	Córdoba.	Phone	95	701	16	36	
	
Hospital	de	Jerez	
Principal	investigator:	Elvira	Pérez	Escolano	(Infectious	Diseases	Unit).	
Hospital	de	Jerez-	Servicio	de	Medicina	Interna	
Ctra.	de	Circunvalación	s/n.	11407	Jerez	de	la	Frontera	(Cádiz).	Phone	95	603	23	96	
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Hospital	Universitario	Marqués	de	Valdecilla	
Principal	investigator:	Ramón	Agüero	Balbín	(Chief	of	the	Pneumology	Department).		
Hospital	Universitario	Marqués	de	Valdecilla-	Servicio	de	Neumología	
Avda.	Valdecilla	nº	25.	39008	Santander.	Phone	94	220	33	65		
	
Complexo	Hospitalario	de	Pontevedra	
Principal	investigator:	Luis	Anibarro	García	(Infectious	Diseases	Unit).	
Complexo	Hospitalario	de	Pontevedra-	Unidad	de	Tuberculosis.	
C/Loureiro	Crespo	nº2,	36001	Pontevedra.	Phone	98	680	00	00	
	
Hospital	Son	Llàtzer	
Principal	investigator:	Carmen	Cifuentes	Luna	(Infectious	Diseases	Unit).	
Hospital	Son	Llàtzer-	Servei	de	Medicina	Interna.	
Ctra.	Manacor,	km	4.	07198	Palma	de	Mallorca.	Phone	871	202	000		
	
Hospital de Cantoblanco-La Paz 
Principal Investigator: Marta Ramírez Lapausa (Department of Internal Medicine)  
Hospital de Cantoblanco- Unidad de Aislamiento respiratorio. 
Carretera de Colmenar Viejo km 14.5. 28049 Madrid 
 
Parc Sanitari Sant Joan de Déu 
Principal Investigator: Xavier Casas García (Respiratory Medicine) 
Parc Sanitari Sant Joan de Déu- Servei de Pneumologia. 
C/ Doctor Antoni Pujadas, 42. 08830 Sant Boi de Llobregat  (Barcelona) 
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INTRODUCTION	
	
Study	Rationale	And	Scientific	Background		
	
Contact	investigation	of	tuberculosis	(TB)	cases	is	the	most	readily	available	intervention	to	
identify	recently	 infected	 individuals	and	has	been	considered	as	an	essential	component	
of	the	tuberculosis	control	and	elimination	strategy	in	most	low-incidence	countries.1	
Diagnosis	 of	 tuberculosis	 infection	 is	 currently	 based	 on	 tuberculin	 skin	 test	 (TST).2,3	
However,	TST	has	two	main	limitations:	low	specificity	due	to	cross-reaction	with	BCG	and	
non-tuberculous	 mycobacteria	 (NTM)	 antigens,	 and	 low	 sensitivity	 in	 subjects	 with	
impaired	 cellular	 immunity.	 In	 routine	 clinical	 practice,	 a	 positive	 TST	 in	 people	 with	
significant	contact	with	a	tuberculosis	case	is	considered	indicative	of	recent	infection	and	
preventive	 treatment	 is	 offered	 to	 avert	 development	 of	 active	 disease.	 This	 strategy	
avoids	 leaving	 untreated	 people	 at	 risk,	 but	 overestimates	 recent	 infection	 and	 leads	 to	
overtreatment.		
To	overcome	the	drawbacks	of	TST,	new	in	vitro	assays	based	on	interferon-gamma	(IFN-
gamma)	 release	 in	 response	 to	specific	Mycobacterium	tuberculosis	 (MTC)	antigens	have	
been	 developed.4	 Two	 IFN-gamma	 release	 assays	 (IGRAs)	 are	 currently	 available:	 the	 T-
SPOT.TB	 (Oxford	 Immunotec,	 Abingdon,	 UK),	 which	 is	 based	 on	 the	 enzyme-linked	
immunospot	 (ELISpot)	assay;	and	 the	whole	blood-based	QuantiFERON®-TB	Gold	 In-Tube	
(QFT)	 (Cellestis	 Ltd,	 Carnegie,	 Australia),	 which	 use	 ELISA	 to	 detect	 IFN-gamma	 in	 the	
culture	supernatant.	 IGRAs	have	better	specificity	and	equal	or	greater	sensitivity	 for	 the	
detection	 of	 tuberculosis	 and	 latent	 tuberculosis	 infection	 (LTBI),	 as	 well	 as	 a	 better	
correlation	with	the	degree	of	exposure	to	a	source	of	tuberculosis.		
IGRAs	 are	 good	 markers	 of	 recent	 infection	 and	 represent	 a	 promising	 technique	 for	
investigating	tuberculosis	contacts.	Clinical	experience,	particularly	with	QFT,	suggests	that	
people	positive	on	the	QFT	test	have	a	higher	risk	of	developing	active	disease	than	those	
who	are	negative,	 regardless	of	 the	TST	 result.5,6	 In	a	prospective	study	by	Diel	et	al	601	
adult	household	contacts	were	evaluated	with	TST	and	QFT	simultaneously,	and	preventive	
treatment	was	only	offered	to	those	with	positive	QFT	result.5	Over	a	three-year	follow-up,	
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6	of	41	(15%,	all	of	whom	refused	treatment)	developed	tuberculosis.	In	contrast,	none	of	
181	 subjects	 who	 had	 negative	 QFT	 and	 positive	 TST,	 and	 were	 therefore	 not	 treated,	
developed	tuberculosis.		
In	 a	 recent	 update	 of	 this	 cohort	 with	 a	 further	 816	 close	 contacts,	 none	 of	 the	 824	
untreated	 contacts	 who	 were	 QFT	 negative	 (410	 of	 them	were	 TST	 positive)	 developed	
active	TB	over	the	3.7±	0.92	person-years	of	follow-up,	yielding	a	negative	predictive	value	
of	100%.7	Of	 the	1033	contacts,	19	untreated	contacts	developed	active	disease	 (they	all	
had	been	QFT	positive	and	had	refused	treatment).	
These	results	suggest	that	a	positive	QFT	result	may	identify	better	subjects	at	higher	risk	
of	developing	active	disease	after	 close	contact	with	a	 tuberculosis	 case,	whereas	 risk	of	
progression	 for	 those	with	negative	QFT	may	be	 very	 low,	 regardless	of	 their	 TST	 result.	
However,	 other	 authors	 have	 got	 different	 results,	 turning	 this	matter	 into	 a	 conflicting	
evidence.5,8	
Even	 though	 IGRAs	 are	 being	 increasingly	 used	 in	 clinical	 practice,	 and	 though	 several	
scientific	 societies	 have	 adopted	 them	 as	 the	 reference	 method	 to	 guide	 therapeutic	
decisions,	 the	 best	 strategy	 in	 the	 context	 of	 contact	 tracing	 remains	 to	 be	 defined.9	
Important	 questions	 remain	 to	 be	 answered,	 particularly	 the	 significance	 of	 discordant	
results	between	IGRAs	and	TST,	in	terms	of	the	long-term	development	of	tuberculosis.			
The	purpose	of	this	study	 is	to	assess	the	appropriateness	of	a	sequential	strategy	of	TST	
followed	 by	 QFT	 for	 diagnosing	 tuberculosis	 infection	 and	 for	 deciding	 preventive	
treatment	 in	 close	 contacts	 of	 tuberculosis.	 This	 strategy	 will	 be	 compared	 with	 the	
standard	practice	for	diagnosis	of	tuberculosis	infection,	that	is,	TST	alone.	
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OBJECTIVES	AND	PURPOSE	
	
PRIMARY	OBJECTIVE		
	
To	prove	 that	 the	 incidence	of	 tuberculosis	among	subjects	evaluated	by	TST	combined	
with	QFT	is	not	higher	than	among	subjects	evaluated	by	TST	alone.		
To	 prove	 that	 the	 proportion	 of	 subjects	 diagnosed	 with	 tuberculosis	 infection,	 and	
therefore	treated,	will	be	lower	among	subjects	evaluated	by	TST	combined	with	QFT	
than	among	subjects	evaluated	by	TST	alone.		 	 	 	 	
	
SECONDARY	OBJECTIVES	
	
To	compare	both	strategies	in	terms	of	health	resources	and	expenditures.	
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TRIAL	DESIGN	
	
STATEMENT	OF	THE	ENDPOINTS	
	
Primary	endpoints	
1. Development	of	active	tuberculosis	(differences	in	incidence	in	a	two-year	follow-up	
period).	Diagnosis	of	TB	will	be	based	on	these	definitions:	
o Definitive	diagnosis:	isolation	of	MTC	in	clinical	samples.	
o High	probability	diagnosis:	suggestive	symptoms	of	TB	and	a	positive	result	
of	a	molecular	test	in	respiratory	samples	or	sterile	fluids	(PCR).	
o Probable	diagnosis:	suggestive	clinical	and	radiographic	signs	of	TB	without	
microbiological	confirmation	and	a	favorable	response	to	specific	therapy.	
2. Proportion	of	treated	patients	(diagnosed	with	LTBI)	in	both	groups.	
	
	
Secondary	endpoints	
1. Crude	mortality,	related	to	the	trial	or	its	drugs.	
2. Adverse	 effects:	 If	 a	 patient	 develops	 severe	 hepatic	 toxicity	 (grade	 3-4	 of	 the	
National	 Cancer	 Institute	 Common	 Toxicity	 Criteria	 version	 3.0),	 drugs	 will	 be	
stopped.	 In	 case	 of	 immunoallergic	 phenomena,	 if	 the	 reaction	 is	 early,	mild	 and	
transient,	treatment	won’t	be	stopped.	However,	if	toxicity	is	sustained,	regardless	
of	severity,	the	responsible	drug	will	be	withdrawn.	
3. Treatment	withdrawal	 due	 to	 toxicity	 or	 non-compliance:	 A	 proper	 compliance	 is	
defined	 as	 taking	 all	 prescribed	medications	 for	 the	 length	 of	 time	 necessary	 (6-
month	treatment	for	isoniazid	or	4	months	for	rifampin).	
4. Health	resources	by	means	of	direct	costs.	
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DESIGN	
	
Prospective,	 randomized,	 non-blinded,	 multicenter	 study	 with	 parallel	 group	 design,	
comparing	two	therapeutic	strategies	according	to	two	different	diagnostic	approaches	of	
tuberculosis	infection	in	close	contacts.	
	
RANDOMIZATION	
	
Eligible	patients	(who	meet	all	of	the	 inclusion	criteria	and	none	of	the	exclusion	criteria)	
will	be	randomly	assigned	to	one	of	the	two	study	arms.	Randomization	will	be	performed	
stratifying	 by	 center	 in	 a	 1:1	 allocation	 ratio.	 The	 randomization	 list	 will	 be	 computer-
generated	 by	 version	 9.2	 from	 SAS	 system	 for	Windows	 (Copyright©	 2002-2008	 by	 SAS	
institute	Inc.).		
	
STUDY	SCHEMA	
	
Having	ruled	out	active	disease,	patients	will	be	assigned	to	arm	A	or	arm	B.	
All	participants	will	be	given	TST,	and	only	those	patients	in	ARM	B	with	a	positive	TST	will	
have	QFT	tested.	
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The	 window	 period	 will	 be	 avoided	 by	 repeating	 TST	 or	 QFT	 if	 less	 than	 8	 weeks	 have	
elapsed	since	the	last	contact	with	the	index	case	and	the	first	test	is	negative.		
	
Definition	of	LTBI	and	thus,	decision	to	treat	will	depend	on	the	assigned	arm:	
	
ARM	A	(standard	practice):	treatment	decisions	will	rely	on	TST	result.	
ARM	B	(experimental	practice):	treatment	decisions	will	rely	on	QFT	result.	
	
	
DESCRIPTION	OF	THE	PRODECURES:	DIAGNOSTIC	TESTS	AND	TREATMENT	
	
1.	Tuberculin	skin	test	(TUBERCULIN	PPD	RT/23	2TU)	
Descriptive	name	of	medicine:		
Tuberculin	Purified	Protein	Derivative	(PPD)	for	intradermal	(Mantoux)	test.	
Composition:	
Sterile	solutions	in	concentrations	of	2	TU	PPD,	wholly	prepared	from	a	master	seed	lot	of	
Mycobacterium	 tuberculosis.	 The	 tuberculin	 dilutions	 are	 prepared	 with	 phosphate	
buffered	 saline	 containing	 0,01%	 chinosol	 (potassium	 hydroxyquinoline	 sulphate)	 as	
preservative	and	0,005%	Tween	80	(polysorbatum	80)	as	stabiliser.	The	antigen	fulfills	the	
World	Health	Organization	requirements	for	PPD.	
Identification:	
Colourless	solution	 in	1,5	mL	or	5	mL	clear	vials	sealed	with	a	 rubber	stopper	and	 flip-off	
aluminium	overseal.	
Pharmacological	action	of	the	medicine:		
The	 active	 substances	 are	 the	 proteins	 of	 tubercle	 bacilli	 which	 cause	 induration	 as	 a	
specific	skin	response	of	the	delayed	type	at	the	site	of	injection	in	individuals	infected	with	
tuberculosis.	 Induration	may	be	palpable	as	early	as	5	hours	after	 injection,	but	normally	
reaches	a	peak	only	after	48	to	72	hours.	The	reaction	subsides	over	the	course	of	several	
days.	
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Indications:	
The	intradermal	(Mantoux)	skin	test	employing	PPD	RT/23	is	used	as	an	aid	in	the	diagnosis	
of	 tuberculosis	 infection.	 Reactivity	 to	 the	 test	 may	 be	 depressed	 or	 suppressed	 if	 the	
individual	 is	 suffering	 from	advanced	 tuberculosis	disease,	acute	viral	 infection	 (including	
immunization	 with	 live	 viral	 vaccine	 during	 past	 14	days),	 or	 overwhelming	 bacterial	
infection.	 Patients	 receiving	 corticosteroids	 or	 other	 immunosuppressive	 agents,	 or	 who	
are	suffering	from	malignant	conditions,	may	also	react	poorly	to	the	tuberculin	test.	
Contraindications:	
Known	 hypersensitivity	 to	 the	 test,	 such	 as	 may	 occur	 in	 individuals	 who	 are	 known	
tuberculin	 reactors	 and	who	 have	 been	 repeatedly	 tested	with	 tuberculin,	 or	 in	 persons	
who	have	previously	suffered	from	tuberculosis.	
Dosage	and	directions	for	use:		
Where	 clinical	 tuberculosis	 is	 suspected,	 or	 where	 testing	 for	 an	 immune	 response	
following	vaccination	is	the	objective,	the	test	may	be	performed	with	2	TU	in	order	to	limit	
outspoken	local	reaction.	Where	used	for	epidemiological	purposes,	such	as	to	define	the	
tuberculin	test	response	profile	in	a	cross-section	of	the	population,	2	TU	is	used.	
The	test	is	made	by	intradermal	injection	of	exactly	0,1	mL	of	the	tuberculin	solution.	It	is	
essential	that	the	injection	be	given	in	the	upper	layer	of	the	skin,	since	a	possible	positive	
reaction	 will	 be	 difficult	 to	 interpret	 if	 the	 tuberculin	 is	 injected	 too	 deeply.	 A	 suitable	
injection	will	result	in	the	formation	of	a	white	papule	about	10	mm	in	diameter,	which	will	
remain	 visible	 for	 approximately	 10	minutes.	 The	 most	 suitable	 site	 for	 the	 test	 is	 the	
middle	 third	 of	 the	 flexor	 side	 of	 the	 lower	 arm.	 A	 disposable	 1.0	mL	 graded	 tuberculin	
syringe	fitted	with	a	26	gauge	short	barrel	needle	should	be	used	for	the	injection.	Syringes	
used	for	tuberculin	tests	must	not	be	used	more	than	once.	
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Interpretation	of	the	test:		
The	test	is	judged	48	to	72	hours	after	injection.	The	transverse	diameter	of	the	induration	
is	measured	in	millimeters,	excluding	any	surrounding	erythematous	zone.	An	induration	≥	
5	mm	should	be	considered	positive	in	contact	tracing.	
		Side-effects	and	special	precautions:			
Pain	and	pruritus	may	occur	at	the	injection	site,	with	vesiculation,	ulceration,	or	necrosis	
in	 highly	 sensitive	 persons.	 If	 given	 to	 patients	with	 tuberculosis,	 a	 severe	 reaction	may	
occur.	Discomfort	at	 the	 test	 site	may	be	 relieved	by	cold	packs	or	 topical	glucocorticoid	
ointment	 or	 cream.	 Transient	 bleeding	 may	 occur	 at	 the	 site	 of	 injection,	 but	 is	 of	 no	
significance.	Adrenaline	should	be	immediately	available	in	the	event	of	an	anaphylactic	or	
an	 acute	 hypersensitivity	 reaction	 occurring.	 An	 immediate,	 local	 inflammatory	 type	
reaction	may	occur	due	to	the	constituents	of	the	diluent.	Allergic	reactions	to	tuberculin	
tests	have	been	reported.	Less	frequently,	swelling	of	the	lymph	nodes	may	occur.	Patients	
should	not	rub	or	massage	the	injection	site.	
(Information	from	Statens	Serum	Institut	(SSI);	Copenhagen.	Denmark)	
	
2.	QuantiFERON®-TB	Gold	In-Tube		
QuantiFERON®-TB	Gold	In-Tube	(QFT)	is	an	in	vitro	diagnostic	test	using	a	peptide	cocktail	
simulating	ESAT-6,	CFP-10	and	TB7.7	(p4)	proteins	to	stimulate	cells	 in	heparinised	whole	
blood.	Detection	of	interferon-γ	(IFN-γ)	by	Enzyme-Linked	Immunosorbent	Assay	(ELISA)	is	
used	 to	 identify	 in	 vitro	 responses	 to	 these	 peptide	 antigens	 that	 are	 associated	 with	
Mycobacterium	tuberculosis	 infection.	QFT	 is	an	 indirect	test	for	M.	tuberculosis	 infection	
(including	disease)	and	is	intended	for	use	in	conjunction	with	risk	assessment,	radiography	
and	other	medical	and	diagnostic	evaluations.	
The	 QFT	 test	 is	 a	 test	 for	 Cell	 Mediated	 Immune	 responses	 to	 peptide	 antigens	 that	
simulate	mycobacterial	proteins.	These	proteins,	ESAT-6,	CFP-10	and	TB7.7	(p4),	are	absent	
from	all	BCG	strains	and	 from	most	non-tuberculosis	mycobacteria	with	 the	exception	of	
M.	kansasii,	M.	szulgai	and	M.	marinum.	
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Individuals	 infected	with	M.	 tuberculosis	complex	organisms	usually	have	 lymphocytes	 in	
their	blood	that	recognize	these	and	other	mycobacterial	antigens.	This	recognition	process	
involves	the	generation	and	secretion	of	the	cytokine,	IFN-γ.	The	detection	and	subsequent	
quantification	of	IFN-γ	forms	the	basis	of	this	test.	A	high	determination	of	IFN-γ	suggests	
TB	infection.	
	
3.	Isoniazid	
Isoniazid	 is	 the	 hydrazide	 of	 isonicotinic	 acid	 and	 is	 one	 of	 the	 primary	 drugs	 for	 TB	
treatment.	 	The	activity	of	 isoniazid	 is	 limited	 to	 the	mycobacteria	of	 the	M.	tuberculosis	
complex;	 it	 is	 bactericidal	 for	 rapidly	 dividing	 organisms	 and	 bacteriostatic	 for	 “resting”	
bacilli.	 	The	probable	mechanism	of	action	 is	the	 inhibition	of	the	biosynthesis	of	mycolic	
acids,	a	component	of	the	mycobacterial	cell	wall.		
	
Administration	on	the	trial:		
Isoniazid	will	be	the	first	therapeutic	option	for	all	participants.	A	single	300	mg	tablet	of	
Cemidon®	will	be	provided	during	6	months,	given	on	an	empty	stomach.	The	total	amount	
of	 tablets	 taken	 per	 patient	 should	 be	 168.	 If	 treatment	 is	 stopped	 for	 any	 reason	 for	 a	
period	lower	than	2	weeks,	isoniazid	should	be	taken	again	until	the	completion	of	the	168	
doses.	 If	 the	 period	 without	 treatment	 overcomes	 a	 fortnight,	 treatment	 should	 begin	
again,	no	matter	the	number	of	previous	dosages.	
	
4.	Rifampicin	
Rifampin	is	a	semi-synthetic	rifamycin	derivative	that	is	highly	active	against	mycobacteria,	
most	gram-positive	bacteria,	and	some	gram-negative	bacteria.	 	 It	 is	bactericidal	 for	both	
intracellular	 and	 extracellular	microorganisms.	 	 By	 inhibiting	 prokaryotic	 DNA-dependent	
RNA	 polymerase,	 it	 suppresses	 the	 early	 elongation	 of	 the	 nucleotide	 chain	 in	 RNA	
synthesis.	
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Administration	on	the	trial:		
Rifampicin	will	be	used	as	a	second-line	treatment.	A	single	600	mg	tablet	of	Rimactan®	or	
Rifaldin®	will	be	provided	during	4	months,	given	on	an	empty	stomach.	The	total	amount	
of	 tablets	 taken	 per	 patient	 should	 be	 112.	 If	 treatment	 is	 stopped	 for	 any	 reason	 for	 a	
period	lower	than	2	weeks,	rifampin	should	be	taken	again	until	the	completion	of	the	112	
doses.	 If	 the	 period	 without	 treatment	 overcomes	 a	 fortnight,	 treatment	 should	 begin	
again,	no	matter	the	number	of	previous	dosages.	
	
DATA	RECORDED	FROM	PARTICIPANTS			
	
The	master	 file	 will	 contain	 each	 of	 the	 documents	 required	 in	 the	 guidelines	 for	 Good	
Clinical	Practice	(CPMH/ICH/135/95).	
The	trial	staff	will	ensure	that	the	participants’	anonymity	is	maintained.		The	participants	
will	be	identified	only	by	a	participant	ID	number	on	the	Case	Report	Form	(CRF)	and	any	
electronic	database.		All	documents	will	be	stored	securely	and	only	accessible	by	trial	staff	
and	authorized	personnel.		
The	CRF	will	include	demographic	data,	medical	history,	information	regarded	to	the	index	
case	 and	 the	 diagnostic	 tests	 performed	 to	 rule	 out	 LTBI.	 In	 case	 of	 needing	 treatment,	
information	about	its	compliance	and	adverse	effects	will	be	also	detailed.	
See	attachment	1	“Schedule	of	events”	for	the	complementary	tests	needed.		
	
END	OF	TRIAL		
	
The	end	of	the	trial	is	the	date	of	the	last	visit	of	the	last	participant.	
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STUDY	POPULATION	
	
INCLUSION	CRITERIA	
	
1. Age	≥18	years.	
2. Household	contact	of	a	patient	with	pulmonary	and/or	laryngeal	TB	(defined	as	
positive	smear	or	positive	nucleic	acid	amplification	test,	and/or	positive	culture).	
3. Written	consent	given.		
	
EXCLUSION	CRITERIA	
	
1. Pregnant	or	breast-feeding	women.		
2. Immunosuppressive	conditions,	as	one	of	the	following:		
-		Known	HIV	infection	
-		Treatment	with	corticosteroids	(at	least	10	mg/d)	
-		Transplant	recipients	taking	immunosuppressive	drugs		
-		Treatment	with	tumor	necrosis	alpha	inhibitors		
-		Active	cancer	under	treatment	with	chemotherapy	
-		Uncompensated	cirrhosis		
-		Renal	failure	in	hemodialysis		
	
3. Prior	TB	or	positive	TST.	
4. Abnormal	chest	X-ray	with	apical	fibro-nodular	changes	typical	of	healed	TB.	
5. Isoniazid	or	rifampin	resistant	strain	(index	case).	
6. Contraindication	to	both	isoniazid	and	rifampin.	
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SUBJECT	WITHDRAWAL	CRITERIA		
	
Each	participant	has	the	right	to	withdraw	study	at	any	time.		In	addition,	the	investigator	
may	discontinue	 a	 participant	 from	 the	 study	 at	 any	 time	 if	 the	 investigator	 considers	 it	
necessary	for	any	reason	including:		
- An	 adverse	 event	 requiring	 discontinuation	 of	 the	 study	medication,	 mainly	 liver	
toxicity	due	to	isoniazid	or	rifampicin.	
- Lost	to	follow	up	(not	attendance	to	two	consecutive	visits).	
- Indeterminate	result	of	QFT	after	repeating	it	twice.		
- Isoniazid	or	rifampin	resistant	strain	(index	case).		
- No	culture-confirmed	TB	case	(index	case).	
	
The	type	and	timing	of	the	data	to	be	collected	for	withdrawn	subjects	will	be	the	same	as	
the	subjects	which	continue	running	the	study.	
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TRIAL	INTERVENTION	
	
SCREENING	FOR	LTBI,	TREATMENT	AND	FOLLOW-UP	
	
All	household	members	of	a	TB	patient	will	be	invited	to	participate.	They	should	meet	all	
inclusion	criteria	and	none	of	 the	exclusion	ones.	Having	 ruled	out	active	disease	 (with	a	
clinical	 and	 image	 evaluation	 with	 chest	 X-ray),	 and	 after	 obtaining	 written	 informed	
consent,	participants	will	undergo	randomized	to:	
	
ARM	A	(standard	practice)	
Treatment	decisions	will	be	based	on	TST	result:	in	case	of	a	positive	result,	treatment	will	
be	given.		
In	case	of	a	negative	result,	if	less	than	8	weeks	have	elapsed	since	the	last	contact	with	the	
index	 case,	 TST	 will	 be	 repeated	 in	 order	 to	 avoid	 window	 period.	 If	 it	 turns	 positive,	
treatment	will	be	given.		
	
ARM	B	(experimental	practice).		
Procedures	in	this	arm	will	also	include	TST.	As	in	Arm	A,	in	case	of	a	negative	result,	if	less	
than	8	weeks	have	elapsed	since	the	last	contact	with	the	index	case,	TST	will	be	repeated	
in	order	to	avoid	window	period.		
Those	subjects	with	a	positive	TST	will	have	QFT	done.		Treatment	decisions	will	be	based	
on	QFT	results:	in	case	of	a	positive	result,	treatment	will	be	given.	
If	 QFT	 is	 done	 after	 a	 first	 positive	 TST	 and	 it	 results	 in	 a	 negative	 determination,	 QFT	
should	be	repeated	8	weeks	later,	in	order	to	overpass	the	window	period.	
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Diagnostic tests 
TST:	 The	 standard	Mantoux	 test	 consists	 of	 an	 intradermal	 injection	 of	 2	 TU	 of	 Statens	
Serum	 Institute	 (SSI)	 tuberculin	 RT	 23	 in	 0.1	 ml	 solution	 for	 injection.	 The	 solution	 is	
injected	 intradermally	 (between	 the	 layers	 of	 dermis)	 and	 read	 48	 to	 72	 hours	 later.	 An	
induration	≥	5	mm	will	be	considered	as	a	positive	reaction,	thus	pointing	out	TB	infection.		
QFT:	QuantiFERON®-TB	Gold	In-Tube	(Cellestis)	will	be	done	following	the	manufacturer's	
instructions.	 It	 consists	 on	 a	 negative	 control	 tube	 (without	 antigen)	 and	 a	 tube	 with	
specific	 antigens	 of	 MTC	 (ESAT6,	 CFP10	 and	 TB7.7).	 After	 blood	 collection,	 as	 soon	 as	
possible,	 and	within	16	hours,	both	 tubes	will	 be	 incubated	at	37ºC	 for	16-24	hours	and	
then	centrifuged	at	2000-3000	g	 (RCF)	 for	15	minutes.	Afterwards,	 concentration	of	 IFNγ	
will	be	measured	on	200	µl	of	plasma	from	each	tube	by	means	of	ELISA.	Results	will	be	
calculated	using	QuantiFERON®-TB	Gold	In-Tube	Analysis	Software.	A	positive,	negative	or	
indeterminate	result	will	be	obtained.	In	case	of	an	indeterminate	one,	the	test	should	be	
repeated.	If	it	remains	indeterminate,	the	subject	will	be	withdrawal	from	the	trial,	and	the	
therapeutic	decision	will	relay	on	the	TST.	
	
Treatment of patients with LTBI 
See	Section	4.5	“Description	of	the	diagnostic	tests	and	treatment”,	on	pages	13-14.	
		
Follow-up of patients  
Visits	listed	below	are	protocol-specified	study	visits	for	all	recruited	subjects:		
	
- Baseline	 visit:	 in	which	 PI	 tells	 the	 patient	whether	 he/she	 requires	 treatment	 or	
not,	based	on	 the	 results	of	 the	diagnostic	 test	 in	each	arm.	By	 this	 time,	a	 clinic	
interview	to	rule	out	active	TB	symptoms	and	a	chest	X-ray	will	have	been	carried	
out.		
- Months	6,	12,	18	and	24:	clinical	assessment.			
- Months	6	and	24:	chest	X-ray.	
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In	 addition,	 people	 taking	 medication	 will	 also	 undergo	 the	 following	 visits	 and	
complementary	tests:	
- Baseline	 visit:	 patients	 diagnosed	 with	 LTBI	 will	 have	 blood	 drawn	 for	 CBC	 with	
differential	 and	 platelet	 count,	 serum	 or	 plasma	 creatinine,	 and	 liver	 function	
tests.		
- Months	1	and	3:	an	extra	visit	for	compliance,	adverse	event	assessment	and	blood	
analysis	 (with	the	same	measured	parameters	as	 in	baseline	visit)	will	be	carried	
out.	
	
See	Attachment	1	“Schedule	of	events”	for	more	details.	
	
Monitoring	subject	compliance	
In	 case	 of	 taking	 isoniazid,	 compliance	 will	 be	 measured	 with	 the	 Eidus-Hamilton	 test,	
which	detects	N-acetyl	isoniazid	in	urine	and	confirms	that	the	drug	is	being	ingested:	with	
little	drops	of	two	reagents	added	to	urine,	a	red	colour	develops.		
In	case	of	taking	rifampin,	the	orange	colour	of	urine	will	confirm	the	compliance.	
Both	tests	will	be	done	in	the	outpatient	clinic	during	routine	visits.	Missing	tables	will	also	
be	accounted.	
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DRUGS	AND	DIAGNOSTIC	TESTS:	STORAGE	AND	DISTRIBUTION	
	
TST:	PPD	RT/23	should	be	stored	away	from	light,	and	at	a	temperature	between	2°C	and	
8°C.	 Once	 a	 vial	 of	 PPD	 RT/23	 tuberculin	 has	 been	 opened,	 its	 contents	 should	 be	 used	
within	8	hours.	Any	remaining	liquid	should	be	discarded.	
	
QFT:	 Store	 blood	 collection	 tubes	 at	 4°C	 to	 25°C.	 The	 shelf	 life	 of	 the	QuantiFERON®-TB	
Gold	blood	collection	tubes	is	15	months	from	the	date	of	manufacture	when	stored	at	4°C	
to	25°C.	
	
Drugs	(Isoniazid	and	Rifampin)	should	be	stored	in	a	cool,	dry	place.	Each	batch	of	tablets	
will	be	labeled	in	the	Pharmacy	Department	and	then	carried	to	the	outpatient	clinic	where	
participants	 will	 be	 attended.	 PI	 in	 each	 center	 will	 record	 the	 batch	 number	 and	 its	
expiration	date,	 in	order	 to	warrant	sample	traceability	as	RD	223/2004	establishes,	with	
the	rest	of	data	required.	
	
MEDICATIONS	PERMITTED	AND	NOT	PERMITTED	DURING	THE	TRIAL	
	
In	 case	 of	 patients	 taking	 isoniazid,	 they	 should	 not	 be	 treated	with	 carbamazepine	 and	
disulfiram,	because	of	the	potentiation	of	its	action.	
In	 case	 of	 patients	 taking	 rifampin,	 all	 the	 following	 drugs	 are	 not	 permitted:	 Protease	
inhibitors,	delavirdine,	cyclosporine,	tacrolimus,	itraconazol	and	ketoconazol.	
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ASSESSMENT	OF	EFFICACY	
	
EFFICACY	PARAMETERS	
- The	primary	endpoint	will	be	development	of	active	disease	after	a	two-year	period	
of	follow-up.	
- The	secondary	endpoint	will	be	the	health	resources	used	and	costs.	
	
METHODS	AND	TIMING	FOR	ASSESSMENT		
- Development	of	active	disease	will	be	assessed	through	clinical	evaluation	and	chest	
X-ray	 following	 the	 schedule	 of	 events.	 In	 case	 of	 clinical	 suspicion,	 respiratory	
samples	will	be	taken	for	microbiological	analysis.	
- Health	 resources	 will	 be	 computed	 by	 recording	 number	 of	 visits	 and	
complementary	tests	needed	in	each	case.	
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ASSESSMENT	OF	SAFETY	
	
SAFETY	AND	TOLERABILITY	ENDPOINTS	
	
o TST	and	QFT:	the	safety	and	tolerability	endpoint	in	both	diagnostic	tests	will	
be	 the	measures	 taken	 in	order	 to	 remove	 the	 local	discomfort	 that	 these	
tests	may	cause.	
o Drugs:	 the	 primary	 endpoint	 for	 analysis	 of	 safety	 and	 tolerability	 is	
discontinuation	 of	 assigned	 treatment	 for	 any	 reason.	 Other	 aspects	 that	
will	be	assessed	as	secondary	endpoints	include	mortality,	the	occurrence	of	
3	 and	 4	 grade	 toxicities	 (according	 to	 modified	 National	 Cancer	 Institute	
Common	 Toxicity	 Criteria	 Version	 3.0.)	 and	 the	 rates	 and	 types	 of	 toxicity	
thought	 possibly,	 probably,	 or	 definitely	 related	 to	 the	 drug	 by	 the	
investigator.	
	
METHODS	AND	TIMING	FOR	ASSESSMENT	
o TST	and	QFT:	any	incidence	and	injury	caused	by	any	diagnostic	test	will	be	
recorded.	
o Drugs:	 in	those	subjects	receiving	treatment,	tolerability	will	be	assessed	in	
each	 visit	 during	 the	 treatment	 period	 by	means	 of	 clinical	 interview	 and	
checking	 of	 normal	 liver	 parameters	 in	 the	 blood	 analysis,	 following	 the	
schedule	of	events.	
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ADVERSE	EVENT	REPORTING		
	
All	 symptoms	 and	 laboratory	 findings	 will	 be	 graded	 according	 to	 severity	 using	 the	
modified	National	Cancer	Institute	Common	Toxicity	Criteria	Version	3.0.		
DEFINITIONS	
• An	 adverse	 event	 (AE)	 is	 defined	 as	 any	 unintended	 or	 abnormal	 clinical	
observation	that	is	not	of	benefit	to	the	patient.			
• A	serious	adverse	event	 (SAE)	 is	defined	as	any	experience	that	 is	 fatal	or	
life-threatening,	 is	persistently	or	significantly	disabling	 (as	determined	by	
the	 principal	 investigator),	 requires	 inpatient	 hospitalization,	 or	
prolongation	 of	 hospitalization,	 is	 a	 congenital	 anomaly,	 or	 overdose	 of	
study	drugs.	Any	Grade	4	toxicity	is	considered	a	SAE.			
	
REPORTING	
Any	 Serious	 Adverse	 Event	 (this	 includes	 any	 Grade	 4	 toxicity)	must	 be	 reported	 to	 the	
sponsor	within	48	hours	of	the	site's	awareness	of	the	event.	The	initial	communication	will	
be	followed	by	a	detailed	report.		
Those	 adverse	 events	 that	 are	 serious,	 unexpected,	 and	 possibly,	 probably,	 or	 definitely	
related	to	the	study	drugs,	will	be	reported	by	the	sponsor	to	the	Health	Authority	in	Spain	
(AEMPS)	in	the	form	of	a	written	Safety	Report	within	a	15-day	period	of	time.		
AEMPS	should	also	be	notified	of	any	death	or	 life-threatening	adverse	event	before	 the	
first	7	days	of	the	notification	to	the	sponsor.	The	initial	communication	will	be	followed	by	
a	detailed	report	in	an	8-day	period	of	time.	These	SAE	will	be	reported	using	the	European	
standard	electronic	format.	
Similarly,	the	sponsor	will	report	every	SAE	to	the	Reference	Ethics	Committee	and	the	rest	
of	Ethics	Committees	involved,	with	the	same	time	limit	as	the	reports	to	AEPMS.	
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In	 addition,	 the	 following	 adverse	 events	must	 be	 reported	 on	 an	Adverse	 Event	 Report	
Form:	
- new	 medical	 diagnosis	 (at	 the	 time	 of	 enrollment,	 if	 the	 patient	 already	 has	 a	
medical	diagnosis	whose	signs	or	symptoms	worsen	during	the	study	to	a	Grade	3	
or	4,	this	is	an	adverse	event	that	must	be	reported)	
- any	grade	3	adverse	event	
- study	drug	discontinuation,	temporary	or	permanent,	due	to	an	adverse	event	
- pregnancy			
	
CLINICAL	MANAGEMENT	OF	ADVERSE	EVENTS	
	
In	general,	for	grade	1	toxicities,	the	patient	will	be	followed	carefully	and	the	study	drugs	
will	be	continued.		For	grade	2	toxicities,	the	patient	will	be	followed	more	carefully,	with	
additional	 laboratory	 and/or	 clinic	 visits	 as	 necessary,	 and	 the	 study	 drugs	 may	 be	
temporarily	 held	 at	 the	 investigator's	 discretion.	 For	 any	 grade	 3	 toxicity	 that,	 in	 the	
principal	investigator’s	judgment	is	due	to	study	drug(s),	the	causative	study	drug(s)	should	
be	 held.	 	 The	 clinician	 should	 rule	 out	 other	 possible	 causes	 of	 the	 symptoms	 before	
discontinuing	study	medication.	 	When	possible,	concomitant	medications	should	be	held	
first	at	the	discretion	of	the	principal	investigator	if	he/she	suspects	they	are	contributing	
to	the	toxicity.		Depending	on	the	nature	and	severity	of	the	toxicity,	the	degree	to	which	it	
resolves,	and/or	the	emergence	of	alternative	explanations	for	the	toxicity	or	the	subject’s	
deterioration,	the	study	drugs(s)	may	be	restarted	at	the	discretion	of	the	investigator.		For	
any	recurring	grade	3	or	grade	4	toxicities,	the	study	drugs	should	be	temporarily	held	and	
may	be	permanently	stopped	at	the	discretion	of	the	investigator.		For	thrombocytopenia	
(platelet	count	<	75,000/cu	mm)	attributed	to	rifampin,	rifamycins	should	generally	not	be	
restarted.		For	other	grade	3	or	4	rifamycin-attributable	toxicities,	rifamycins	may	be	held	
and	may	be	permanently	stopped	at	the	discretion	of	the	investigator.	
Any	patient	with	grade	4	 renal,	hepatic,	 cardiac	or	hematological	 toxicity	will	have	his	or	
her	study	medications	held	immediately.		The	laboratory	test	or	clinical	finding	in	question	
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will	be	reassessed	as	soon	as	possible.	The	repeat	test	will	guide	management	of	the	event	
as	follows:	
- If	the	repeat	assessment	shows	toxicity	of	grade	3	or	 lower,	and	if	the	patient	has	
continued	to	receive	study	drugs	between	the	two	testing	dates,	 then	the	patient	
will	be	managed	according	to	the	appropriate	toxicity	level	of	the	repeat	test.	
- If	 the	 repeat	 test	 shows	 toxicity	 of	 grade	 3	 or	 lower,	 and	 if	 the	 patient	 has	 not	
received	 study	 drugs	 between	 the	 two	 testing	 dates,	 then	 the	 patient	 will	 be	
managed	at	the	discretion	of	the	investigator	with	regard	to	the	re-administration	
of	study	drugs,	and	otherwise	according	to	the	toxicity	level	of	the	repeat	test.	
- If	 the	 repeat	 test	 shows	 grade	 4	 toxicity,	 then	 the	 patient	 will	 be	 permanently	
discontinued	from	study	medications.	 	The	patient	will	continue	to	be	 followed	 in	
the	study.			
	
For	other	grade	4	toxicities,	the	study	drugs	will	be	temporarily	held	and	may	be	restarted	
or	permanently	stopped	at	the	discretion	of	the	investigator.			
If	 a	 patient	 develops	 hepatic	 toxicity	 requiring	 study	 drug	 discontinuation,	 the	 following	
evaluation	 will	 be	 undertaken:	 assessment	 for	 history	 of	 injection	 or	 non-injection	 drug	
use,	alcohol	ingestion,	use	of	other	hepatotoxic	drugs,	and	performance	of	serologic	tests	
for	viral	hepatitis	(IgM	antibody	for	Hepatitis	A,	Hepatitis	B	surface	antigen,	IgM	antibody	
to	Hepatitis	B	core	antigen,	antibody	to	Hepatitis	C).			
	
DISCONTINUATION	OF	STUDY	DRUGS	DUE	TO	ADVERSE	EVENTS	
	
Certain	events	or	conditions	may	necessitate	temporary	or	permanent	discontinuation	of	
the	 study	medication.	 	Patients	who	experience	 such	events	or	 conditions,	however,	will	
still	be	"on	study"	and	will	be	followed	until	study	completion.		Any	patient	for	whom	the	
study	medication	is	temporarily	discontinued	will	be	restarted	on	study	medication	as	soon	
as	 possible.	 	 If	 study	 drugs	 are	 permanently	 discontinued,	 further	 LTBI	 therapy	may	 be	
administered	at	 the	 investigator's	discretion.	These	patients	will	be	 followed	 in	 the	study	
according	to	the	guidelines	and	time-points	established	in	the	protocol.			
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Temporary	Discontinuation	
Criteria	for	temporary	discontinuation	of	study	therapy	
- Development	 of	 a	 toxicity	 that,	 depending	 on	 its	 nature	 and	 severity,	 requires	
temporary	 discontinuation	 of	 the	 study	 medication	 until	 the	 toxicity	 resolves	 as	
indicated	in	the	preceding	toxicity	management	section.	
- Development	 of	 another	medical	 condition	 that	makes	 the	 administration	 of	 the	
study	 drug	 inadvisable.	 	 The	 decision	 to	 discontinue	 temporarily	 the	 study	
medication	 in	 this	 situation	 will	 be	 at	 the	 investigator's	 discretion.	 	 The	 period	
during	 which	 the	 patient	 is	 off	 study	 medication	 will	 be	 as	 short	 as	 clinically	
possible.	
	
Permanent	Discontinuation	
Criteria	for	permanent	discontinuation	of	study	therapy	
- Development	 of	 a	 toxicity	 that	 warrants	 permanent	 discontinuation	 of	 any	 study	
drug.	
- The	patient	refuses	further	study	therapy.	
- It	is	the	investigator's	judgment	that	it	is	no	longer	in	the	best	interest	of	the	patient	
to	continue	study	therapy.	
- Termination	of	the	study.	
	
If	 a	 patient	 refuses	 further	 study	 therapy,	 the	 patient	 will	 be	 treated	 with	 a	 non-study	
regimen,	 but	 will	 continue	 with	 scheduled	 follow-up	 study	 visits.	 If	 a	 patient	 withdraws	
consent,	the	patient	will	be	treated	with	a	non-study	regimen,	and	all	study-specific	follow-
up	will	stop.	
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STATISTICAL	METHODS	AND	SAMPLE	SIZE	
	
STATISTICAL	ANALYSIS	
	
The	 primary	 efficacy	 analyses	 will	 be	 performed	 in	 the	 per-protocol	 (PP)	 population,	
though	a	sensitivity	analysis	will	be	performed	on	 intention-to-treat	 (ITT)	population.	The	
ITT	population	will	consist	of	all	randomized	subjects,	while	the	PP	population	will	include	
ITT	 patients	 who	 comply	 with	 the	 protocol.	 Safety	 analyses	 will	 be	 performed	 on	 all	
randomized	patients	(ITT	population)	
	
The	main	point	of	analysis	will	be	the	difference	between	the	incidences	of	tuberculosis	in	
both	 arms,	 under	 the	 hypothesis	 of	 non-inferiority.	 Incidences	 will	 be	 compared	 with	 a	
unilateral	confidence	interval	of	97.5%	for	the	difference.	The	number	of	treated	patients	
within	 each	 treatment	 arm	will	 be	 similarly	 analyzed.	 The	 difference	 in	 health	 resources	
and	costs	between	the	two	arms	will	be	the	secondary	point	of	evaluation.		
	
The	 baseline	 characteristics	 and	 the	 rest	 of	 outcome	 measures	 in	 the	 study	 will	 be	
compared	 between	 study	 arms	 by	 means	 of	 χ2	 test	 for	 categorical	 variables,	 and	 for	
continuous	variables,	by	means	of	t-Student	test	or	nonparametric	Mann-Whitney	tests	(if	
normality	of	the	variable	can	be	assumed).	The	incidence	of	tuberculosis	will	be	reported	as	
cumulative	incidence	and	as	the	incidence	rate	(cases	per	100,000	person-years).	P	values	
are	based	on	 two-tailed	with	a	 significance	 level	<0.05.	 Statistical	 analysis	will	be	 carried	
out	with	SPSS	(version	15	for	Windows).	
	
SAMPLE	SIZE	CALCULATION	
	
The	 sample	 size	 was	 calculated	 to	 demonstrate	 the	 non-inferiority	 of	 the	 experimental	
strategy	(TST	and	QFT)	with	respect	to	standard	practice	(TST	alone)	in	terms	of	preventing	
TB	 development	 and	 reducing	 the	 amount	 of	 TB	 infection	 diagnosis	 in	 the	 experimental	
group.	Assuming	an	alpha	of	0.025	and	a	beta	of	0.20,	a	loss	to	follow-up	of	20%	and		an	
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incidence	of	tuberculosis	in	the	first	two	years	of	household	contacts	of	TB	patients	of	0.5%	
(Diel	et	al,	ARCCM	2008),	870	individuals	are	needed	(435	per	arm).	This	sample	size	is	also	
sufficient	to	detect	a	10%	minimal	difference	in	the	number	of	subjects	needing	treatment	
between	the	two	groups	(assuming	the	same	error	types),	thus	covering	the	required	size	
to	account	for	the	two	primary	endpoints.	
	
INTERIM	ANALYSES	AND	STOPPING	RULES	
	
An	interim	analysis	will	be	performed	two	years	after	the	inclusion	of	the	400th	patient	in	
order	to	discard	lack	of	efficacy	of	the	experimental	strategy	(higher	incidence	of	TB	in	the	
group	with	less	treated	patients).	Our	“stopping	rule”	establishes	that	the	trial	would	stop	
if	the	97.5%	confidence	interval	for	the	estimated	incidence	of	TB	lies	strictly	to	the	left	of	
the	non-inferiority	margin.	
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ETHIC,	DEONTOLOGICAL	AND	REGULATORY	CONSIDERATIONS	
	
The	Investigator	will	ensure	that	this	study	is	conducted	in	accordance	with	the	principles	
of	 the	Declaration	of	Helsinki,	 ICH	Guidelines	 for	Good	Clinical	Practice	and	RD	223/2004	
(article	7),	and	in	full	conformity	with	relevant	regulations	
The	 protocol,	 informed	 consent	 form	 (ICF),	 participant	 information	 sheet	 (PIS)	 and	 any	
applicable	 documents	 will	 be	 submitted	 to	 an	 appropriate	 Ethics	 Committee	 (EC)	 and	
Regulatory	Authority	(AEMPS)	for	written	approval.			
	
All	 substantial	 amendments	 to	 the	 original	 approved	 documents	 will	 be	 also	 sent	 to	 an	
appropriate	Ethics	Committee	(EC)	and	Regulatory	Authority	(AEMPS)	for	written	approval.	
	
INFORMED	CONSENT	
The	participant	must	personally	sign	and	date	the	latest	approved	version	of	the	informed	
consent	form	before	any	study	specific	procedures	are	performed.	
Written	 and	 verbal	 versions	 of	 the	 Participant	 Information	 Sheet	 (PIS)	 and	 Informed	
Consent	Form	(ICF)	will	be	presented	to	the	participants	detailing	no	 less	 than:	 the	exact	
nature	 of	 the	 study;	 the	 implications	 and	 constraints	 of	 the	 protocol;	 the	 known	 side	
effects	and	any	risks	involved	in	taking	part.	It	will	be	clearly	stated	that	the	participant	is	
free	 to	withdraw	 from	 the	 study	 at	 any	 time	 for	 any	 reason	without	 prejudice	 to	 future	
care,	and	with	no	obligation	to	give	the	reason	for	withdrawal.	
The	participant	will	be	allowed	as	much	time	as	wished	to	consider	 the	 information,	and	
the	 opportunity	 to	 question	 the	 Investigator	 or	 other	 independent	 parties	 to	 decide	
whether	they	will	participate	in	the	study.	Written	Informed	Consent	will	then	be	obtained	
by	means	of	participant	dated	signature	and	dated	signature	of	the	person	who	presented	
and	 obtained	 the	 informed	 consent.	 The	 person	 who	 obtained	 the	 consent	 must	 be	
suitably	 qualified	 and	 experienced,	 and	 have	 been	 authorized	 to	 do	 so	 by	 Principal	
Investigator.	A	copy	of	the	signed	ICF	will	be	given	to	the	participants.	The	original	signed	
form	will	be	retained	at	the	study	site.		
	
	
		
Protocol	Identifying	number:	QFT-ECC-01	 	 Version	6:	April	1,	2011	
	 	 	
34	
SUBJECT	CONFIDENTIALITY	
	
The	 trial	 staff	 will	 ensure	 that	 the	 participants’	 anonymity	 is	 maintained,	 as	 Ley	 de	
protección	de	datos	de	carácter	personal	(15/99)	orders.		The	participants	will	be	identified	
only	by	a	participant	 ID	number	on	 the	CRF	and	any	electronic	database.	 	All	documents	
will	 be	 stored	 securely	 and	 only	 accessible	 by	 trial	 staff	 and	 authorized	 personnel.	 The	
study	 will	 comply	 with	 the	 Data	 Protection	 Legislation,	 which	 requires	 data	 to	 be	
anonymized	as	soon	as	it	is	mandatory	to	do	so.			
	
INSURANCE	
An	insurance	policy	has	been	arranged	with	Zurich®	to	cover	study	participants.	
	
AGREEMENT	TO	PUBLISH	
Miguel	Santín	MD,	PhD	as	Sponsor	of	the	trial	agrees	to	make	publicly	available	the	main	
study	results,	regardless	of	their	outcome.	
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FUNDING		
	
This	 trial	 has	 received	 a	 grant	 from	 Ministerio	 de	 Sanidad,	 Política	 Social	 e	 Igualdad	
(Convocatoria	 SAS	 2481/2009	 from	 September	 17th),	with	 a	 global	 amount	 of	 106.000	 €,	
approved	on	January	2010.	A	deferral	has	been	granted	to	ensure	the	feasibility	of	the	trial	
on	December	30th,	2010.		
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Attachment	1:	Schedule	of	Events	
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Supplementary	material	
Table	1:	Characteristics	of	the	cohort	according	to	the	study	period	
	 1st	period	
(n=	230)	
2nd	period	
(n=	162)	
3rd	period	
(n=	334)	
	
p-value								
Male	gender	(%)	 88	(38.3)	 78	(47.6)	 146	(43.7)	 0.25	
Age	years,	mean	(SD)	 51.3	(12.2)	 48.9	(12.6)	 47.7	(14.5)	 <0.01	
Born	in	high-burden	TB	countries	(%)	 7	(3.0)	 14	(8.6)	 37	(11.1)	 <0.01	
BCG-vaccinated	(%)	 37	(16.1)	 39	(24.1)	 125	(37.4)	 <0.01	
Previous	TB	infection	(%)	 11	(4.8)	 1	(0.6)	 14	(4.2)	 0.87	
IMID	(%)	
Rheumatoid	arthritis		
Ankylosing	spondylitis		
Psoriasis	*	
Inflammatory	bowel	disease		
Others		
	
129	(56.1)	
28	(12.2)	
70	(30.4)	
3	(1.3)	
-	
	
73	(45.1)	
24	(14.8)	
61	(37.7)	
4	(2.5)	
-	
	
109	(32.6)	
60	(18)	
120	(36)	
23	(6.9)	
22	(6.6)	
	
<0.01	
0.06	
0.21	
<0.01	
	
Immunosuppressive	treatment	(%)	
Corticosteroid	therapy	(%)	
187	(81.3)	
133	(71.1)	
125	(77.2)	
75	(60)	
239	(71.6)	
135	(56.2)	
0.01	
<0.01	
Anti-TNF-α	agent	
- Infliximab		
- Adalimumab		
- Etanercept		
- Certolizumab		
- Golimumab			
194	(84.3)	
60	(30.9)	
99	(51)	
106	(54.6)	
7	(3.6)	
4	(2.1)	
130	(80.2)	
52	(40)	
65	(50)	
44(33.8)	
5	(3.8)	
3	(2.3)	
218	(65.3)	
50	(22.9)	
106	(48.6)	
96	(44)	
8	(3.7)	
17	(7.8)	
<0.01	
<0.01	
0.89	
<0.01	
0.99	
0.01	
*	Includes	cutaneous	psoriasis	and	psoriatic	arthritis.		
SD:	standard	deviation,	TB:	tuberculosis,	BCG:	Bacillus	Calmette-Guérin,	IMID:	
immune-mediated	inflammatory	disease,	TNF:	Tumor	necrosis	factor.		
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Table	2:	Characteristics	of	four	patients	who	developed	Tuberculosis		
	 1st	period	
(n=	230)	
2nd	period	
(n=	162)	
3rd	period	
(n=334)	
No.	of	cases	 1	 1	 2	
Sex,	Age	(years)	 Man,	59	 Man,	55	 Woman,	77	 Man,	46	
Underlying	disease	 Rheumatoid	
Arthritis	
Cutaneous	
Psoriasis	
Rheumatoid	
Arthritis	
Rheumatoid	
Arthritis	
TNF-α		antagonist	 Adalimumab	 Infliximab	 Adalimumab	 Not	given	
LTBI	diagnosis		 No	
Two-step	TST							
(-)	
Yes	
Two-step																				
TST(+)/QFT(-)	
No	
Single-step					
TST(-)/QFT	(-)	
No	
Single-step				
TST(-)/QFT(-)	
Treatment	for	LTBI		 Not	given	 Rifampicin							
(4	m)	
Not	given	 Not	given	
Type	of	TB	 Disseminated	 Pleural	 Pulmonary	 Pleural	
Diagnosis	
		
Sputum	
culture	
Lymphocytic	
exudative	
pleural	effusion	
with	high	ADA*	
activity.	
Response	to	
treatment.	
Sputum	
culture	
Lymphocytic	
exudative	
pleural	effusion	
with	high	ADA*	
activity.	
Response	to	
treatment	
Days	from	1st	dose	
of	anti-TNF	
173		 209		 356		 1	year	after	
screening	
					*ADA:	Adenosine	Deaminase,	TNF:	Tumor	necrosis	factor	TNF,	LTBI:	latent	tuberculosis	
infection,	TST:	tuberculin	skin	test,	QFT:	QuantiFERON®-TB	Gold	In-Tube.	
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Table	1.	Characteristics	of	the	11	studies	included	
	
Reference	
(year)	
Design	 Country	
(income	
status)	
Population	
(age	group)	
HIV+ve	
individuals		
in	cohort	
IGRA	
	
TST		
cut-off	
(mm)	
PT	offered	 Individuals	in	
the	original	
study/in	the	
analysis	
(n/n)	
Song16		
(2007)	
Retrospective	 South	Korea	
(High)	
TB	case-contacts	
(Adolescents)	
Unknown*	 QFT-GIT	 ≥10		 Yes,	
QFT-GIT	(+)	
1826/1826	
Hill24		
(2008)	
Prospective	 The	Gambia	
(Low)	
TB	case-contacts	
(Adults	and	children)	
Yes	(2%)	 ELISPOT	
(in	house)	
≥10		 No	 2381/1648	
Bakir22	
(2008)	
Prospective	 Turkey	
(Middle)	
TB	case-contacts	
(Children)	
Unknown*	 ELISPOT	
(in	house)	
	
≥5	and	
≥15	
Yes,	
<6	years	and		
≥6	years	and	
TST	(+)†	
1024/287	
Kik17		 Prospective	 Netherlands	 TB	case-contacts	 No,	 T-SPOT	 ≥5,	≥10,	 No	 433/433	
(2009)	 (High)	 (Adults)	 exclusion	
criterion	
	 and	≥15		
Kik17		
(2009)	
Prospective	 Netherlands	
(High)	
TB	case-contacts	
(Adults)	
No,	
exclusion	
criterion	
QFT-GIT	
	
≥5,	≥10,	
and	≥15		
No	 433/433	
Laffite19	
(2009)	
Retrospective	 Switzerland	
(High)	
Anti-TNF	candidates	
(Adults)		
Unknown*	 T-SPOT	
	
≥10		 Yes,	
T-SPOT	(+)	
50/46	
Diel18	
(2010)	
Retrospective	 Germany	
(High)	
TB	case-contacts	
(Adults	and	children)	
No,	
exclusion	
criterion	
QFT-GIT	
	
≥5,	≥10,	
and	≥15		
Yes,	
QFT-GIT	(+)	
1417/901	
Leung25		
(2010)	
Retrospective	 China	
(Middle)	
Patients	with	silicosis	
(Adults)	
Unknown*	 T-SPOT	
	
≥5,	≥10,	
and	≥15	
Yes,	
TST	(+)	
331/241	
Harstad21	
(2010)	
Prospective	 Norway	
(High)	
Asylum	seekers	
(Adults)	
Unknown	 QFT-GIT	
	
≥6,	≥15		 N.R.‡	 823/810	
Mahomed26	
(2011)	
Prospective	 South	Africa	
(Middle)	
Cohort	study	
(Adolescents)	
Unknown	 QFT-GIT	
	
≥5		 No	 6363/5244	
Garcovich20	
(2011)	
Prospective	 Italy	
(High)	
Anti-TNF	candidates	
(Adults)	
Unknown*	 QFT-GIT	
	
≥5			 Yes,	
QFT-GIT	(+)	
50/44	
Chang23	
(2011)	
Not	stated	 South	Korea	
(High)	
Anti-TNF	candidates	
(Adults)	
Unknown*	 QFT-GIT	
	
≥10		 Yes,	
QFT-GIT	(+)	
107/83	
*Prevalence	of	HIV	infection	unknown,	but	probably	low.		
†In	 accordance	 with	 Turkish	Ministry	 of	 Health	 guidelines,	 PT	 was	 offered	 to	 all	 children	 younger	 than	 6	 years,	 regardless	 of	 TST	 results;	
children	6	 years	or	older	with	 a	positive	 result	 in	 the	 first	 TST	 (≥10	mm	 in	unvaccinated	 children	and	≥15	mm	 in	 vaccinated	 children);	 and	
children	6	years	or	older	with	conversion	from	negative	to	positive	TST.	‡3%	of	those	with	QFT-GIT	(+)	were	treated.	
TB=	 tuberculosis;	 HIV=	 human	 immunodeficiency	 virus;	 IGRA=	 interferon-gamma	 release	 assays;	 TST=	 tuberculin	 skin	 test;	 PT=	 preventive	
treatment;	T-SPOT=	T-SPOT.TB;	QFT-GIT=	QuantiFERON-TB	Gold	In-tube;	TNF=	tumor	necrosis	factor;	N.R.=	not	reported.	
	Table	2.	Summary	of	the	modified	Newcastle-Ottawa	scale	assessment	of	studies	included	
	 TB	contact		
study	
(n=	5)	
Anti-TNF	
candidates	
screening	
(n=	3)	
Other	cohorts	at	
risk	for	TB	
(n=	3)	
Overall	
(n=	11)	
Selection	 	 	 	 	
Representative	sample	 5	 3	 3	 11	
IGRA	and	TST	from	same	source	population	 5	 3	 3	 11	
Active	TB	excluded	at	baseline	
							yes	
							not	reported	
	
4	
1*	
	
3	
--	
	
2	
1*	
	
9	
2	
Comparability	 	 	 	 	
Adjustment	of	confounders	 3	 0	 1	 4	
Outcome	 	 	 	 	
Assessment	of	outcome	
							active	follow-up	(ascertainment	of	symptoms)	
						record	linkage	
	
3†	
2	
	
3	
--	
	
2	
1	
	
8	
3	
>50%	of	incident	cases	culture-confirmed	
						yes	
						no	
						not	reported					
	
2	
2	
1	
	
N.A.	
N.A.	
N.A.	
	
2	
--	
1	
	
4	
2	
2	
IGRA/TST	incorporated	into	reference	standard	
						yes	
						no	(or	not	reported)	
	
2	
3	
	
--	
3	
	
2	
1	
	
4	
7	
Follow-up	≥2	years		 5	 1	 2	 8	
≥80%	of	cohort	followed	up	
						yes	
						not	reported	
	
4	
--	
	
3	
--	
	
2	
1	
	
9	
1	
Outcome	report	
						cumulative	incidence	
						incidence	rate	
						cumulative	incidence	and	incidence	rate	
	
3	
1	
1	
	
NA	
NA	
NA	
	
1	
--	
2	
	
4	
1	
3	
*Not	explicitly	reported,	but	probably	performed.	
†TST	(+)	were	regularly	followed	at	the	clinic,	and	TB	was	investigated	by	ascertaining	health	complaints	potentially	due	to	TB.	TST	(-)	were	not	
followed	up,	and	TB	assessment	was	record-linked.	
TB=	 tuberculosis;	 NA=	 not	 applicable;	 TST=	 tuberculin	 skin	 test;	 IGRA=	 interferon-gamma	 release	 assays;	 TNF=	 tumor	 necrosis	 factor.
	Table	3.	Results	of	TST	and	IGRAs	in	the	11	studies	included	
Reference	
(year)	
IGRA	
test	
N		 TST	(+)	
n	(%)	
IGRA	(+)	
n	(%)	
P	
Value*	
TST	(+)/	
IGRA	(+)	
n	(%)	
P	
value†	
TST	(-)/	
IGRA	(-)	
n	(%)	
TST	(+)/	
IGRA	(-)	
n	(%)	
TST	(-)/	
IGRA	(+)	
n	(%)	
Song16	
(2007)	
QFT-GIT	 1826	 ≥10	mm:	270	(14.8)	 203‡	 --	 203‡	 <0.001	 --	 67	 --	
Hill24	
(2008)	
ELISPOT	
(in	house)	
1648	 ≥10	mm:	658	(40.0)	 605	(36.7)	 0.06	 428	(26.0)	 <0.001	 813	(49.3)	 230	
(14.0)	
177	(10.7)	
Bakir22	
(2008)	
ELISPOT	
(in	house)	
287	 ≥5	mm:	93	(32.4)	
	
46	(16.0)	 <0.001	 20	(7.0)	 <0.001	 168	(58.5)	 73	(25.4)	 26	(9.1)	
Kik17	
(2009)	
T-SPOT	
	
433	 ≥5	mm:	299	(69.1)†	
	
181‡	 --	 181‡	 <0.001	 --	 118		 --	
Kik17	
(2009)	
QFT-GIT	
	
433	 ≥5	mm:	327	(75.5)†	
	
160‡	 --	 160‡	 <0.001	 --	 167		 --	
Laffite19	
(2009)	
T-SPOT	
	
46	 ≥10	mm:	18	(39.1)	 8	(17.4)	 0.02	 8	(17.4)	 0.02	 28	(60.9)	 10	(21.7)	 0	
Diel18	
(2010)	
QFT-GIT	
	
901	 ≥5	mm:	555	(61.6)†	
	
145	(16.3)	 <0.001	 143	(15.9)	 <0.001	 346	(38.4)	 410	
(45.5)	
2	(0.2)	
Leung25	
(2010)	
T-SPOT	
	
241	 ≥5	mm:	161	(66.8)	
≥10	mm:	136	(56.4)	
≥15	mm:	89	(36.9)	
151	(62.7)	
	
0.35	
0.16	
<0.001	
124	(51.5)	 <0.001	
..	
<0.001	
53	(22.0)	 37	(15.4)	 27	(11.2)	
Harstad21	
(2010)	
QFT-GIT	
	
810	 ≥6	mm:	415	(51.2)	
≥15	mm:	121	(14.9)	
237	(29.3)	
	
<0.001	
<0.002	
207	(25.6)	 <0.001	
<0.002	
255	(31.5)	 208	
(25.7)	
30	(3.7)	
Mahomed26	
(2011)	
QFT-GIT	
	
5244	 ≥5	mm:	2894	(55.2)	 2669	(50.9)	 <0.001	 2383	(45.4)	 <0.001	 2064	(39.4)	 511	(9.7)	 286	(5.5)	
Garcovich20	
(2011)	
QFT-GIT	
	
44	 ≥5	mm:	5	(11.4)	 2	(4.5)	 0.4	 2	(4.5)	 0.4	 39	(88.6)	 3	(6.8)	 0	
Chang23	
(2011)	
QFT-GIT	
	
83	 ≥10	mm:	35	(42.2)	 36	(43.4)	 0.9	 19	(22.2)	 0.008	 48	(57.8)	 16	(19.3)	 0	
*p	value	for	the	difference	in	prevalence	of	positive	results	between	TST	and	IGRA.	
†p	value	for	the	difference	in	prevalence	of	positive	results	between	TST	and	TST/IGRA.	
‡IGRA	performed	only	in	individuals	with	positive	TST	
TST=	tuberculin	skin	test;	IGRA=	interferon-gamma	release	assays;	T-SPOT=	T-SPOT.TB	
